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RESUMO  
A quimioterapia é a forma mais comum de tratamento de cancro, contudo falha frequentemente devido 
à aquisição de resistência celular. É urgente o avanço na compreensão dos mecanismos celulares de 
resistência celular, bem como de novas estratégias ao seu combate. A nanomedicina, têm desenvolvido 
novas ferramentas para o diagnostico e tratamento do cancro. Nesta tese explorámos cinco estratégias 
para ultrapassar a resistência adquirida a fármacos: i) novos compostos anticancerígenos, ii) 
nanovetorização e direcionamento de compostos, iii) hipertermia com nanopartículas de ouro (AuNP) 
e sua combinação com quimioterapia, iv) bloqueio da angiogénese, através de quimioterapia, AuNP e 
radiação laser, v) silenciamento genético de bombas de efluxo mediado por AuNP. 
Começámos por caracterizar o mecanismo de ação de um novo composto anti tumoral (ZnD), que 
mostrou elevada toxicidade em células derivadas de cancro do colon (HCT116 DR) resistente a 
doxorubicina, um fármaco de primeira linha. Vetorizámos o ZnD utilizando AuNP, resultando num 
aumento de toxicidade em xenógrafos de HCT116 DR em ratinho. Tirando vantagem das propriedades 
foto térmicas das AuNP, combinámos quimioterapia com foto-hipertermia de radiação visível, 
revelando-se eficaz contra HCT116 DR. Sendo a angiogénese um dos marcos do desenvolvimento 
cancerígeno, procurámos comprometê-la utilizando um péptido anti-angiogénico, vetorizado em AuNP 
conjuntamente com irradiação laser. Conseguimos com esta estratégia uma redução de 91% de 
vascularização in vivo. Tentámos também silenciar o ARN mensageiro da bomba de efluxo ABCB1, 
causa principal de resistência à doxorubicina, através de AuNP funcionalizadas com oligonucleótidos 
complementares. Concluímos que apesar do silenciamento ser efetivo, as células não voltavam ao 
fenótipo sensível, necessitando de mais estudos. 
No geral, esta tese mostra o potencial da nanotecnologia no tratamento do cancro, tanto através da 
quimioterapia, como de técnicas de cirurgia, onde os lasers verdes já são utilizados. Este trabalho, pode 
ser aplicado a tumores resistentes a fármacos, aumentado a eficácia do tratamento.  
 
Termos-chave: Cancro; Nanopartículas de Ouro; Nanomedicina; Fototerapia; Hipertermia; Resistência 
Fármacos. 
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ABSTRACT 
The most common type of cancer treatment, chemotherapy, often fails due to the acquisition of 
resistance. It is therefore of the utmost importance to better understand the cellular mechanisms of 
resistance, while developing new strategies to tackle drug resistance. Nanomedicine promises to 
develop new tools for diagnosing and treating of diseases, improving human health. This thesis explored 
five main strategies to overcome drug resistance in cancer cells: i) new anti-cancer compounds, ii) 
nanovectorisation and targeting of compounds, iii) gold nanoparticles (AuNP) for hyperthermia and 
combination with chemotherapy iv) AuNP assisted angiogenesis arrest with laser ablation and 
chemotherapy v) AuNP mediated gene silencing of efflux pumps. 
We started by characterizing the mechanism of action of a new anti-tumour compound (ZnD), that was 
able to reduce the viability of a colon cancer cell line (HCT116 DR) resistant to doxorubicin (DOX), a 
first-line chemotherapeutic. We vectorized our compound with AuNP, resulting in increased toxicity to 
HCT116 DR mouse xenografts. Taking advantage of the photothermal properties of AuNP, we 
combined chemotherapy with photo hyperthermia by irradiating AuNP with a green laser. 
Hyperthermia was especially effective against HCT116 DR. 
Since angiogenesis is a milestone in cancer development, we aimed to prevent it, using an anti-
angiogenic peptide vectorized with AuNP and laser irradiation, resulting in a vascularization reduction 
of 91% in vivo. We have observed that ABCB1 efflux pump was the major cause of resistance of DOX 
resist cell line, therefore we silenced its mRNA with an anti-sense oligonucleotide AuNP. Our results 
showed that although the silencing was effective, cells did not return to a sensitive phenotype, requiring 
further experiments. 
Altogether this thesis shows the potential of nanotechnology for cancer treatment, both in chemotherapy 
and in surgery, where green lasers are already used. This work can be applied to drug resistant tumours, 
increasing the efficacy of treatment. 
 
Keywords: Cancer; gold nanoparticles; Nanomedicine; Phototherapy; Hyperthermia; Drug 
Resistance. 
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CHAPTER 1 – INTRODUCTION 
 
The literature review presented in this chapter provides for a general contextualization of the thesis, 
which shall be more focused within each individual chapter. Also, some of the information herein 
presented has been published, whole or in part, elsewhere. The author of this thesis reviewed and 
critically discussed the references cited in the text. 
• Pedrosa P, Vinhas R, Fernandes A, Baptista PV. Gold Nanotheranostics: Proof-of-Concept or 
Clinical Tool? Nanomaterials. 2015, 5(4):1853-1879 DOI: 10.3390/nano5041853 
• Pedrosa P, Carvalho A, Baptista PV, Fernandes AR. Inorganic Coordination Chemistry: where we 
stand in cancer treatment? In Basic Concepts Viewed from Frontier in Inorganic Coordination 
Chemistry. Edited by Dr. Takashiro Akitsu. IntechOpen. 2018 DOI: 10.5772/intechopen.80233 
• Rodrigues C, Raposo L, Pombo I, Pedrosa P, Fernandes AR, Baptista PV. Nanotheranostics targeting 
the tumour microenvironment. Frontiers in Bioengineering and Biotechnology. 2019, 7:197 DOI: 
10.3389/fbioe.2019.00197 
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1.1 Cancer  
Cancer is the second leading cause of death worldwide [1]. Among the most frequent human cancers, 
prostate cancer in men and breast cancer in women are the most frequent, while for children, blood 
cancers are the most common. Colorectal cancer is the second most common in Europe representing 
13% of the incidence in 2018, and the most common in Portugal representing 18% of the incidence in 
the same period. In the same year, lung and colorectal cancer together were responsible for more than 
30% of cancer deaths. The expenditure on cancer in Europe in 2014 was estimated to be €83.2 billion 
representing €164 per capita in Europe and €61 per capita in Portugal. These data depict the social and 
economic impact of this disease (Fig. 1.1) [2, 3].  
 
Fig. 1.1 Incidence and mortality rates of different types of cancer in Europe and Portugal. 
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Cancer must be understood as a complex combination of a variety of diseases that impact multiple 
aspects of cells and molecular regulation within tissues [4]. Due to its complexity and to distinct modes 
of presentation, coupled to the individual heterogeneity, these alterations usually take time to present 
clear symptoms, whose late diagnosis severely hampers effective treatment. Early diagnosis 
significantly increases the success of treatment, raising the importance of routine check-ups to detect 
pre-malignant lesions and alterations, as well as initial (usually) less aggressive forms of the disease 
[5]. About 90 to 95% of cancers develop due to environment aspects and lifestyle. Currently, it is 
proposed that between 30% and 50% of cancer derived fatalities are preventable by modifying lifestyle 
and avoiding exposure to major risk factors, such as: tobacco, alcohol consumption, obesity, 
sedentarism, and chronical infections [6–8].  
Cancer cells are the result of several mutations in crucial genes that compromise their normal 
function, disturbing the cell cycle, and leading to uncontrolled proliferation. Proto-oncogenes are 
responsible for adequate control of cell division and growth, becoming oncogenes after genetic 
mutation. In addition, tumour suppressor genes can work as a defence mechanism but when mutated 
can allow uncontrolled cell division. Most of these molecular alterations are induced by direct mutations 
to the DNA, epigenetic changes of chromatin or the result of altered expression patters of regulatory 
pathways, both at the RNA and protein level. Still, cells have highly effective DNA repair mechanisms 
that attempt to correct any physico-chemical damage to DNA, such as base excision repair, nucleotide 
excision repair or mismatch repair. While mostly preventing the onset of genome mutations, these 
mechanisms sometimes fail to correct the damage and, as a result, mutations prevail and accumulate 
[9–11].  
Risk factors increase the chances of cancer by increasing the probability of mutations in the genome. 
Chemical compounds, especially those interacting with DNA, have a role in the formation of gene 
mutations. Carcinogenic substances influence the cytoplasm and nucleus of cells directly or indirectly, 
and lead to genetic disorders and mutations. Other sources of gene mutation rely on radiation or 
infections such as. Human Papilloma Virus in cervical and oropharyngeal cancers, and Helicobacter 
pylori in stomach cancer [6–8].  
1.2 Cancer progression 
For mutated cells to progress into cancer they must be able to: have self-sufficient cell division, be 
insensitive to cell division stop signals, resist to cell death, have infinite division potential, form new 
blood vessels (neo-angiogenesis), invade other tissues, survive in hypoxia and evade the immune 
system. With the continuous division of cancer cells, and acquisition of mutations, they become 
genetically unstable. It is common to observe heterogeneous tumour masses, that may respond 
differently to therapy. After disease establishment, early and precise diagnosis is the key for adequate 
therapy and increased survival [5, 11]. In the following subsection we will elaborate on each cancer 
hallmark, to understand cancer progression (Fig. 1.2). 
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Fig. 1.2 Schematics of the Hallmarks of Cancer Progression. Reprinted from Cell, 144-5(29), Douglas 
Hanahan, Robert A., Hallmarks of Cancer: The Next Generation, Copyright 2019, with permission 
from Elsevier. 
1.2.1 Sustaining proliferative signalling 
Sustaining proliferative signalling is the basic step for cancer development. Healthy tissues have a 
tight control of their division cycle and production of growth factors. Cells become tumorigenic by 
deregulating its mitosis and maintaining a continuous signal to divide. This deregulation can happen in 
different ways: cancer cells can produce growth factors which they ultimately respond to, in an 
autocrine proliferative stimulation; they can stimulate healthy tissue to produce growth factors; they 
can increase the number of growth factor receptors, becoming hyperresponsive to normal growth factor 
levels; or they can structurally alter their growth factor receptor, to be always active independently of 
ligand interaction [10, 11]. An example of the latter are deregulations in epidermal growth factor 
receptor (EGFR). EGFR is part of the ErbB receptor family of receptor tyrosine kinases. It exerts critical 
functions in epithelial cell physiology and is frequently overexpressed and/or mutated in several human 
cancers [12]. Receptor transphosphorylation, which is dependent of ligand binding, activates an 
intracellular signalling cascade of multiple pathways that deliver the information to the nucleus for the 
activation of genes responsible for cell proliferation, survival, differentiation and angiogenesis [12, 13]. 
These mutations lead to the continuous signalling for cell proliferation. 
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1.2.2 Evading growth suppressors 
For cancer progression, a second step must be accomplished after sustained proliferation. Cells must 
be able to evade growth suppressors. Tumour suppressors are generally proto-oncogenes that limit cell 
growth, regulating proliferation [14]. Retinoblastoma and TP53 associated proteins are the two classical 
tumour suppressors that regulate complementary cellular regulatory circuits that decide if cells should 
divide, halt division, or undergo apoptosis [15, 16]. Retinoblastoma proteins work as a gatekeeper, 
analysing mainly extracellular signals and deciding if cells should proceed with the cell cycle. On the 
other hand, TP53 proteins generally decide upon different types of intracellular stress signals. If the 
nucleotide pool levels are unbalanced, there is a deprivation of glucose, oxygenation or excessive 
genomic damage, TP53 pathway can stop cell cycle progression until the cell returns to a normal 
condition. When the conditions are extreme, TP53 can also summon apoptotic signals. When defected, 
these pathways allow uncontrolled cell division [14–16]. 
1.2.3 Evading programmed cell death 
The next step in cancer development is the capacity of cancer cells to evade programmed cell death, 
persisting in stress conditions. Apoptosis is one of the cell’s natural form of suicide. It is a type of 
programmed cell death characterized by cell shrinkage, membrane blebbing, chromatin condensation 
and nuclear fragmentation (apoptotic bodies) [17]. Apoptotic cells are phagocytised before they release 
toxic products to the intercellular space, thus they do not induce an inflammatory response. Apoptosis 
can be triggered by an intrinsic or extrinsic pathway. The extrinsic pathway is triggered by binding of 
external signalling [17], involving for example the Fas ligand/receptor. The intrinsic pathway is more 
frequently associated as a barrier to cancer development. It can be activated by intracellular stimuli, 
including DNA damage, growth factor deprivation, and oxidative stress. It depends on the release of 
cytochrome c and other pro-apoptotic proteins from the intermembrane space of mitochondria. This 
interaction is followed by the assembly of the death-inducing signalling complex [18, 19] . Cancer cells 
are, generally, more sensitive to apoptosis, meaning that they are closer to triggering the apoptotic 
pathway than normal cells. This sensitivity comes from the dual upregulation of proapoptotic and 
antiapoptotic proteins and environmental stressors that endure low availability of nutrients or hypoxia 
[20, 21]. Tumour cells can evolve several tactics to circumvent apoptosis. TP53 is commonly affected, 
abolishing the critical damage sensor from the apoptosis. Cancer cells can also evade apoptosis by 
increasing the expression of antiapoptotic factors (BCL-2, BCL-XL) or survival signals (IGF11/2), or 
by downregulating proapoptotic regulators (BAX, BIM, PUMA) [22].  
1.2.4 Enabling replicative immortality 
For a tumour to persist, after passing the described steps, it must enable replicative immortality. 
Normal cells have a limited number of division cycles before they enter a senescent state, when cells 
stop dividing but remain viable until they ultimately die by apoptosis. This mechanism of limiting cell 
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cycles is regulated by telomeres. Telomeres are multiple tandem hexanucleotide repeats in the 
extremities of chromosomes that protect end-to-end chromosomic fusions. During the cell cycle these 
repeats are progressively lost, generating unstable dicentric chromosomes and cell death. an alternative 
recombination-based telomere maintenance mechanism. Hence, telomere shortening works like an 
internal clock that determines the number of divisions a cell can undertake. To survive, cancer cells 
overexpress telomerase, a DNA polymerase that extends the telomeres. By keeping the telomeres’ 
length long enough to avoid triggering apoptosis, these cells keep replicating in an immortal state [23, 
24].  
1.2.5 Tumour microenvironment and energy metabolism 
When cells divide indefinitely a tumour mass is generated, and a cellular environment is created 
where the centre of the mass and the periphery have different conditions. The tumour microenvironment 
is created by the interplay between growing tumour cells and surrounding environment. Its composition 
varies according to the anatomical region of the tumour and the genetic and phenotypic traits of tumour 
cells [25, 26]. However, common features can be found. The micro-environment of epithelial tumours 
is generally composed by tumour cells, the extracellular matrix, stromal cells (including fibroblasts, 
mesenchymal stromal cells), cells from the blood and lymphatic systems and occasionally adipocytes, 
and cells from the immune system (including macrophages, T and B lymphocytes and natural killer 
cells). Different microenvironments force cancer cells to adapt in order to survive creating a heterogenic 
mass of cells. The first constraint observed in tumour cells is oxygen and nutrient supply that cannot be 
sustained by adjacent blood vessels [11]. In these settings, the oxygen scarcity experienced by growing 
tumour cells induces the expression of cellular response to hypoxia, principally via hypoxia-induced 
factors (HIF) [27]. HIF family of transcriptional factors is composed by HIF1, HIF2 and HIF3 proteins 
that activate genes involved in glucose metabolism, angiogenesis, cell proliferation, migration and 
immune system modulation [27–29]. The HIF together with high energetic requirements, trigger a 
metabolic adjustment in tumour cells from oxidative phosphorylation to the aerobic glycolysis, in a 
process known as Warburg effect [30]. This metabolic switch remains even in the presence of oxygen 
and results in an increased production of lactate. To compensate the lower efficiency of glycolysis 
compared with mitochondrial oxidative phosphorylation, cancer cells upregulate glucose transporters 
increasing the glucose concentration in the cytoplasm [14, 31, 32]. Glycolytic switch also allows the 
channelling of glycolytic intermediates into various biosynthetic pathways, which include nucleosides 
and amino acids synthesis. The high level of lactate in the cytoplasm leads to the upregulation of efflux 
pumps for lactic and carbonic acid secretion, giving tumour cells the conditions to survive and thrive, 
contributing also for multidrug resistance (MDR) [33, 34]. The accumulation of lactate in the tumour 
extracellular space leads to its acidification. Interestingly, it has been found in some tumours two 
subpopulations of cancer cells that cooperate in their energy metabolism. One subpopulation consists 
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of anaerobic glycolytic cells that secrete lactate, whereas the second subpopulation preferentially 
imports the lactate and uses it as their main energy source, in the citric acid cycle [35–37].  
The glycolytic metabolism and increased proliferation of tumour cells result in increased reactive 
oxygen species (ROS) production, promoting genomic instability on one side, and inducing antioxidant 
defences on the other side [30]. To increase the levels of oxygen and nutrients in the tumour and reduce 
toxic waste concentration, tumour cells promote the formation of new blood vessels. 
1.2.6 Inducing angiogenesis 
The word cancer appeared due to the resemblance of a tumour and surrounding vessels to a ‘crab’ 
which is the meaning of the word in Latin. Because of the inhospitable conditions of the tumour 
microenvironment cells start to secrete factors that promote the formation of new blood vessels – 
angiogenesis. Angiogenesis is an important hallmark in cancer progression and it has been demonstrated 
that solid tumours cannot grow bigger than 2-3 mm without creating their own blood supply [38]. The 
low levels of oxygen induce the expression of vascular endothelial growth factor A (VEGF-A) and its 
receptor (VEGFR) via HIF-1α [39]. The VEGF pathway can also be upregulated by sequestering of 
VEGF ligands in the extracellular matrix. Upon the activation and release of extracellular matrix-
degrading proteases VEGF ligands are released. VEGF-A is a potent and specific inducer of mitosis for 
vascular endothelial cells and signals the production of matrix metalloproteinases (MMPs). The MMPs 
degrade the extracellular matrix of cells permitting the migration of endothelial cells. In turn, the 
endothelial cells start to divide and migrate, organizing themselves into hollow tubes that gradually 
develop into a network of blood vessels, helped by adhesion factors, such as integrin α and β [40–43]. 
In this process, the negative regulators that inhibit the formation of blood vessels work as an internal 
counterbalance of angiogenesis by expressing a set of proteins that include, angiostatin, interferon, 
platelet factor 4, endostatin, prolactin 16 kDa fragment, thrombospondin, and tissue inhibitor of MMP-
1, -2, and -3. To initiate angiogenesis, the upregulation of angiogenic factor is as essential as the 
downregulation of the anti-angiogenics. Angiostatin for example induces apoptosis in endothelial cells 
and in tumour cells, while inhibiting the migration and the formation of tubules in endothelial cells [44, 
45]. The unbalanced concentration levels of angiogenic and anti-angiogenic signals, end up in the 
formation of vessels with defective or discontinuous basement membranes, resulting in leaking 
vasculature with chaotic organization unevenly distributed along the tumour, excessive vessel 
branching, erratic blood flow and micro haemorrhaging [41].  
Interestingly, some studies propose a correlation between the levels of angiogenic factors in tissue 
and the aggressiveness of a tumour, using these values as predictors for high risk patients with a poor 
prognosis. The association between the expression of VEGF and prognosis has been described in 
colorectal cancer [46–48], breast cancer [49–52], and lung cancer [53–55], among others [56–58].  
The formation of lymphatic vessels, named tumour-associated lymphoangiogenesis, is sustained by 
the secretion of VEGF-C and VEGF-D by tumour cells, immune cells, and other stromal cells. In this 
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event, lymphatic endothelial cells form single layer lymph capillaries with minimal basement 
membrane, that join to collecting lymphatic vessels with a basement membrane and valves that prevent 
retrograde flow. The formation of lymphatic vessels around a tumour is correlated with poor prognosis, 
since it favours metastatic propagation in distal organs. On the other side, lymphatic endothelial cells 
have a prominent role in immune system modulation, contributing for anti-tumour immunity [59, 60]. 
1.2.7 Evading the immune system  
The participation of the immune system in tumour development is not fully understood. It is believed 
that the immune system monitors and eliminates the formation of nascent tumours. This is majorly 
supported by the rise of certain cancers in immunocompromised individuals [61] and by the high 
incidence of malignancies in patients receiving immunosuppressive therapy after organ transplantation 
or HIV infection [62]. However, the fact that people with fully functional immune systems also develop 
cancer, indicates that this concept of immunosurveillance is only part of the story. Today the most 
consensual concept is immunoediting, that constitutes a dynamic process that simultaneously prevents 
tumours, and shapes the immunogenicity of developing tumours. Immunoediting can be defined in three 
parts: elimination, equilibrium and escape [63–65]. Although these parts will further be explained 
separately, it is noteworthy that they continually shift between each other over time, representing an 
interplay between tumour and immune system, depending on the immune system state and properties 
of the tumour microenvironment. Elimination represents the common view of immunosurveillance, 
when a forming tumour is rejected and killed by the immune system. If the tumour is not completely 
destroyed, it may enter a senescent state (equilibrium) in which the immune system controls tumour 
growth and which may stay unaltered for many years. This concept is supported by fact that tumours 
can remain dormant in cured patients for many years, and relapse after long periods [63, 66]. In certain 
cases, tumour cells may escape from immune restriction and start proliferating in an uncontrolled 
manner, leading to tumours. This happens due to selective pressure in tumour cells by the immune 
system, where only cell that are less immunogenic or more resistant to lysis survive [67]. Tumours can 
also create an immunosuppressive microenvironment by recruiting specific immune cells that favour 
tumour growth and progression [68, 69]. Importantly, the molecular signals composition of the tumour 
microenvironment determine the clinical outcome by promoting the tumour escape to 
immunosurveillance or tumour constrain [70]. Once in the tumour microenvironment, monocytes can 
differentiate into two different types of macrophages depending on the chemical composition at the 
tumour location: M1-type macrophages are formed in the presence of interferon gamma, and M2-type 
macrophages appear when exposed to different interleukins (IL, e.g. IL-4 or IL-10), transforming 
growth factor beta (TGF-), granulocyte-macrophage colony stimulating factor, annexin A1 or tumour 
cell-surface molecules [71, 72]. This macrophage polarization is crucial for tumour prognosis, as M1-
type are correlated with a good prognosis, while tumour associated macrophages generally have the M2 
phenotype and contribute for tumour growth, angiogenesis, invasion and metastasis [71–74]. 
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Inflammation is usually displayed in the tumour, promoted initially by tumour cells (intrinsic pathway) 
[75]. A pro-inflammatory environment is usually accompanied by a poor prognosis [70, 75] . Tumour 
associated macrophages-mediated secretion of IL-1 cytokines contribute for chronic inflammation and 
strengthen a pro-tumoral micro-environment [76]. The role of the lymphoid lineage cells in tumour 
progression is also contradictory. While B cells and regulatory T cells create an immunosuppressive 
microenvironment, innate cytotoxic lymphocytes, natural killer cells and natural killer T cells are 
immunostimulant [64, 77–79]. In different types of cancers, the increased expression of Granulocyte-
macrophage colony stimulating factor and VEGF induce the production of myeloid-derived suppressive 
cells at the bone marrow that are recruited to the tumour microenvironment where they remain 
undifferentiated [80]. The presence of myeloid-derived suppressive cells is generally correlated with a 
poor prognosis, as they are involved in angiogenesis and suppression of natural killer cells and CD8+ 
cytotoxic T cells [80, 81].  
1.2.8 Activating Invasion and Metastasis 
In epithelial cancers, growing tumour cells are supported in an extracellular matrix with altered 
biochemical and biomechanical properties when compared with healthy tissue. The low oxygenation 
and inflammatory environment induce alterations in extracellular matrix proteins that result in 
desmoplasia, characterized by the growth of fibrous or increased thickness of tumour surrounding 
connective tissue. The degree of desmoplasia increases as the tumour progresses and is preponderant in 
metastatic dissemination and clinical outcome [82, 83]. 
Stromal cells are also important for tumour development and prognosis. Mesenchymal stromal cells 
are recruited to the tumour due to the inflammatory environment and, according to its chemical 
composition, they may promote or inhibit the tumour progression [84, 85]. Moreover, the inflammation 
and consequent secretion of TGF- induce the differentiation of fibroblasts into cancer associated 
fibroblasts. Besides tumour cells, cancer associated fibroblasts are the most abundant cell type in 
tumours and play an important role in increased desmoplasia [86–88]. 
The presence of hypoxia increases desmoplasia and the interactions between the several cell players 
in the tumour microenvironment favours the epithelial-to-mesenchymal transition of tumour cells 
resulting in the formation of cancer stem cells [73, 89, 90]. The epithelial-to-mesenchymal transition 
process results in disruption of intracellular adhesion and loss of cell polarity, conferring migratory 
ability to cancer stem cells. These cells can enter adjacent blood or lymph vessels and travel to another 
anatomical location where they can experience the reverse process - mesenchymal-to-epithelial 
transition. The formation of distant tumour nodes is called micro metastases, that grow into micro 
metastatic lesions and later macroscopic tumours. This step is termed colonization - implantation of a 
primary tumour into a secondary location [73, 89, 90]. MMPs have an important role in epithelial-to-
mesenchymal transition, being responsible for the detachment of tumour cells from the extracellular 
matrix promoting cancer stem cells formation [91]. 
  10 
 
In an initial stage, it is the genomic profile of tumour cells that determines tumour maturation. As 
the cancer progresses, the intercellular communication between tumour and neighbour cells dictates 
tumour microenvironment and tumour progression, contributing for intra- and inter-tumour 
heterogeneity [11, 92]. Central in these communications are exosomes, endosomal pathway derived 
vesicles with 30-100 nm diameter, composed by a lipid bilayer with membrane proteins, entrapping 
soluble proteins, signalling molecules, including cytokines, chemokines and growth factors, and nucleic 
acids including mRNA and miRNA [93]. Importantly, the content of the exosomes depends on the cell 
of origin, often reflecting the physiological condition of the cell [94]. After release to the extracellular 
milieu, exosomes can be internalized by secondary cells adjacent to the primary cell or travel through 
the vascular or lymphatic system to other anatomical location where they can be internalized by local 
cells. Once internalized, exosomes are able to modify the phenotype of the recipient cell that will adjust 
to the incoming signals [95, 96]. Tumour cell derived exosomes have an important role in tumour 
progression, including for example in immune system modulation, contributing to tumoral transition of 
adjacent cells and preparation of the metastatic niche at a new anatomical location [96, 97]. 
1.3 Different types of colorectal, lung and breast cancer 
Depending on the type of cancer they have different origins and different presentations. For example, 
sarcomas originate in muscle tissue, adenoma in gland cells, carcinoma in mesenchymal tissue, 
lymphoma in lymphocytes, etc. As colorectal, breast and lung cancers are the most incident and deadly, 
we used these types of cancer as models for our work. Thus, we will explore their different 
presentations.  
In colorectal cancers, adenocarcinomas are the clear majority. The first stages of the tumours start 
with polyps that continue to grow and can then turn into malignant tumours. Polyps can grow in two 
different shapes, flat and pedunculated. Flat polyps are harder to detect in colon cancer screening and 
are more common than previously thought. Pedunculated polyps have a mushroom-like shape. There 
are five types of polyps: adenomatous (tubular adenoma), hyperplastic, serrated, villous adenoma and 
inflammatory. Certain types are more likely to become cancerous than others. Adenomatous represent 
about 70% of all polyps, which when found, are generally tested for cancer. Only a small percentage 
become cancerous, but almost all malignant polyps began as adenomatous. Villous adenomas represent 
approximately 15 % of polyps detected in colon cancer screening. This type of polyp has a high risk of 
turning cancerous and as they are commonly flat shaped, they are more difficult to remove. The process 
of polyps developing to colon cancer is in the span of years. With regular screening and accurate 
diagnostic, they can be found and surgically removed before they grow. Other less common types of 
colon cancer can also occur, colorectal sarcomas (gastrointestinal stromal tumours), lymphomas and 
carcinoids. Colon cancer has a high genetic component, up to 15% of colorectal cancer patients have 
family members with colorectal cancer, excluding colorectal cancer syndromes [98–100]. 
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Lung cancer has two main classifications: small cell lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC). These two types have different outcomes and are treated differently. NSCLC begins in the 
epithelial cells and can be: an adenocarcinoma, if cancer starts in mucus gland cells (40 % of all NSCLC 
cases); a squamous cell carcinoma if it begins in the cells that line the airways (30 % of all NSCLC 
cases); a large-cell undifferentiated carcinoma if cells can be found anywhere in the lung (10 to 15 % 
of all cases of NSCLC). NSCLC accounts for almost 90% of lung cancer cases. SCLC can begin in 
nerve cells or hormone-producing cells. Once the lung tumour grows, cancer cells may be carried away 
in the blood stream, or lymph. It is common, especially for SCLC to invade chest lymphatic nodes [101, 
102].  
Breast cancer has two forms, invasive or non-invasive. Invasive breast cancer spreads into 
surrounding tissues while the non-invasive stays in the milk ducts (ductal carcinoma) or lobules (lobular 
carcinoma) in the breast. Ductal carcinoma makes up most breast cancers. Lobular carcinoma when 
circumscribed to one breast is not considered cancer. Both ductal and lobular carcinomas can become 
invasive. However, the second has an associated risk factor for developing invasive breast cancer in 
both breasts. Other less common types of breast cancer are medullary, mucinous, tubular, metaplastic, 
papillary or inflammatory. The latter is a faster-growing type of cancer that accounts for 1% to 5% of 
all breast cancers. Breast cancers can be hormone receptor-positive if they express oestrogen (ER+) or 
progesterone receptors (PR+). This type of cancer depends on these hormones to proliferate, and 
although it may occur at any age, it is more common in women after menopause. About 60% to 75% 
of breast cancers are hormone receptor positive. About 15% to 20% of breast cancers rely on human 
epidermal growth factor receptor 2 (HER2) to progress. These cancers have an overexpressed HER2 
gene and are called “HER2-positive”. HER2-positive breast cancers grow more quickly and can be 
either hormone receptor-positive or hormone receptor-negative. Tumours that express none of the 
receptor are triple-negative, corresponding to approximately 15% of invasive breast cancers. Triple-
negative breast cancer is more common among younger women, and women with a mutation in the 
BRCA1 or BRCA2 genes. Thus, it is recommended that women with triple-negative breast cancer 
younger than 60 years old be tested for BRCA gene mutations [103, 104].  
Most types of cancer can also be categorized into four stages depending on their progression state. 
Stage I is characterized by a small tumour that has not grown deeply into other tissues. It also has not 
spread to the lymph nodes or other parts of the body. It is often called early stage cancer and can in 
general be surgically removed. Stage II indicate larger tumours that have grown more deeply into nearby 
tissue. However, it has not spread to lymph nodes. Stage III is generally associated with lymph node 
invasion but not to other parts of the body. Stage IV. means that the cancer has spread to other organs 
besides the primary organ. It is also called advanced or metastatic cancer. 
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1.4 Cancer therapy 
Cancer therapy relies on the selective killing of aberrant malignant cells while protecting healthy 
tissue. Surgery is still the most effective treatment for localized primary tumours, curing more patients 
than any other single therapy, even after the appearance of radiation therapy and chemotherapy in the 
1940s [105, 106]. Currently, the standard of care is focusing on the development of a combination of 
therapeutic strategies to strike cancer cells in a highly specific and direct way, ensuring that all the 
malignant and aberrant cells are destroyed. The understanding that the immune system plays a relevant 
role in the development of cancer, has also opened the gate for therapeutic strategies that make use of 
this powerful innate system to tackle cancerous cells. Bellow, I shall discuss some of these critical 
aspects in further detail. 
1.4.1 Surgery 
The increasing success in cancer treatment can be attributed mainly to the major improvements in 
surgery. The beginning of the 20th century marked a turn in the development of cancer surgery 
techniques, such as Halstedian principals. In the first fifteen years of the century, several surgery 
techniques were carried out for the first time for oncological purposes, such as radical suprapubic 
prostatectomy, abdominoperineal resection, radical hysterectomy and lobectomy [105, 106]. Later, non-
invasive procedures appeared, such as laparoscopic colectomy, videothoracoscopy, radiofrequency 
ablation and radiosurgery, limiting the size of incisions, wound healing time, pain and risk of infection 
[107–109]. Over the years, surgery has become gradually more sophisticated and less aggressive. 
Mastectomy – whole breast removal – has been replaced in some cases by quadrantectomy and more 
recently lumpectomy – only removing the tumour – without loss of survival [110]. Tissue conserving 
surgical procedures have also been proposed, such as breast-conserving surgery, with sentinel-node 
ablation to improve aesthetic results and avoid lymphedema; laryngoscopic laser surgery in early 
laryngeal cancer [111]; and a robotic surgical system (Da Vinci®) designed to facilitate complex 
surgery using a minimally invasive approach, controlled by a surgeon from a console. The system is 
commonly used for prostatectomies, but it can also be used for lung and colorectal cancer surgery [112, 
113]. The main trend in surgery remains, to reduce the impact on healthy tissues while removing as 
much tumour cells as possible. This field will see a revolution in the following decades with the 
evolution of new computerized imaging tools, lasers and robotics, reducing the cost effectiveness of 
surgeries, and expanding its application to different cancer types. 
1.4.2 Radiotherapy 
The discovery of X-ray radiation in the end of the 19th century paved the way to radiotherapy. 
Radiation therapy, based on high-powered energy beams, like X-rays or protons, is used to destroy 
cancer cells since they are more susceptible to radiation than normal cells. Radiation source can be 
external, from a machine, or internal, using radioactive isotopes inside the body (brachytherapy). The 
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X-rays or radioactive particles are painless and invisible and do not contaminate surrounding people 
after treatment. The first cancer case cured exclusively by radiation occurred in 1898. Today it is applied 
in approximately 45% of new cancer cases and is responsible for 40% of cancer cures with lower cost 
than other therapies. It is commonly used in combination with surgery and/or chemotherapy (as 
adjuvant therapy) [114, 115]. In lung cancer treatment, radiotherapy is used in every stage of both 
NSCLC and SCLC. In the early stages of disease development, when patients cannot undergo surgery, 
stereotactic radiotherapy is applied. In contrast, radio chemotherapy or radical radiotherapy are used 
locally in advanced stages. In stage IV cases radiotherapy can be employed as a palliative treatment 
[116, 117]. For colorectal cancer, radiotherapy is not standard treatment. It is used in advanced disease 
cases (stage III/IV) as neoadjuvant. Two preoperative regimens have been established, short-course 
radiotherapy and long-course chemoradiotherapy, both reducing the risk of local relapse. In fewer cases, 
intraoperative and particle radiotherapy can be used as treatment options for locally relapse patients 
[118]. Radiation therapy is also used in the treatment of breast cancer, but not in all cases. It is used in 
early stages as a preventive measure for women who had breast-conserving surgery to avoid relapse in 
the breast or nearby lymph nodes or in most advanced stages as adjuvant therapy to reduce metastatic 
tumour size. Brachytherapy can also be used along with external beam radiation to boost radiation to 
the tumour site [119].  
With the advance in computer science, it is possible to create three-dimensional X-ray therapy, such 
as intensity-modulated radiation therapy. It takes advantage of computed tomography (CT) scans to 
map the tumour, providing a three-dimensional reconstruction that can be accurately targeted [120]. 
One of the latter advances in this field is image-guided radiation therapy. This technology records a 
video sequence of tumour/patient movement, compensating body movement such as breathing. This 
reduces toxicity to other tissues, since the beam is focused to tumour volume instead of healthy tissues 
[121]. The current trends in radiotherapy have been fractionated dose delivery, localized radiation by 
means of improvement of computer-based tomography and advances in X-ray production. 
1.4.3 Chemotherapy 
Chemotherapy uses one or more chemical chemotherapeutic agents as part of a standardized 
regimen, intending to cure, prolong the life, or reduce the symptoms of cancer patients [122]. 
Chemotherapy can be used as: neoadjuvant, aiming to reduce the size of the primary tumour before 
local treatment (radiotherapy or surgery); combined therapy, when it is used simultaneously with other 
types of treatment; adjuvant, given after a local treatment to prevent micro metastasis, and reduce 
relapse rates; and maintenance, giving low-dose treatment to prolong remission [123]. Chemotherapy 
works by killing cancer cells usually by blocking cell division and/or promoting cell death via apoptosis. 
It is generally administered systemically, and its action is not specific to tumour cells. However, as 
tumour cells divide more rapidly than normal cells, they are more affected. Many side effects of 
chemotherapy are associated with this lack of selectivity. In the last years, a lot of effort has been put 
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in the development of novel targeted therapies towards specific molecular or genetic targets, which 
inhibit growth-signals like receptor tyrosine kinases (referred to as targeted therapy) [12, 124, 125] or 
growth-promoting signals from classic endocrine hormones (referred as hormonal therapy) [126, 127].  
The tyrosine kinase inhibitors are a family of small molecules or peptides that inhibit either cytosolic 
or receptor tyrosine kinases. These molecules work by directly competing with the ATP binding site of 
tyrosine kinases (genistein, lavendustin C, imatinib, erlotinib, gefitinib), by allosteric inhibition of the 
tyrosine kinase (lavendustin A), by inhibiting ligand binding to receptor tyrosine kinases (e.g., 
cetuximab), inhibiting tyrosine kinase interaction with other proteins (e.g., UCS15A, p60-v-Src 
inhibitor peptide) or by destabilizing the tyrosine kinase (e.g., herbimycin A and radicicol). Among 
these only imatinib, cetuximab, erlotinib and gefitinib are common in clinical practice, while the 
majority are not available for clinical use [12, 124, 125]. The type of therapy is common in several 
types of cancer including lung and colorectal cancer [128, 129]. 
Hormone therapy consists in the manipulation of the endocrine system to inhibit the production or 
activity of specific hormones or by administration of hormones. Hormonal therapy is used for several 
types of cancers including breast and prostate. It is commonly used as adjuvant or neoadjuvant therapy 
to reduce the risk of cancer relapse, however in some cases it can be used metastasis and relapses [126, 
127]. There are three main types of hormone therapies: inhibitors of hormone synthesis, hormone 
receptor antagonists and hormone replacement. Aromatase inhibitors are inhibitors of hormone 
synthesis used for the treatment of breast cancer in postmenopausal women. Oestrogen production in 
the ovaries ceases when women reach menopause, but other tissues continue producing oestrogen 
through effect of aromatase on androgens produced by the adrenal glands. Blocking the activity of 
aromatase drops the oestrogen levels to extremely low levels, arresting growth of hormone-responsive 
cancer cells [126, 130, 131]. Hormone receptor antagonists compete with the normal receptor of a given 
hormone preventing receptor activation. Target receptors are located on the cell surface, for as peptide 
and glycoprotein hormones, or intracellularly, as steroid hormone receptors. Selective oestrogen 
receptor modulators and anti-androgens are two types of hormone receptor antagonists [132]. In contrast 
with these therapies that seek to block hormone signalling to cancer cells, hormone replacement therapy 
works by giving specific hormone agonists that inhibit cell growth or have cytotoxic effect on tumour 
cells. Although it is not clear the mechanism of action of these therapies, progestogens, androgens, and 
oestrogens, are used for the treatment of hormone-responsive, advanced breast cancer [133]. 
Anthracyclines appeared in the early 1960’s and are considered a mainstay of cancer chemotherapy 
for several decades being doxorubicin (DOX) the most used. DOX is one of the most potent 
antineoplasic drugs in single or combined therapy due to its wide spectrum of action. It is used to treat 
a large variety of solid tumours and haematological malignancies [134, 135]. DOX acts by intercalating 
in DNA base pairs and by binding to DNA-associated enzymes. It hampers DNA replication, RNA 
transcription and promotes DNA breaks. Cell growth is inhibited at phases G1 and G2, and with the 
failure of the DNA repair system, the apoptosis pathway is triggered. Its side effects can be severe, 
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affecting different organs including the heart, brain, liver and kidney, thus dosage needs to be carefully 
considered from case to case [136–138]. Several attempts have been made to decrease DOX side effects 
including targeted drug delivery [139–145]. DOX-loaded pegylated liposomes are approved for clinical 
practice. Encapsulation into liposomes greatly reduces the interaction with the plasma allowing longer 
bloodstream retention after intravenous administration. PEGylation allows the liposomes to go 
undetected by the immune system and avoid clearance. The liposomes' small size allows them to pass 
through the leaky blood vessels that supply the tumour. Encapsulated DOX accumulates at the tumour 
site in contrast to free DOX, with significant impact to the therapeutic window of the drug [144, 146]. 
A breakthrough in chemotherapy was the appearance of metal complex agents which erupted with 
the discovery of cisplatin, approved for clinical use by the Food and Drug Administration (FDA) in 
1978 (Table 1.1). Accompanied by the success of cisplatin-based drugs, other coordination compounds 
based on platinum, gold, ruthenium, titanium, copper, etc. were explored for their anticancer potential 
with some reports of (pre)clinical and clinical candidates [147]. In biological systems, reactions rely on 
metal ions, such as zinc, iron and copper, for normal functioning. Such transition metals are involved 
in several biological processes, from electron transfer to protein active sites or as enzyme cofactors. 
Their intracellular concentration is tightly regulated, otherwise it can lead to the development of various 
pathological disorders [148]. A common characteristic of these metals is their ability to form ROS at 
higher concentrations, which explains, to some extent, their role as cancer modulators [149]. Cancer 
cells are known to have a different redox metabolism from normal cells, with augmented levels of 
intracellular ROS, mostly due to increased metabolic activity and hypoxia, especially in the core of 
solid tumours. Anticancer metal complexes, due to their redox properties, have been shown to disturb 
cancer cellular redox homeostasis resulting in enhanced levels of oxidative stress which are not well 
tolerated. For most metal compounds DNA is the main intracellular target (e.g., cisplatin, carboplatin, 
oxaliplatin). The interaction of these molecules with DNA can cause damage, creating adducts in cancer 
cells that block their division and lead to cell death [150, 151].  
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Table 1.1 Clinically approved metal compounds for anti-cancer therapeutic application.  
Name Description Target Cancer Approved 
Platinol Cisplatin Metastatic testicular, ovarian 
and bladder cancers 
FDA approval 
 
Paraplatin Carboplatin Advanced ovarian Cancer FDA approval 
Eloxatin Oxaliplatin Advanced colorectal cancer in 
combination with 5-FU and 
leucovorin 
FDA approval 
Aqupla Nedaplatin urological tumours Approval in Japan 
Lobaplatin 1,2-diammino-l-
methylcyclobutane-
platinum(II)-lactate 
Inoperable metastatic breast 
and small cell lung cancer 
Approval in 
China 
Heptaplatin Cisplatin analogue Gastric cancer Approval in 
Korea 
 
The current trend in chemotherapy development is targeted chemotherapy, by coupling established 
formulations with new carriers that specifically target cancer cells, thus increasing specificity and 
reducing side effects. 
1.4.4 Immunotherapy 
Cancer immunotherapies are the most recently approved, including preventive and therapeutic 
cancer vaccines, immune checkpoint inhibitors, a bi-specific T- cell engager, chimeric antigen receptor 
T-cell therapy, and monoclonal antibodies [66, 75, 79]. Among these, chimeric antigen receptor T cells 
had great interest lately for curing patients in terminal stages. In this type of treatment, a patient's T 
cells are purified from their own blood and altered in the laboratory to recognise a certain protein 
receptor on the patient’s cancer cells [152]. Because cancer immunotherapy acts in the immune system, 
it can work independent of tumour type or mutations. Immunotherapy can be combined with 
chemotherapy, or radiotherapy. The efficacy of chemotherapy combined with immunotherapy may 
depend on the drug, and the administration regimen.  
One of the fields that has seen greater advances is the development of monoclonal antibodies 
production [153, 154]. Several therapies have emerged targeting specific receptors that are 
overexpressed in cancer cells. Cetuximab (Erbitux) is a monoclonal antibody that acts against the 
extracellular domain of EGFR. It was FDA approved in 2003, in combination with chemotherapy for 
colon cancer and in 2006 for head and neck cancers. The EGFR is part of the ErbB receptor family of 
receptor tyrosine kinases. It exerts critical functions in epithelial cell physiology [12] and is frequently 
overexpressed and/or mutated in several human cancers. The receptor transphosphorylation, which is 
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dependent of ligand binding, activates an intracellular signalling cascade of multiple pathways that 
deliver the information to the nucleus for the activation of genes responsible for cell proliferation, 
survival, differentiation and angiogenesis [12, 13].  
Cetuximab showed clinical benefit for colorectal cancers that overexpress EGFR independent of 
EGFR mutations, however they have low efficiency in K-RAS mutated tumours [129, 155, 156]. It has 
been shown that it has synergistic anti-tumour effects in combination with radiotherapy, in squamous 
cell carcinoma of oropharynx and larynx. Cetuximab improved locoregional control and overall 
survival when administered in these settings [157, 158]. It was found to be well tolerated in combination 
with cisplatin, or carboplatin, and fluorouracil and it can sensitize cells to radiation and chemotherapy, 
possibly by blocking the associated activation of DNA protein kinase enzymes involved in the repair 
of DNA damage induced by radiation and chemotherapy [159]. Combined radiation and cetuximab 
therapy nearly doubled the median survival in certain patients with stage I head and neck cancer [160]. 
Other EGFR targeting molecules won FDA approval: Panitumumab showed activity as single treatment 
in metastatic colorectal cancer resistant to standard chemotherapy; gefitinib and erlotinib, among others 
[161].  
Bevacizumab (Avastin) is another monoclonal antibody currently used in therapy regimens. It 
targets VEGF preventing its interaction with VEGF receptors (VEGFR-1 and VEGFR-2). It was first 
approved in the EU in 2005, for the treatment of metastatic colorectal cancer and later approved for 
treatment of several primary and metastatic cancers as well as for the treatment of recurrent, platinum-
sensitive or platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer [162]. 
As stated before, VEGF promotes the proliferation and migration of vascular endothelial cells, 
increasing vascular permeability, and promotes survival of endothelial cells via the inhibition of 
apoptosis. Solid tumour growth is dependent on the formation of new blood vessels – angiogenesis – to 
supply oxygen and nutrients to the tumour core. Angiogenesis plays a critical role in tumour growth, 
invasion and metastasis. Therefore, blocking tumour angiogenesis can be a therapeutic option to treat 
solid tumours. Anti-angiogenic therapy poses some advantages over conventional chemotherapy since 
it is not directed at killing cells by affecting mitosis but by blocking their supply of nutrients. As 
angiogenesis is a rare event in tissues other than growing tumour, it is well tolerated by patients and has 
few side effects [43, 48, 163–166].  
Recognition and management of toxicity associated with cancer immunotherapy will be a key factor 
for clinical success. The continuous research of tumour associated markers that can be used as antigens 
will be essential for the development of cancer immunotherapy. 
1.4.5 Gene therapy 
Gene therapy started to be fully developed in the early 1990s with the first clinical trials. It consists 
on editing or modulating the genetic information of an individual to treat a disease. Gene therapy can 
target nuclear DNA, using genome editing tools such as clustered regularly interspaced short 
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palindromic repeats (CRISPR/Cas9), or RNA, using anti-sense oligonucleotides and RNA interference 
[167–169]. DNA targeting therapies tend to have a permanent effect in cells, while RNA strategies are 
transient. Both strategies seek to restore missing functionality, or shutdown a dysfunctional gene. The 
main challenge in gene therapy is to deliver the genetic material to cells, using transfection vectors. 
They aim at sustaining stable nucleic acid transport and expression with minimal side effects. These 
transfection vectors can be liposomes, viral particles, recombinant proteins or inorganic nanoparticles, 
each bearing individual advantages and disadvantages [167–169]. Viral vectors for gene transfer 
include adenoviruses, which are the most common gene delivery systems in clinical settings, adeno-
associated viruses, herpes simplex-1 viruses, retroviruses and lentiviruses. Viruses can be efficient gene 
carriers, but they have limited DNA cargo capacity and can cause immunogenicity. Synthetic delivery 
systems generally avoid immune responses and carry higher amounts of cargo [170]. Single-stranded 
antisense oligonucleotides (ASO) consist in a synthetic oligonucleotide vectorized in cells, that is 
complementary to an RNA target. The enzyme RNase H cleaves the RNA strand of DNA-RNA hybrids, 
decreasing their pool and consequent protein translation. Also, ASOs can block gene expression by 
sterically blocking the ribosome to anchor to RNA. In RNA interference a small double strand RNA is 
vectorized inside cells targeting a specific mRNA sequence. Then the RNA-induced silencing complex, 
loses one of the strands, and the remaining strand (the guide strand) binds to complementary RNA. This 
process is mediated by the RNA-induced silencing complex which ultimately cleaves the targeted RNA. 
One of the main challenges in gene silencing methods in that oligonucleotides are unstable inside cells. 
For that reason, modified nucleic acids, or nanotechnology materials are used to increase their stability 
[171, 172].  
Some gene therapy products are already available in the market for clinical use. The first approved 
for human use, only in China, was Gendicine for the treatment of head and neck squamous cell cancer 
in combination with radiotherapy. Other approved gene therapies rely on the use of engineered T cells. 
Chimeric T cell receptors are extracted from a patient and genetically modified to “attack” a specific 
protein. Cells are then injected back into the patient targeting cancer cells and working as a living drug. 
Two therapies are approved for clinical practice, for treatment of B-cell acute lymphoblastic leukaemia 
(Tisagenlecleucel, Kymriah) and large B-cell lymphoma (Axicabtagene ciloleucel, Yescarta) [173].  
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1.4.6 Thermal therapy 
Thermal therapy, also called hyperthermia, is a type of treatment in which body tissues are exposed 
to temperatures up to 45°C. Treatment can be local, regional or whole-body. Exposure of tissues to high 
temperatures increases the fluidity of membranes, promotes protein denaturation, and can cauterize 
blood vessels [174]. Research has shown that hyperthermia can be used to specifically heat neoplasic 
tissue, with minimal effect on normal cells, allowing their use in cancer therapy [175–177]. 
Hyperthermia treatment is generally performed using microwaves, ultrasounds, radiofrequency or 
lasers. By focusing the radiation to a specific site, it can affect cancer cells with a minimally invasive 
procedure. Most of these methods rely on the use of a probe inserted through a body cavity to the tumour 
site. These methods are most often applied to treat tumours that cannot be removed with standard 
surgery or for patients who cannot go through surgery. Its efficacy is related to the temperature achieved 
during the treatment, as well as its duration and tissue tolerance. To assure the desired temperature, the 
tumour and surrounding tissues are monitored with thermometers [174–177]. Imaging techniques, such 
as computed tomography can be used to guide the probes proper positioning [178, 179]. Hyperthermia 
can be repeated for relapse tumours. It is almost always used in combination with other therapies like 
surgery, radiation or chemotherapy. Drug sensitization through hyperthermia can be found in several 
anti-cancer drugs, specially alkylating agents. The increase in temperature enhances tissue perfusion 
and facilitates the absorption of the chemotherapeutic through the cell membrane. Even cells that have 
shown to be resistant to a specific drug, can respond when combined with thermal therapy. Thus, 
chemotherapy becomes more effective, and less toxic. Results from clinical trials have shown 
hyperthermia to be beneficial in the treatment of several types of solid tumours, with improved overall 
survival, compared with patients who only receive radiotherapy or chemotherapy [180–182]. An 
example is the work developed by Valdagni and Amichetti to treat head and neck tumours. They 
demonstrated, on a Phase III randomized trial, that combined treatment of hyperthermia and radiation 
therapy, significantly improved patients’ survival and did not increase acute or late toxicity [183]. Also, 
medical reports on the conjugation of liposomal DOX and hyperthermia show that the combined therapy 
is effective and well tolerated [184, 185]. Hyperthermia is a promising approach to improve cancer 
treatment, but it is still largely experimental. With the developments in technology the benefits of 
hyperthermia will significantly increase. The refinements in heating delivery and monitoring strategies 
will enable an accurate thermal dose control, arriving to deeper organs without affecting superficial 
tissue. Integration with emerging imaging technologies, such as non-invasive magnetic resonance-
based thermometry, and nanotechnology thermal probes will push hyperthermia to the next level of 
cancer treatment. 
  20 
 
1.5 Cancer resistance to treatment 
One of the main causes in cancer treatment failure is the acquisition of resistance to chemotherapy. 
Many cancer types are initially susceptible to pharmaceutical treatment but, over time they start to 
develop drug tolerance. Drug resistance is a well-studied phenomenon that results from events that 
increase cancer cell survival (Fig. 1.3). The major mechanisms of acquired drug resistance are: change 
in drug metabolism, change in drug target, increased drug efflux, decreased drug uptake, increased 
DNA damage repair, and increased resistance to apoptosis. Some anticancer drugs require metabolic 
activation, thus one of the ways cancer cells can develop to resist is through decreasing drug activation 
[186–188]. An example is platinum resistance that can occur through overexpression of metallothionein 
and thiol glutathione, that inactive the drug [151, 189]. Cells can also alter the drug target, to reduce the 
efficacy of the drug. For example, certain anticancer drugs target topoisomerase II, which prevents 
DNA super-coiling and under-coiling, stabilizing the DNA-topoisomerase II complex. This leads to 
inhibition of DNA synthesis, halting the mitotic processes. Resistance to topoisomerase II-inhibiting 
drugs has been described by mutations in the topoisomerase II gene, avoiding drug recognition [190]. 
The same is observed in EGFR family and down-stream signalling (RAS, SRC, RAF, and MEK), 
generally overexpressed in many tumours. Mutations in these genes hinder drug recognition and 
compromise therapy [161].  
DNA damage repair has a key role in anticancer drug resistance. Radiotherapy as well as many 
chemotherapy drugs directly or indirectly damage DNA. DNA damage response mechanisms can repair 
the drug-induced damage. In platinum chemotherapy harmful DNA crosslinks, leading to apoptosis. 
However, resistance to platinum-based drugs can arise by nucleotide excision repair and homologous 
recombination, reversing platinum damage, meaning that the efficacy of DNA-damaging therapies 
relies on the failure of the cancer cells DNA damage response. Mutations in apoptosis-related genes can 
also result in drug tolerance. For instance, apoptosis is triggered by the tumour suppressor TP53, in 
response to chemotherapy, which is found mutated in 50% of cancers. Alternatively, inactivation of 
P53 regulators such as caspase-9 and its cofactor, also leads to drug resistance. In several types of 
cancers, BCL-2 family proteins, as well as other antiapoptotic proteins, are highly expressed, avoiding 
apoptosis and increasing cell survival [114, 134, 191]. 
One of the most studied mechanisms of cancer resistance is via drug efflux. Efflux pumps are a 
member of transporter family proteins that bind to a given substrate in the transmembrane domain and 
mediated by ATP hydrolysis, push the substrate out of the cell. ABC transporter family is the most 
studied and is highly expressed in the epithelium of the liver, intestine and blood brain barrier, 
preventing overaccumulation of toxins within the cell. Being part of physiological processes, ABC 
transporters are also involved in the mechanism of drug resistance in cancer cells. The most studied are 
multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 1 (MRP1), and breast 
cancer resistance protein. These transporters have unspecific substrates, being able to efflux a variety 
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of xenobiotics, protecting cancer cells from many first line chemotherapies. They are commonly 
overexpressed in resistant cancer cells [192–194].  
Reducing the uptake of the drugs can also occur. If a drug depends on a transporter to enter the cell 
cancer cells can acquire resistance by reducing the numbers of transporters. Mutations in these 
transporters can also inhibit and reduce the absorption of the drugs. The resistance to Methotrexate, for 
example, is mediated by the human folate carriers. Gene mutation in these carriers reduces the tendency 
of the drugs to bind the transporter in the patients with acute lymphoblastic leukaemia [188].  
Characterising the genetic profile of tumours can have important implications in the treatment of 
relapses. Primary resistance to EGFR inhibitors therapy has been found in patients with alterations in 
specific genes. Resistance to gefitinib and erlotinib therapy is described in patients with point mutations 
in EGFR (T790), BRAF, PIK3CA, or up regulation in MET, HER2 or loss of PTEN [191]. Resistance 
to ALK inhibitors occurs due to upregulation or mutations in ALK (L1196M), or activation of EGFR 
or KRAS, that bypass the inhibition induced by crizotinib [195]. Second generation inhibitors afatinib 
and ceritinib are FDA approved and promise treatment to patients who no longer respond to first 
generation tyrosine kinase inhibitors for EGFR or ALK. 
Cancer progenitor cells are often drug resistant. These cells remain dormant in patients seemingly 
in remission and can later cause cancer relapse. Due to the plethora of mechanisms of cancer resistance, 
the current paradigm believes that combination therapy increases the chances of an effective treatment 
because it reduces the probability of simultaneous resistance via two or more mechanisms. The future 
steps in anticancer therapy should not only be focused on combined therapy but also in strategies to 
eliminate cancer progenitor cells. To achieve that continuous efforts, need to be performed to 
understand the underlying mechanisms of progenitor cancer cells persistence. 
 
Fig. 1.3 Schematics of different mechanisms of acquired drug resistance.  
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1.6 Nanomedicine 
The most consensual definition states that nanotechnology is the study and use of structures 
between 1 and 100 nanometres in size. The need for a less general definition lead the European 
commission do name it as “the study of phenomena and fine-tuning of materials at atomic, molecular 
and macromolecular scales, where properties differ significantly from those at a larger scale”. The 
National Technology Initiative defines nanotechnology as “the understanding and control of matter at 
dimensions between approximately 1 and 100 nanometres, where unique phenomena enable novel 
applications”. From these definitions we should take three important points about nanotechnology, i) it 
relies on nanometre scale, ii) the properties of the nanomaterial need to differ significantly from the 
bulk, iii) needs to be controllable. Nanotechnology has been revolutionizing several sectors like: energy, 
environment, information technology and medicine [196], and it was described “as an upcoming 
economic, business and social phenomenon” by Thomas Theis (Director of Physical Sciences at the 
IBM Watson Research Center) [197]. 
Growing interest in the medical applications of nanotechnology is leading to the rapid 
development of nanomedicine [198]. The Medical Standing Committee of the European Science 
Foundation states that “Nanomedicine is the science and technology of diagnosing, treating, and 
preventing disease and traumatic injury, of relieving pain, and of preserving and improving human 
health, using molecular tools and molecular knowledge of the human body”. Several nanomaterials 
have been described in the last decades, made of noble metals, carbon, heavy metals, etc. and can take 
many forms: nanoparticles, nanowires, nanotubes and nanofilms. Each nanomaterial can have unique 
properties at nanoscale. For example, carbon nanotubes are excellent conductors with exceptional 
strength; iron oxide nanoparticles are superparamagnetic; while gold nanoparticles (AuNP) have unique 
optical properties. Nanostructures’ primary advantages are that their size is at the same scale of 
biomolecules, and their augmented surface area-to-volume ratio allows an increased interphase area in 
a small mass; they have favourable drug release profiles, and can be modified with targeting agents that 
allow them to reach tumour tissue and release drugs in a stable and controlled manner [199]; they can 
be used to encapsulate and vectorize small molecules that have poor solubility, facilitating their travel 
through the bloodstream and renal clearance. Nanoparticles, due to their reduced sized, have also the 
advantage of accumulating naturally in tumours by EPR effect [199]. Currently, a wide variety of 
nanoformulations are being investigated for cancer treatment, including lipid-based, polymer-based, 
inorganic, viral, and drug-conjugated nanoparticles. Some of these are already approved for clinical use 
(Table 1.2).  
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Table 1.2 Currently approved nanomedicines in the clinic. Adapted from [199]. 
Name Type Active drug Year approved Diameter Type of cancer 
Zinostatin 
stimalamer 
Polymer 
protein 
conjugate 
Styrene maleic 
anhydride 
neocarzinostatin 
(SMANCS) 
Japan (1994) 
not 
described 
Renal cancer 
Doxil/caelyx 
Liposome 
(PEGylated) 
Doxorubicin 
FDA (1995), EMA 
(1996) 
80-90 nm 
HIV-associated 
Kaposi’s sarcoma, 
ovarian cancer, 
metastatic breast 
cancer, multiple 
myeloma 
DaunoXome 
Liposome 
(non-
PEGylated) 
Daunorubicin FDA (1996) 45 nm 
HIV-associated 
Kaposi’s sarcoma 
Lipo-Dox Liposome Doxorubicin Taiwan (1998) 180 nm 
Kaposi’s sarcoma, 
breast and ovarian 
cancer 
Myocet Liposome Doxorubicin EMA (2000) 190 nm Breast cancer 
Abraxane 
Nanoparticle 
albumin 
bound 
Paclitaxel 
FDA (2005) 
EMA (2008) 
130 nm 
Advanced non-
small-cell lung 
cancer, metastatic 
pancreatic cancer, 
metastatic breast 
cancer 
Oncaspar 
PEG protein 
conjugate 
L-Asparginase FDA (2006) 50-200 nm Leukaemia 
Genexol-PM 
PEG-PLA 
polymeric 
micelle 
Paclitaxel South Korea (2007) 20-50 nm 
Breast cancer, Lung 
cancer, Ovarian 
cancer 
MEPACT 
Liposome 
(non-
PEGylated) 
Mifamurtide EMA (2009) 
not 
described 
Osteosarcoma 
NanoTherm 
Iron oxide 
nanoparticle 
- EMA (2010) 20 nm 
Thermal ablation 
glioblastoma 
Marqibo 
Liposome 
(non-
PEGylated) 
Vincristine FDA (2012) 100 nm 
Philadelphia 
chromosome 
negative acute 
lymphoblastic 
leukemia 
MM-398 
(Onivyde) 
Liposome 
(PEGylated) 
Irinotecan FDA (2015) 80-140 nm 
Metastatic 
pancreatic cancer 
(2nd line) 
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1.6.1 Gold Nanoparticles 
AuNP have been extensively studied mostly due to their unique optical properties, easy 
synthesis and functionalization, and low toxicity. AuNP exhibit a surface plasmon resonance conferring 
them a light extinction cross sections, 5 to 6 times higher than common fluorophores. They can enhance 
fluorescence or quench fluorophores in its vicinity, and enhance the Raman scattering of molecules on 
a process called surface enhanced Raman scattering. They also have the capacity to convert light to heat 
with efficiencies that can reach almost 100% depending on their size. AuNP range in diameter from 
small atom clusters of 2-5 nm up to 100 nm particle, and each size can have different properties. Smaller 
particles tend to extinct light in blue region of the spectrum, and have almost neglectable scattering, 
while bigger particles extinct light in the red region mainly by scattering. Also, their shape can vary, 
from spheres, hollow, rods, diamonds, prisms, cages, either single solid bodies or in a core shell format 
with other metals [200, 201]. Different combinations of sizes and shapes can serve different purposes, 
taking advantage of each NP optical properties, photothermal capability in the infrared and near-infrared 
(NIR), biofunctionalization potential and toxicity [202, 203].  
Many synthesis methods of AuNP have been described, in water, organic solvents or even 
interphases. The most common are water-based and rely on the same principle: chloroauric acid 
(HAuCl4) is dissolved in water, then a reducing agent reduces Au3+ ions to Au0. These atoms start to 
aggregate in clusters growing in diameter until they get saturated of capping agent that protects them 
from aggregation, and then they precipitate in the form of sub-nanometre particle. The concentration of 
gold salt, reducing agent and capping agent is crucial to set the final AuNP size and shape. One of the 
quickest protocols describes the synthesis in five minutes, by adding sodium citrate to chloroauric acid, 
assisted by microwave radiation. Gold surface has a high affinity to certain groups, namely thiols, 
amines and phosphates. The development of several surface functionalization tools enabled AuNP to 
be decorated with almost any kind of biomolecules, from imaging moieties (e.g., fluorophores, 
quenchers, reporters) to targeting molecules (e.g., antibodies, peptides, sugars), stabilizers (e.g. PEG), 
and even therapeutic agents (e.g., chemicals, therapeutic oligonucleotides) (Fig. 1.4).  
The number of potential applications in medicine as increased since they have been considered 
to exhibit low toxicity and high chemical stability [204–206]. Despite the divisive studies about AuNP’ 
toxicological impact in vivo, spherical AuNP between 10 and 60 nm in diameter are generally 
considered as non-toxic. In fact, toxicity may vary with administration route, concentration and surface 
coverage but also with the nanoparticles’ sizes and shapes. The difficulty in standardization of the 
nanoconjugates, their characterization and of the effect of monitorization, has largely hampered forming 
a clear-cut definition for nanosafe AuNP [207, 208]. For example, larger particles, 45 nm in size, have 
been demonstrated to exhibit higher cytotoxicity at a lower concentration (10 μg·mL-1) than those 13 
nm in size (75 μg·mL-1) [209]. Oral and intraperitoneal administration routes showed higher toxicity 
than tail vein injection [210]. Sharp-edged nanoparticles tend to have higher cytotoxicity than rounded 
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ones, with several studies showing that lower concentrations are needed for stars and flowers to induce 
toxicity, compared to nanospheres [211, 212]. On the other hand, sharp-edged conformations are more 
prone to endosomal escape favouring drug delivery [213]. Extensive and standardized studies on 
nanotoxicity are needed to effectively assess the effect of AuNP in the human body, but that can only 
be achieved after stablishing characterization criteria for the nanomaterial, that assure that the 
comparable materials are being used across studies.  
 
Fig. 1.4 Different types of nanoparticles and their applications in theragnostic. Schematic overview of 
the possible functionalization and application of AuNP as nanocarriers for theragnostic.  
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1.6.2 Targeting and Delivery 
AuNP can be functionalized with molecules to provide for targeting and to enhance stability and 
biocompatibility in vivo. There is a wide range of stabilizers available that may also act as therapeutic 
agents (e.g., miRNA, siRNA, DNA, peptides and antibodies) or to reduce NPs’ immunogenicity (e.g., PEG). 
In fact, polyethylene glycol (PEG) of different molecular weights is one of the most frequently used 
biomolecules to increase NPs’ circulation half-life and improve cellular uptake [214, 215]. When 
referring to PEG grafting to AuNP’ surfaces, bi-functional PEGs (with a thiol group in one extremity and 
another group at the other end – amine, carboxylic, biotin, azide) have been widely used for direct 
coupling to another molecule of interest via straightforward chemistry with high yield [204, 216]. AuNP 
can be further engineered to trick the immune system, avoid removal from circulation (by becoming 
trapped in the liver, kidneys, spleen) or to cross biological barriers (e.g., blood-brain barrier), in order 
to increase therapeutic efficacy and allow systemic tracking [217]. 
Passive targeting takes advantage of the fact that vessels surrounding the tumours are leaky, due to 
incomplete endothelial linings, allowing nanomedicines to reach the tumour through the enhanced 
permeability retention (EPR) effect alone. Generally, particles between 10 nm and 60 nm in diameter 
tend to passively accumulate in tumour tissues enabling, for instance, higher drug payload at the tumour 
site and circulating half-lives about 100 times longer than that of free anticancer drugs, with reduced 
systemic toxicity [218, 219]. However, this strategy depends greatly on the degree of tumour 
vascularization and angiogenesis and on heterogeneous blood flow, which limit drug uptake and 
homogenous distribution within the tumour. Several approaches may overcome these limitations, for 
instance, using vasoconstrictive drugs. These agents cause normal vessels to constrict and blood pressure 
to increase, while tumour vessels do not respond to this effect because of insufficient muscular structure, 
thus leading to a relative increase in the input function of tumour tissues [220]. These leaky effects may 
also have an important role in the treatment of other pathologies. Spivak and co-workers developed and 
tested a gold nanoformulation for drug delivery and treatment of heart failure by demonstrating that 
levosimendan functionalized AuNP (Simdax®) were able to accumulate in the endothelial cells of 
infarcted arterioles and capillaries. The nanoformulation showed significant cardioprotective effects in 
DOX-induced heart failure rats, higher than that of Simdax® alone. When comparing the route of 
administration (intravenous injection, sonoporation – cell permeation by ultrasounds and local, and 
intrapleural (local delivery) injection, the best results were obtained using intrapleural injection, 
showing the importance of the administration route for effective treatment [221]. 
Another strategy relies on attaching targeting moieties to the nanoparticle surface. Typically, 
nanoparticles reach target cells through ligand-receptor interactions that induce receptor-mediated 
endocytosis and drug release inside the cell [219]. Peptide conjugation to AuNP is one method by which 
active and specific targeting may be used for enhanced tumour accumulation/delivery [222]. Successful 
targeting has also been achieved via functionalizing AuNP with antibodies that target specific receptors 
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overexpressed by cancer cells. EGFR and folate receptors are two well-known overexpressed proteins in 
cancer cells used for designing antibody-gold nanoconjugates for active targeting [223, 224]. EGFR exists 
on the cell surface and it is mostly activated by binding of EGF and TGF-α. Genetic mutations led to 
EGFR permanent activation and uncontrolled cell division independently of the EGF or TGFα presence. 
About 30% of epithelial cancers show misregulation in EGFR or other family members [225]. The use of 
Cetuximab (Erbitux®, Merck, Germany), an FDA approved monoclonal antibody that specifically binds 
EGFR and turns off its downstream signalling pathways, has been shown to be a useful targeting and 
therapeutic moiety in mice, vectorizing the nanoparticles to the tumour site [224, 226, 227]. Most of the 
accumulated particles stayed in the tumour for 72 h post tail-vein injection [223]. Others have also 
described the use of EGFR targeted ligands for active targeting [228], such as C225 antibody [229, 230]. 
It was shown that using this antibody, increases the uptake of nanoparticles by mice xenographs in EGFR-
positive compared to EGFR-negative cells [230]. Folate receptor is responsible for the internalization of 
folic acid and several studies confirmed that about 80%-90% of ovarian tumours overexpress this 
receptor [231]. Drug-folate conjugates have therefore been at the forefront for selective tumour 
targeting in preclinical studies [139, 232–236]. It was demonstrated that folate functionalized 
nanoparticles were 4.7 times more directed to tumour cells and internalized by endocytosis into 
lysosomes when compared to non-functionalized NPs [237].  
Targeting has been crucial for the development of vectorization systems capable of site-specific 
accumulation/retention enabling nanoparticles to deliver their cargo on site for improved therapeutic 
effect [218]. Some authors have been focusing their attention on developing nanovectorization systems 
that mediate cargo delivery upon a particular stimulus, such as pH, increased heat, ultrasound, light and 
magnetic field. Tumour cells usually become hypoxic and exhibit high glycolytic activity, thus 
producing carbonic and lactic acids [238]. Coating nanoparticles with pH Low Insertion Peptides 
increase efficiency of targeting acidic diseased tissues. Being membrane peptides, they have affinity to 
cellular membranes and targets extracellular acidity. In contrast to other pH-sensitive systems, it tracks 
acidity at the surface of cancer cells [239]. Photothermal conversion of light into heat can increase target 
cells’ temperature, enough to directly kill cells [240], but also to release therapeutic moieties at the 
tumour site [241]. In fact, a study shows the photothermal induced release of DOX from DOX-loaded 
gold nanocages. By the degradation of a thermal sensitive polymer covering the NPs when the medium 
reaches 45 °C, DOX is released in a time dependent manner. Authors were able to significantly decrease 
cell viability of breast cancer cells in vitro, by precisely controlling DOX release [242]. In a similar 
manner, ultrasounds and magnetic fields can locally increase temperature and precisely deliver cargo. 
Despite the broad range of targeting approaches, there is still much more to explore in this field with 
many groups still looking for new effective targeting moieties that allow tumour specific accumulation 
and retention for improving drug release and therapeutic efficacy [218, 238]. 
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1.6.3 Therapeutic Agents 
Drug discovery coupled with preclinical studies strongly focus on overcoming general issues that 
hamper the efficacy of drugs, such as limited solubility, high toxicity, high dosage, nonspecific delivery 
and short circulating half-lives. Due to the advances in nanotechnology-based drug delivery, the current 
idea has been to repackage classic drugs using targeted delivery systems to increase patient compliance, 
extend the product life cycle and reduce healthcare costs. These agents might be a small drug, a 
peptide/antibody, a ribozyme, a siRNA or an ASO [243]. Probably the most studied and used concept 
has been the previously mentioned Doxil® (Janssen Products, LP, Horsham, PA), where DOX has 
shown improved efficacy when encapsulated into PEGylated liposomes. In fact, traditional 
chemotherapy drugs have followed suit and been encapsulated and delivered in similar engineered 
vesicles.  
AuNP and DOX nanoformulations attempted to mimic their liposome counterpart and showed 
promising advantages, such as increased targeting and functionalization as well as the possibility to couple 
with phototherapy and to act as imaging/contrast agents [142, 146]. Various AuNP shapes have been 
functionalized with DOX – stars [244], clusters [245], shells [246], hollow spheres [247], etc. – showing 
the versatility of the nanoconstructs and their ease of functionalization. All previous examples were 
tested in vivo and have shown increased efficiency when compared with DOX alone, as well as lower 
levels of cytotoxicity. 
AuNP have been also applied in approaches with other anti-tumour drugs (e.g., platinum (IV) 
prodrugs [248], 5-Fluorouracil [249], Irinotecan [237], Camptothecin [250]). Dhar and collaborators 
showed a significant increase in cytotoxic effects for the Pt(IV)-AuNP complex when compared with 
the free Pt(IV) prodrug, as well as the free cisplatin. The Pt(IV) prodrug was activated into its cytotoxic 
form, cisplatin, only after crossing the cell membrane and undergoing intracellular reduction [248]. 
Camptothecin is a cytotoxic quinoline alkaloid which inhibits DNA topoisomerase I [251]. 
Camptothecin showed remarkable anticancer activity in preliminary clinical trials for a broad spectrum 
of tumours but also low solubility and adverse effects. Shi and collaborators described the use of gold 
hollow, nanocage shells layered with mesoporous silica and a thermosensitive polymer loaded with 
Camptothecin. The drug is tightly packed inside the nanoconstruct with a “leakage” of only 6.8% to the 
medium after 14 h in in vitro conditions. NIR triggered release of the drug leading to increased tumour 
cell death, compared with the only NIR and nanocarrier experiment [250]. For rheumatoid arthritis 
treatment, iron-AuNP have been functionalized with methotrexate allowing for simultaneous chemo-
phototherapy and imaging with lower dose (0.05%) without compromising efficacy and/or increasing 
toxicity [252]. 
Gene therapy has been receiving increasing attention in tumour suppression due to the possibility to 
downregulate specific oncogene expression or to sensitize cells in an intra-cellular targeting process. In 
particular, small interfering RNA has shown potential to downregulate specific gene expression in 
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cancer cells [204]. Since naked siRNAs show extremely short half-lives due to cellular RNases activity 
and poor chemical stability, the development of efficient delivery vehicles for in vivo applications 
remains a major obstacle in translating siRNA into effective therapeutics. AuNP have been widely used 
as nanovectorization for gene silencing strategies [253–258]. Almost all the different shapes and sizes 
of AuNP reported above have been used to vectorize gene silencing elements into cancer cells [258–
260]. Feng Yin reported the use of a light-triggered therapy using gold nanorods as nanocarriers for 
dual-delivery of DOX and KRAS gene siRNA. The synergistic effect of the chemo- and gene-therapy 
allowed the reduction of the tumour volume rate by 90% in vivo [261]. Gold spheres were described for 
siRNA targeting and delivery [262, 263] using models of increasing complexity (cells, hydra and mice), 
achieving effective silencing of c-MYC gene (~65% reduction in expression). It was also shown that 
covalently bounded siRNAs were more effective silencers than siRNAs adsorbed on the surface of the 
NPs [263]. Different molecular concepts for gene silencing rather than siRNA have also been used to 
block a particular gene. 
Our group was pioneer in the use of hairpin ssDNA structures vectorized via AuNP to particularly 
silence any possible RNA mediated pathway inside the cell [258, 264, 265]. In fact, the molecular 
actuator thus developed – gold nanobeacon – can be visualized in situ while silencing (See Figure 2), 
since the hairpin may be further functionalized with a fluorophore, whose fluorescence is triggered once 
the silencing event occurs. The potential of this system has been further characterized in vitro and in 
vivo with low toxicity [206, 263, 266]. Furthermore, this system was shown to be effective in vivo in a 
promising approach to combat multi-drug resistant tumours, combining in the same particle an 
antitumor agent (5-fluorouracil) with silencing of MRP1, a gene associated with acquired resistance in 
several tumours. In vivo results showed a remarkable tumour size reduction, from the synergic effect of 
the two agents [249].  
 
Fig. 1.5 Schematics of a multifunctional approach, coupling targeting, chemotherapy, gene therapy, 
phototherapy and diagnostics by fluorescent imaging. 
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1.6.4 Phototherapy 
Photothermal therapy (PTT) is based on the selective sensitization of cells to thermal damage, or 
hyperthermia, near 45 °C. What is more, traditional PTT may be coupled to AuNP and profit two ways: 
(i) the possibility to vectorize additional cargo and use the nanoparticle as scaffold for selective 
targeting; and (ii) enhance PTT by the AuNP’ ability to convert absorbed photons into thermal energy. 
By modulating the AuNP’ shape and/or shell thickness, it is possible to shift the localized surface 
plasmon resonance (LSPR) peak of AuNP toward the NIR, allowing deeper light penetration into 
tissues. Moreover, the laser energy required to achieve this transformation is far below that stipulated 
in medical safety standards. AuNP-mediated PTT is predominantly associated with nanorods, 
nanoshells and nanocages [202, 267]. One of the reported strategies was to use functionalized gold 
nanorods with chemotoxic cisplatin, biocompatible polypeptide poly-l-glutamic acid and tumour 
targeting folic acid. When administered systemically on tumour-bearing mice, and in combination with 
localized NIR laser, the resulting hybrid nanoparticles were able to significantly inhibit tumour growth 
and dissemination of cancer cells from the primary site to the lung by eliminating the peripheral tumour 
blood vessels (a similar approach is depicted in Fig. 1.5).  
Another interesting strategy that can be coupled to nanosized structures is photodynamic therapy, 
which involves the administration of a nontoxic agent that acts as a photosensitizer and a laser source. 
Photoexcitation of the photosensitizer leads to the generation of free radicals, which destroy tumour 
tissue. The chosen wavelength of irradiating light should ideally be one that is absorbed to a greater 
degree by the tumour tissue relative to the surrounding healthy tissue [228, 268]. Combining 
photodynamic therapy with AuNP has proven to be a good strategy to overcome two of its major 
limitations: the dark toxicity of the photosensitizer and the poor selectivity of the cellular uptake of 
between the target cells and normal tissues. In fact, a study describes the targeted delivery of AuNP 
functionalized with EGF peptide and the photodynamic agent Pc 4. In vitro experiments show that the 
nanoconjugate is two-fold more efficient at killing tumour cells than free Pc 4, due to enhanced 
localization in early endosomes [228]. In another research work, AuNP were functionalized with 
methylene blue, a known photosensitizer; polystyrene-alt-maleic acid, a polymer that prevents methylene 
blue leakage; and transferrin, for specific receptor-mediated endocytosis. Au@polymer/methylene blue-
transferrin were excited by a dark red-light source at 660 nm and showed a two-fold enhancement of 
photodynamic therapy efficiency toward in vitro cervical cancer cells over the use of free methylene 
blue at four times dosage. Besides being an effective and easy way to induce cell apoptosis, this system 
proved to be safe since no significant dark toxicity was found [269]. 
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1.6.5 Tackling angiogenesis 
The development of new blood vessels from pre-existing vessels is essential to modulate tumour 
microenvironment, increasing the levels of oxygen, nutrients and decreasing toxic metabolites [40]. A 
major advantage of AuNP in cancer treatment is their capacity to disrupt signal transduction from 
tumour mesenchymal cells to epithelial cells as well as inhibiting angiogenic phenotypes in vitro [270]. 
Among VEGF subtypes, the isoform VEGF165, a heparin binding protein, is the most potent cytokine 
in angiogenic process. By binding with tyrosine kinase receptor VEGFR-2, a cascade signal is initiated 
ultimately leading to the proliferation and migration of endothelial cells and angiogenesis [271, 272]. 
Therapeutic antibodies targeting VEGF165 have been developed and are currently applied in the clinics 
to inhibit VEGF165. Naked AuNP have been reported as inhibitors of pro-angiogenic such as 
VEGF165, basic fibroblast growth factors and placental growth factor [165]. The naked surface of 
AuNP inhibits heparin-binding growth factors, by changing its conformation. However, they do not 
affect the activity of non–heparin binding growth factors, like VEGF121 and EGF. These results have 
been corroborated in vivo, where VEGF/vascular permeability factor induced permeability was 
inhibited by AuNP [271, 272]. Zhang et al., 2019 state that AuNP also influence angiogenesis, 
diminishing the tube formation and migration of endothelial cells, by blocking the VEGF-VEGFR2 
signalling from tumour microenvironment cells to endothelial cells [270]. Another study stated that 
AuNP promote tumour vasculature normalization while increasing blood perfusion and reducing 
hypoxia [273].  
Not only naked AuNP but also AuNP-conjugates have been described as modulators of 
angiogenesis. Recombinant human endostatin is an anti-angiogenic agent used for tumour treatment. 
Pan et al., 2017 developed a recombinant human endostatin–AuNP that reduced cell migration and tube 
formation in vitro (human umbilical vein endothelial cells cells), induced by anterior gradient 2 
(AGR2). AGR2 is one of the latent tumour angiogenesis factors, and have been mostly related to tumour 
cell proliferation, transformation, migration and drug resistance. Results of in vivo experiments, using 
metastatic colorectal cancer xenografts, indicated that recombinant human endostatin–AuNP increase 
pericyte expression while inhibiting VEGFR2 and anterior gradient 2. These indicate that this nano-
conjugation might be used to normalize tumour vessels using AGR2 as an anti-angiogenic tumour target 
[274]. Kanaras group as reported a peptide, designed to selectively interact with VEGFR1 for inhibition 
of angiogenesis. By grafting the peptide on AuNP, authors show that the nano-construct can influence 
the extent and morphology of vascular structures, without causing toxicity [275, 276]. By exposing a 
chicken chorioallantoic membrane (CAM) to the AuNP-peptide, our group showed that the nano-
formulation is more effective at inhibiting angiogenesis than the free peptide [277]. These studies show 
that AuNP can be used to alter the expression of anti-angiogenic factors, under biological conditions. 
The use of nanoparticles to control angiogenesis opens a new door in targeted drug delivery and therapy 
for angiogenesis. 
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1.6.6 Multimodal Imaging 
The implementation of imaging techniques for diagnostic purposes enables the non-invasive 
assessment of anatomical, functional and molecular information, with image-guided drug delivery 
gaining much attention nowadays [278]. The imaging modalities most often used in the clinics are CT, 
ultrasound, magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon 
emission computed tomography (SPECT), photoacoustic tomography and fluorescence imaging [279]. 
When choosing an imaging technique, one should take into consideration several parameters: target tissue, 
resolution, sensitivity, contrast and implementation. CT is a commonly used diagnostic imaging tool 
offering broad availability at a relatively modest cost. This modality usually provides image contrast to 
visualize tissue density differences and may be tuned to distinguish between normal and cancerous 
tissue. However, the iodinated molecules that are typically used as CT contrast enhancers tend to 
undergo a rapid renal clearance and nonspecific vascular permeation causing a decrease in the technique 
sensitivity. MRI displays high spatial resolution and soft tissue contrast but is expensive and time-
consuming. Ultrasound imaging offers high resolution at much lower cost than MRI or PET/SPECT 
but has low depth penetration. PET/SPECT are particularly suited for targeted in vivo molecular 
imaging and their advantages include high sensitivity, absence of tissue penetration limit, and the ability 
to make quantitative measurements, however, these techniques expose the patient to ionizing radiation. 
Photoacoustic tomography allows the reconstruction of images with improved spatial resolution and 
excellent image contrast when compared to conventional optical imaging [279–283]. 
Imaging techniques can take advantage of the photoacoustic phenomenon that is generated upon 
formation of nanobubbles. Shao et al. describe the use of this technique for gold nanoparticle tracking 
in mice, observing individual gold clusters, however, it works best on soft tissues and has depth-of-field 
limitations [284]. AuNP are also optimal contrast agents for CT, due to the relatively high X-ray 
attenuation of gold and the stability of gold colloids. Since gold has higher absorption than iodine, 
AuNP can achieve better contrast with lower X-ray dose [285]. On the contrary, AuNP do not possess 
intrinsic properties that enable their visualization through MRI; hence, they are usually combined with 
super-paramagnetic iron oxide, gadolinium or manganese, demonstrating significant contrast 
enhancement in tumour models [252]. Furthermore, in vivo studies with gold nanorods labelled with 
radioactive iodine enabled photothermal therapy towards ovarian cancer and monitoring of 
nanoparticles’ distribution via SPECT/CT imaging. Tumour sites were clearly visualized from the 
SPECT images even at 24 h post-injection [286]. 
Fluorescence imaging is highly suitable for high-throughput screening with high sensitivity, 
providing detailed molecular profiling with subcellular resolution, enabling multicolour imaging and 
being relatively inexpensive, but has low tissue penetration and spatial resolution, thus limiting its 
applications in clinical settings. Using the NIR part of the spectrum for fluorescence-based imaging, 
spatial resolution is improved and autofluorescence is highly reduced making the technique much more 
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attractive for clinical applications [287]. Indeed, a study combined chemo-, photo-, and thermotherapies 
with fluorescence imaging capability for diagnosis under NIR light illumination. For that purpose, it 
was developed a nanoplatform consisting of: a core biodegradable matrix loaded with Dox; a gold 
nanoshell, required for thermal therapy and drug encapsulation/release; and an outer layer consisting of 
plasma protein human serum albumin, for stealthiness, to which the fluorescent dye indocyanine green 
was conjugated, thus providing the nanostructure the capability to emit fluorescence in the NIR range, 
but also to produce singlet oxygen species (essential for the photodynamic therapy); finally, folic acid 
was also covalently linked to the protein surface for targeting. The effectiveness of the contrast agent 
was clearly enhanced by positioning the dye near the metal surface while tuning the plasmon resonance 
of the nanoshell to the emission wavelength of the fluorophore. In vivo fluorescence imaging using 
tumour-bearing mice demonstrated that the nanoconjugates are localized and retained in the tumour 
region for at least 48 h. Moreover, a larger fluorescence emission was perceived when using these 
nanostructures in comparison with the images obtained with similar NPs synthesized without the gold 
nanoshell component [234]. 
Owing to their underlying physical principles and distinct benefits/drawbacks, one can take 
advantage of combining two or more techniques in a single nanocarrier, avoiding a repeated challenge 
to the patient’s immune system and providing more accurate and dependable data on the patient’s 
condition than using a single imaging moiety [288, 289]. Combining CT, surface-enhanced Raman 
scattering (SERS, of molecules adsorbing on a noble metal surface) and thermal imaging, it was possible 
to accurately detect gold stars located in the tumour and further confirm photothermal effectiveness 
with a thermal camera [290]. Other successful examples of combined imaging modalities using AuNP 
include: a multicomponent nanocapsule used for real-time ultrasound and high resolution MRI for 
image guided photothermal tumour ablation [291].  
Since the challenges of efficient tumour treatment include accurately identifying the location and 
size of tumours and monitoring the effectiveness of therapy after treatment, integration of contrast-
enhanced diagnostic imaging capability with photothermal therapy is a winning bet in the fight against 
cancer. Overall AuNP can be compared with toolbox that allows diagnosis, imaging therapy in the same 
platform. This concept is called theragnostic, a new field of medicine which combines specific 
diagnostic and local targeted therapy and treatment response monitoring. Theragnostic allows a 
transition from conventional medicine to a more personalised and precise.  
  
  34 
 
1.6.7 Theragnostic in cancer 
Significant efforts have been made in the past years towards understanding the genetic and 
pathophysiological processes contributing to malignant transformation and tumorigenesis. The 
overwhelming amount of information thus retrieved is now being translated into the field of biomarker 
discovery and foster cancer therapy by selective interference with cancer hallmarks. Despite these 
efforts, conventional cancer therapy, including surgery, chemotherapy and radiation, lack target cell 
specificity and are often disconnected from individual diagnosis. Also, the efficacy of conventional 
therapeutic strategies is often limited by the acquisition of MDR by tumour cells and by poor drug 
penetration into the tumour [292]. This is why several molecular targeted therapeutics have been designed 
to selectively target tumour cells, the benefits being improved efficacy and decreased toxicity [293]. These 
novel targeted therapeutics may be engineered to simultaneously provide information about delivery, 
biodistribution and diagnostics, e.g., as imaging agents allowing disease detection at its early and 
asymptomatic stages [216]. Theragnostic, has promised to significantly increase the precision and 
effectiveness of treatment, shifting the current clinical standard from generalized procedures to a 
personalized or precise approach [294–297]. Consequently, theragnostic shows particular impact in 
heterogeneous diseases that require individualized and tailored methods of treatment and monitoring, such 
as cancer [285, 298, 299], rheumatoid arthritis [300], infection and cardiology [301, 302].  
With proven results in vivo, and single cell precision, plasmonic nanobubbles (PNB) are an example 
of an innovative, valuable tool in theragnostic [303]. PNBs are generated due to the interaction of short, 
high-energy optical pulses and plasmonic nanoparticles. Depending on the laser intensity, the precision 
of the shockwaves can disrupt lysosomes – promoting lysosomal escape – or cellular membranes 
leading to cell death. PNB have therefore a mechanical effect by nature and not a thermal one. The PNB 
have also interesting optical properties, greatly enhancing light scattering around the nanoparticle, and 
have increased photoacoustic signal, making them good imaging probes for diagnostics [229, 230, 304]. 
In mouse models, PNB were able to detect between 3 and 30 residual cancer cells which were 
undetectable with current methods. Then PNB-guided surgery destroyed those cells preventing local 
recurrence. Nanotechnology has proven its capability to engineer solutions to enhance theragnostic 
monitoring therapeutic efficacy noninvasively and in real-time. This tailored approach enables physicians to 
customize treatment based on each patient’s responses and needs, thereby preventing unwanted deleterious 
side-effects or sub-optimal dosage that might lead to drug resistance, incomplete remission and relapse [298, 
305, 306]. 
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1.6.8 From Research Lab to the Clinic 
The use of gold in medicine dates to 2500 BC when Chinese and Arabic physicians used gold 
preparations in their practice. Medieval physicians used mixtures of colloidal gold for various ulcerative 
skin conditions. In the 20th century, several formulations of gold salts were used to treat tuberculosis, 
lupus vulgarus, syphilis and rheumatism. In 1997, Guy Abraham and Peter Himmel reported the use of 
20 nm AuNP for rheumatism treatment in 10 patients with doses of 30 mg [307]. Their results showed a 
“rapid and dramatic” positive effect on the tenderness and swelling of joints with no evidence of toxicity 
in any of the patients. Since then, there have been no follow up studies on AuNP for rheumatism in 
clinical settings. 
Recombinant human tumour necrosis factor alpha (rhTNF) was applied in the 80s with remarkable 
antitumor effects in mice, inducing apoptosis, cytolysis or cytostasis of tumour cells. However, multiple 
phase II studies with more than 156 patients, resulted in only one complete and one partial response at the 
maximum tolerated dose, which may correlate to low therapeutic dose at disease site. CYT-6091 from 
Cytimmune was the first product on clinical trial using AuNP for patients with advanced solid tumours 
(NCT00356980, NCT00436410). The nanoformulation is composed of PEGylated 27 nm AuNP 
functionalized with rhTNF. It was administered systemically to 30 patients at doses of rhTNF that were 
previously shown to be toxic, without detectable side effects [308]. In addition, gold was found in breast 
tumour tissue but not in healthy breast tissue showing the potential of this approach. Phase II clinical 
trials are ongoing, aiming at understanding if this nanotechnology approach induces greater vascular leak by 
dynamic contrast-enhanced MRI and to evaluate the safety and efficacy of CYT-6091. 
AuroLase® is an FDA-approved pilot study that uses silica-gold nanoshells with a NIR laser for 
photothermal therapy (NCT00848042, NCT01679470). Nanoparticles called AuroShells are injected 
intravenously in the patient’s blood stream and accumulate passively in the tumour. This clinical trial 
was designed to evaluate the approach’s effectiveness for the treatment of advanced lung tumours 
resulting from either primary lung cancer or metastatic tumours in the lung. Although the trials are 
complete, the results have not yet been disseminated. 
The results for NANOM FIM, a completed phase I\II clinical trial (NCT01270139) using silica-
AuNP, were recently revealed. Developed for the treatment of coronary atherosclerosis, two approaches 
were taken: core-shell silica-AuNP group and core-shell silica-AuNP iron bearing group. For the 
former, NPs were administered via surgical inclusion of a patch composed of a sliced porous bovine 
pericardium biological scaffold with inserted growing multi-layered purified allogeneic stem cells with 
the initial mesenchymal phenotype. NPs were activated with an NIR laser at seven days after the 
intervention using a plasmon photothermal strategy. For the latter, the iron bearing NPs were managed 
with intracoronary infusion of allogenous stem cells and CD68 targeted micro-bubbles. CD68 targeted 
micro-bubbles were destroyed by ultrasounds and the nanoparticles were magnetically targeted to the 
vessel and lesion. NPs were also detonated with the NIR laser at the end of the procedure under the 
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protection of anti-platelet therapy. For therapeutic analysis, quantitative coronary angiography and 
intravascular ultrasound were performed pre-, post-procedure and at a 12 months follow-up. The results 
showed 12.6% reduction in the percentage atheroma volume post procedure, 44.8% in the 12 months 
follow up for the first group, and 13.1% atheroma volume reduction post procedure, and 44.8% in the 12 
months follow up for the second group. The plasmonic resonance therapy using silica-gold NP proved 
efficient regression of coronary atherosclerosis in both approaches with acceptable levels of safety [309]. 
1.6.9 Commercial Impact  
Nanotechnology R&D continues to grow in importance both in terms of public and private funding. 
Indeed, global demand for nanotechnology medical products grew by 17% from 2009 to 2014 [310]. 
The United States National Nanotechnology Initiative investment in nanotechnology Research & 
Development (R&D), policy and regulation since 2001 now totals a staggering $22 billion, with the 
2016 US federal budget providing more than $1.5 billion for the National Nanotechnology Initiative 
[311]. The European Union and Japan are investing substantial resources in nanotechnology, with a 
comparable level to the United States [312]. The returns are expected to surpass the investment, and the 
medical field appears to be a front runner in nanotechnology innovations. Nanoparticle based drug 
delivery is one of the major areas, providing a wide range of formulations that are now beginning pre-
clinical or clinical trials. Besides the traditional hurdles conventional therapeutics face to enter the 
clinics, nanomedicines also face a lack (or the deficiency) of protocols for the characterization of these 
products in terms of absorption, distribution, metabolism, excretion, and toxicity [313, 314]. However, 
the FDA, in collaboration with the Nanotechnology Characterization Laboratory, has released 
guidelines describing how it defines a nanoscale product – specifically, as having at least one dimension 
between 1 and 100 nm, or as being less than a micron in size, and demonstrating size-dependent behaviour. 
These agencies are now drafting protocols to address nanomedicines’ regulatory and safety gap. The 
European Commission has also established several goals in terms of nanotechnology regulation, 
patenting and business creation, with international cooperation being a key asset to improving R&D. 
Bringing the EU together with countries who are active in nanotechnology research (USA, Japan, 
Switzerland and Russia) could pave the way for standardized protocols and further initiatives [312]. 
The fact that nanotechnology is one of the sections included in the Horizon 2020, the biggest EU R&D 
Innovation Programme, shows the commitment to this subject and its importance in increasing Europe’s 
competitiveness. Its main objectives include scaling up laboratory experience to industrial settings; 
ensuring the safe development and application of nanotechnologies in health and the environment; and 
proving the significant long-term benefits provided by nanotechnology-based systems, in terms of 
health care and quality of life [315]. 
Nanomedicines are still at an early development stage and, thus, their impact on health spending and 
cost effectiveness is still difficult to predict. Can these formulations compete with conventional products 
in the medical sector? For example, examining the cost-effectiveness of chemotherapy (gemcitabine) 
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vs. nanotherapy (PEGylated liposomal DOX) for ovarian cancer showed that the chemotherapy pre-
treatment costs were cheaper by €1285. Nonetheless, these costs were more than offset by administration 
and hospitalization costs, which were €2670 in favour of nanotherapy. The clinical benefit associated 
with nanotherapy was proven, yielding not only positive cost-effectiveness results, but also significant 
financial savings [316]. 
Nanotheragnostics innovations, in particular, can have a significant impact on health costs by 
reducing the number of diagnostic tests and increasing therapy efficacy. Additional savings are expected 
due to the overall reduction of the number of days in hospital for each patient. Hence, the global market 
for nanomaterials used in theragnostic is anticipated to be more than $187 billion in 2017 [317]. Despite 
these figures and expectations, for an overview of these accounts for all the nanoformulations reaching 
the (pre-) clinical stage, where those relating to AuNP alone are just the tip of the iceberg. Another good 
indicator of AuNP’ increasing impact on the medical sector is the number of companies that are devoted 
to R&D in this area alone. Due to high competition among the market players and low yield coupled 
with high expenditures in R&D, most companies choose to invest in specific end-use applications: 
diagnostic tests for the point-of-care market, biomedical imaging or photothermal therapy. Successful 
examples include Nanospectra (Aurolase®) and Cytimmune (Aurimune®) whose flagship products are 
now facing clinical trials. Although the market for gold nanomaterials is still developing, their clinical 
and financial benefits are undeniable. In the future, efforts should be made to improve the bridge 
between academia, R&D companies, regulatory agencies and the pharmaceutical industry. In Table 1.3, 
we compiled a brief list of the theragnostic strategies using AuNP currently in pre-clinical and clinical 
studies. 
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Table 1.3 Compilation of gold strategies. Brief overview of current efforts in AuNP for theragnostic – pre-clinical and clinical studies. 
Particle Targeting Therapeutic Phototherapy Imaging Refs 
PRE-CLINICAL STUDIES 
Silica-Gold Shells (150 nm) - - Photothermal MR [318] 
Gold Hollow Spheres (40 nm) 
Melanocortin Type-1 
Receptor 
- Photothermal PET [319] 
Gold Spheres (60 nm) EGFR - PNB Scattering [229] 
Gold Hollow Spheres (40-50 nm) Folate Receptor 
Irinotecan + siRNA  
NF-κB p65 subunit 
- PET [237] 
Gold Cages (48 nm) -  Photothermal PET [241] 
Gold Clusters (1 nm) Folate Receptor Doxorubicin - Fluorescence [245] 
Gold Hollow Spheres (37 nm) 
Ephrin Type-B 
Receptor 4 
Doxorubicin Photothermal SPECT [247] 
Gold Stars (25 nm) RGD Doxorubicin Photothermal Fluorescence [244] 
Iron Oxide-Gold Spheres (6-18 nm) A33 Antigen - Photothermal MR [320] 
Gold Spheres (33 nm) - Tumour Necrosis Factor α Photothermal Photoacoustic [284] 
Gold Spheres (90 nm) EGFR Cetuximab - Raman Scattering [321] 
Gold Spheres (60 nm) EGFR Doxorubicin PNB Photoacoustic [230] 
Gold Spheres (5 nm) EGFR PC 4 Photodynamic Fluorescence [228] 
Gold-Cage (40-50 nm) + Silica Sphere Shell 
(50 nm) 
- Camptothecin Photothermal Fluorescence [250] 
PLGA-Gold Shell Folate Receptor Doxorubicin Photodynamic;  Fluorescence [251] 
Gold Spheres (14 nm) - - Photothermal X-ray CT [322] 
PLGA-Iron Oxide-Gold Shells (374 nm) - - Photothermal US; MR [291] 
Gold Spheres (3.3 nm) Folate Receptor α-Tocopheryl Succinate - X-ray CT [323] 
Iron Oxide + Gold Clusters (150 nm) Magnetic Doxorubicin Photothermal MR [324] 
PLGA-Gold Shell (115 nm) - Doxorubicin Photothermal MR [246] 
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Gold Rods + Liposome Hybrid - siRNA PLK1 - 
Multispectral Optoacoustic 
Tomography 
[325] 
Gold Bellflowers (180 nm) - - Photothermal Photoacoustic; US [326] 
Gold-Silica Rattles (150 nm) - Doxorubicin Photothermal Fluorescence; MR; Photoacoustic [327] 
Gold (20 nm) Gelatin shell (150 nm) RGD Doxorubicin - Fluorescence [328] 
Gold Stars (70 nm) - - Photothermal Thermal [329] 
Gold Spheres (12 nm); Gold Stars  
(30 nm; 60 nm) 
- - Photothermal 
SERS; X-ray CT;  
Two Photon Luminescence 
[290] 
Gold Rods (10:37 nm) Folate Receptor - Photoacoustic Photoacoustic [236] 
Gold Spheres (15 nm) Scavenger Receptor  siRNA VEGF - Fluorescence [330] 
Gold Rods (22:47 nm) - Doxorubicin + siRNA K-Ras Photothermal Fluorescence [261] 
Gold Spheres (15 nm) - Antisense K-Ras - Fluorescence [253] 
Gold Spheres (14 nm) - 
U5′-fluorouracile + siRNA 
MRP1 
- Fluorescence [249] 
PLGA-Gold-Iron-Gold  RGD; Magnetic Methotrexate Photothermal NIR; MR [300] 
Gold Spheres (30 nm) Sonoporation Levosimendan - US [221] 
Gold Rods  protein A lipoprotein - Photothermal Photoacoustic [331] 
Gold-Silver Core Shell (20 nm) Anti-MRSA antibody - - X-ray CT [332] 
Gold Rods (10:33 nm) Folate Receptor - Photothermal SPECT; X-ray CT [286] 
Gadolinium-Gold (2-2.5 nm) - Healthy Pancreatic Islet Cells - MR; US; CT [333] 
CLINICAL STUDIES 
Gold Spheres (20 nm) - - - - [307] 
Gold Spheres (27 nm) - Tumour Necrosis Factor α - - [308] 
Silica-Gold Shell (60-15 nm; 70-40 nm) - - Photothermal US [309] 
Note: MR – Magnetic Resonance; PET – Positron Emission Tomography; SPECT – Single-Photon Emission Computed Tomography; US – Ultra 
Sound; NIR – Near Infrared; EGFR – Epidermal Growth Factor Receptor; PNB – Plasmonic Nanobubble. 
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1.7 Scope of Thesis 
In chemotherapy, the major obstacles are the low specificity of drugs for cancer cells, triggering 
healthy tissue side effects such as: neutropenia, alopecia, myalgia, nausea, vomiting, diarrhoea and the 
development of acquired resistance that can lead to therapeutic failure. There is a constant need for the 
development of novel chemotherapeutic strategies, with focus on combined therapies that mitigate the 
mentioned obstacles. Nanomedicine has opened the possibility for innovative therapeutic approaches 
that enhance selectivity and efficacy of cancer therapy. AuNP are amongst the most versatile and 
explored metallic nanoparticles for medical purpose, mainly due to their reduced toxicity. 
In this thesis we hope to extend the knowledge of cancer treatment, by studying the mechanism of 
action of chemical and physical agents and active targeting of moieties to the tumour site. The main 
objective of this thesis was to develop new targeted strategies to tackle tumour (acquired) resistance 
that may be effective with reduced toxic side effects. The work has been broadly divided into five 
stages, each one addressing a crucial aspect of developing nanomedicines capable to tackle tumour 
growth and drug resistance.  
1. Characterization of novel chemical agents in biological context, with interest towards metal 
complexes that due to their versatile moieties allow improvement in drug design and whose 
mechanism may override existing drug resistance/adaptation mechanism from tumour cells;  
2. Targeted vectorization of compounds using AuNP towards active targeting to tumour cells 
and loading of effector cargos and assessment of therapeutic effect in vitro and in vivo;  
3. Use of AuNP for photothermal conversion towards directed hyperthermia capable of 
effectively killing cancer cells, and tackle survival/evasion mechanism (e.g. arrest neo-
angiogenesis);  
4. Specific and selective gene silencing to switch off critical genes responsible for drug 
resistance, thus increasing the efficacy of the compounds and decrease resistance; and  
5. Combining these approaches around the crucial role of AuNP and provide cues to optimize 
a single platform to enhance the killing potential against cancer cells, circumventing drug 
resistance and decrease toxic side effect. 
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 MATERIALS AND METHODS 
 
All the materials and methods common to more than one chapter will be presented in this section to 
avoid repetition, and to ease the reading. 
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2.1 Materials 
2.1.1 Reagents 
All chemicals used are presented in Table 2.1 and all equipment in Table 2.2. All chemicals were 
of molecular biology grade. Ultrapure water used in these processes came from a Millipore water 
purification system (Merck Millipore, USA). Oligonucleotides were provided by STABVIDA 
(Portugal). 
Table 2.1 List of reagents 
Name Company Country 
0.45-μm Nitrocellulose Membrane GE Healthcare USA 
0.5 % DeStreak GE Healthcare USA 
24-Well Flate Cell Culture Plate SPL Life Sciences South Korea 
2D Clean-Up Kit GE Healthcare USA 
2-Morpholinoethanesulfonic acid monohydrate, MES Sigma-Aldrich USA 
5-(and-6)-Carboxytetramethylrhodamine, TAMRA Invitrogen USA 
96-Well Flate Cell Culture Plate SPL Life Sciences South Korea 
Aberchrome 540  Extrasynthese France 
Acetic Acid  Sigma-Aldrich USA 
Acrylamide-Bisacrylamide Gel Merck Millipore Germany 
Annexin V-FITC Apoptosis Detection Kit Invitrogen USA 
Anti-Mouse IgG −TRITC Sigma-Aldrich USA 
Anti-mouse IgG, HRP-linked Antibody Cell Signaling Netherlands 
Anti-β-Actin antibody, Mouse monoclonal Sigma-Aldrich USA 
Antibiotic-Antimycotic 100X Invitrogen USA 
Apo-ONE® Homogeneous Caspase-3/7 Assay Promega USA 
Blue Line NEXT individually ventilated cages Tecniplast Italy 
Bovine Serum Albumine, BSA Sigma-Aldrich USA 
Bradford Assay ThermoFisher  USA 
Bromophenol Blue Merck Germany 
Calcium Chloride Sigma-Aldrich USA 
Cell Culture Dish 35mm SPL Life Sciences South Korea 
CellTiter 96® AQueous One Solution Cell Proliferation Assay Promega USA 
Cetuximab, Erbitux Merck Germany 
CHAPS GE Healthcare USA 
Corning® opaque 96 well plates Sigma-Aldrich USA 
Culture flask 75 cm2 VWR USA 
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DAPI-containing Fluoroshield Mounting Medium  Abcam USA 
Dimethyl sulfoxide, DMSO Sigma-Aldrich USA 
Dithiothreitol, DTT Promega USA 
Dulbecco’s Modified Eagle Medium, DMEM Invitrogen USA 
Doxorubicin Sigma-Aldrich USA 
DPX Mountant Sigma-Aldrich USA 
EGFR (D-8) Santa Cruz USA 
Eosin Sigma-Aldrich USA 
Ethanol Sigma-Aldrich USA 
Ethylenediaminetetraacetic Acid, EDTA Sigma-Aldrich USA 
Fetal Bovine Serum, FBS Invitrogen USA 
Formalin solution, neutral buffered, 10% Sigma-Aldrich USA 
Giemsa Stain Sigma-Aldrich USA 
Glycerol Panreact USA 
Gold(III) chloride trihydrate Sigma-Aldrich USA 
Guanidinium thiocyanate, Trisure Bioline UK 
Hematoxylin Sigma-Aldrich USA 
Hidrogen Peroxide Sigma-Aldrich USA 
HS-PEG(8)-COOH Iris Biotech GMBH Germany 
Hoechst 33258 solution Sigma-Aldrich USA 
Hydrochloric acid Sigma-Aldrich USA 
Immobiline Drystrip, IPG strips GE Healthcare USA 
Iodoacetamine Sigma-Aldrich USA 
IPG buffer pH 3-10 GE Healthcare USA 
Isoflurane Esteve Farma Spain 
JC-1 Abnova Corporation USA 
KAPA SYBR® FAST Kit KAPAbiosystems South Africa 
Low Melting Agarose Sigma-Aldrich USA 
Mdr-1 Antibody (D-11), ABCB1 Santa Cruz USA 
Methanol Sigma-Aldrich USA 
Milk Powder, Molico Nestle Swissland 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride, EDC 
Sigma-Aldrich USA 
Illustra™ NAP™ Columns, NAP-5 GE Healthcare USA 
MEM nonessential amino acid Invitrogen USA 
Neutral Red for microscopy Sigma-Aldrich USA 
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N-Hydroxysuccinimide, NHS Sigma-Aldrich USA 
NZY M-MuLV First-Strand cDNA Synthesis Kit Nzytech Portugal 
O-(2-Mercaptoethyl)-O′-methyl-hexa(ethylene glycol), PEG Sigma-Aldrich USA 
Paraffin – polyisobutylene mixture, Paraplast Sigma-Aldrich USA 
Paraformaldehyde Sigma-Aldrich USA 
Phenylmethylsulfonyl Fluoride, PMSF Sigma-Aldrich USA 
Phosphatase Inhibitor, PhosStop Roche Switzerland 
Pierce 660nm Protein Assay Reagent ThermoFisher  USA 
Potassium Chloride Sigma-Aldrich USA 
ProLong® Gold Antifade Reagent with DAPI Invitrogen USA 
Protease Inhibitor, cOmplete Mini Roche Switzerland 
Quartz Spectrophotometer Cuvettes Hellma-Analytics Germany 
RnaseA Sigma-Aldrich USA 
Roswell Park Memorial Institute 1640 medium, RPMI  Invitrogen USA 
SH-EG(8)-(CH2)2-COOH, Carboxilated PEG Iris Biotech Germany 
Sodium Alginate Sigma-Aldrich USA 
Sodium Chloride Sigma-Aldrich USA 
Sodium Dodecyl Sulfate, SDS Sigma-Aldrich USA 
Sodium Hydroxid Sigma-Aldrich USA 
Sodium phosphate dibasic Sigma-Aldrich USA 
Sodium phosphate monobasic monohydrate Sigma-Aldrich USA 
Tariquidar Selleckchem USA 
Tergitol, NP-40 Sigma-Aldrich USA 
Thiourea Merck Germany 
Thymidine Sigma-Aldrich USA 
Triton X100  Sigma-Aldrich USA 
Trizma base Sigma-Aldrich USA 
Trypan Blue Solution, 0.4% Invitrogen USA 
TrypLE™ Express Enzyme (1×), Trypsin Invitrogen USA 
Tween 20 Sigma-Aldrich USA 
Urea BDH Prolabo USA 
WesternBright ECL Kit Advansta USA 
Xylene Sigma-Aldrich USA 
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2.1.2 Equipment 
Table 2.2 List of equipment 
Name Company Country 
Anthos Zenyth 3100  
Anthos Labtec 
Instruments 
Germany 
Attune® Acoustic Focusing Flow Cytometer Life Technologies USA 
Axioplan 2 Imaging Microscope with Nikon DXM1200F 
digital camera. 
Zeiss Germany 
CO2 Incubator Leec UK 
CW32nm DPSS coupled to optical fiber 
Changchun New 
Industries 
Optoelectronics Tech 
China 
Digital Multimeter, MY-64 MASTECH Hong Kong 
Ettan IPGphor 3 IEF System GE Healthcare USA 
Gel Doc imager Bio-Rad USA 
Image Scanner II GE Healthcare USA 
Infinite M200 Microplate reader Tecan Swissland 
Jung RM2035 model rotary microtome  Leica Microsystems Germany 
Leica DFC 480 Leica Microsystems UK 
LSM 510 META confocal point-scanning microscope Zeiss Germany 
Nanodrop ND-1000 Spectrophotometer ThermoScientific USA 
Nanoparticle Analyzer SZ-100 () Horiba Scientific Japan 
SDS-PAGE Mini-PROTEAN®3 System Bio-Rad USA 
Sigma 3-16K, Centrifuge Sigma-Aldrich USA 
Ultrasonic Cleaner S30H Elma Germany 
Sub-Cell model 96 apparatus Bio-Rad USA 
Ti-U Eclipse model inverted microscope equipped with DS-
Qi1Mc digital camera 
Nikon Japan 
UVmini 1240 spectophetometer Shimadzu Germany 
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2.2 Methods 
2.2.1 Cell culture 
HCT116 colorectal carcinoma (ATCC® CCL-247™), A549 lung adenocarcinoma (ATCC® CCL-
185™), breast adenocarcinoma MCF-7 (ATCC® HTB-22™), V79-4 hamster lung fibroblasts (ATCC® 
CCL-93) and Primary Human Fibroblasts (ATCC® PCS-201-010™) obtained from ATCC (Chicago, 
IL) were grown in Dulbecco’s Modified Eagle Medium (DMEM) and supplemented with 10 % (v/v) 
Foetal Bovine Serum (FBS) and 1 % (v/v) antibiotic/antimycotic. MCF-7 (ATCC® HTB-22™) were 
also supplemented with 1% of MEM nonessential amino acid. H1975 (ATCC® CRL-5908™) lung 
adenocarcinoma cells were grown in RPMI (Roswell Park Memorial Institute) 1640 medium 
supplemented with 10 % (v/v) FBS and 1 % (v/v) antibiotic/antimycotic solution. Cells were maintained 
in 75 cm2 culture flasks at 37 ºC in a 99 % humidified atmosphere of 5 % (v/v) CO2. HCT116 DOX-
Resistant (HCT116 DR) cells were derived from HCT116 (ATCC® CCL-247™) by successive 
culturing with increasing concentrations of DOX, over each passage, up to a final concentration of 3.6 
µM of DOX. Analysis of mycoplasma was performed weekly, through PCR testing and/or Hoescht 
staining by a lab technician.  
2.2.2 Cell viability  
2.2.2.1 MTS assay 
For cell viability studies of compounds and nanoformulations, we performed standard 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay - 
CellTiter 96® AQueous One Solution Cell Proliferation Assay. This assay is a colorimetric method to 
estimate the number of viable cells. It is based on the dehydrogenation by metabolically active cells of 
MTS tetrazolium compound into formazan, a soluble coloured product. Briefly, a cell density of 7.5×103 
per well was seeded in a 96-well plate for 24 h, the medium was replaced with fresh medium containing 
the stimuli and incubated for an additional 24 h or 48 h. Then, the culture medium was removed from 
each well and replaced with fresh medium without phenol-red, supplemented with MTS solution. The 
96 well plate was incubated for 45 min (or 1.5 h for irradiation experiments) at 37ºC in a 99 % 
humidified atmosphere of 5 % (v/v) CO2 and the absorbance was measured directly from plates in a 
microplate reader at 490 nm. Before cell viability experiments, MTS assay was performed in the 
absence of cells and using increasing concentrations of the tested compounds to confirm that they did 
not interact with MTS solution. No linear correlation between compound concentration and formazan 
formation was observed. During irradiation experiments, DMEM without phenol read was used and 
cells were grown for 24 h and exposed for16 h to combined or individual therapies. The percentage of 
cell viability for each assay concentration was determined by subtracting a blank to all experiments and 
dividing its absorption by control (  ( 
Equation 2.1). At least three independent biological assays were performed. 
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Cell Viability (%) =
(mean Abs.of treatment group)
(mean Abs.of control group)
× 100  (Equation 2.1) 
2.2.2.2 Trypan blue assay 
Trypan blue is a dye impermeable to live cells. It can be used to access cell death since it can 
penetrate dead cells, or cells with permeability compromised membranes. To perform the assay cells 
were incubated in a well plate, with 100 µL of Trypan Blue 0.4 % (m/v) solution for 10 minutes, washed 
three times with phosphate buffer saline (PBS) 1×, imaged in bright field inverted microscope (Nikon 
TMS) and pictures were taken using a Digital Camera (Sony RX100 MK2).  
2.2.3 3D cell culture 
2.2.3.1 Cells imbedded alginate beads 
HCT116 cells were immobilize in alginate beads. A final concentration of 4×104 cells per mL were 
mixed with sodium alginate to a final concentration of 1% w/v dissolved in water (3:1 – cells:alginate). 
Then, 20 uL were dropped using a micropipette, to a solution of 100 mM of CaCl2 deposited in a 96-
well plate. After 5 to 10 minutes, before the beads become totally transparent, the CaCl2 solution was 
changed by fresh DMEM medium. After growing the cells inside de matrix for 24 h, beads were stained 
with trypan blue for 10 min.  
2.2.3.2 Histological preparation 
Alginate beads embedded with HCT116 for 72 h were fixed in 10% (v/v) neutral-buffered formalin 
solution for 24 h. After fixation, the samples were then washed in water, dehydrated in a progressive 
series of ethanol (30–100% v/v), intermediately infiltrated with xylene and embedded in paraffin. 
Paraffin–embedded samples were sectioned (5 μm thickness) with a rotary microtome. Beads were 
stained with Gill's Alum Hematoxylin and counterstained with alcoholic Eosin Y (H&E). After 
finishing the staining, all sections were dehydrated in ethanol, cleared in xylene and mounted with DPX 
Mountant. Histological analyses were made with Ti-U Eclipse model inverted microscope equipped 
with a DS-Qi1Mc digital camera.  
2.2.4 RNA expression analysis 
Total RNA was extracted from samples using TRIsure™ Reagent method according to the 
manufacturer's instructions. The quality of RNA was assessed using the Nanodrop ND-1000 
Spectrophotometer. Total RNA extracted from samples was reverse transcribed using the NZY M-
MuLV First-Strand cDNA Synthesis kit followed by quantitative polymerase chain reaction (qPCR) 
amplification using KAPA SYBR® FAST kit. The following conditions were used: initial denaturation 
at 95 °C for 5 min; 40 cycles of 95 °C for 30 s, annealing temperature (Ta) °C for 30 s, 72 °C for 1 min; 
and a final extension step at 72 °C for 10 min. The Ta for each set of primers is described in Table 2.3. 
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Table 2.3 List of primers, size of amplicon and melting temperature used for qPCR 
Primers Sequence 5'-3' 
Size 
(bp) 
Ta (°C) 
GAPDH FW GAGGAAAGGTCGCCTGGTGGATCG 
290 55 
GAPDH RV GTGAGGACAAGCAGTGAGGAACG 
IL-8 FW TCACAGCTCCACAAAACCTCA 
120 60 
IL-8 RV CGTCCTACCTTGCGACAGA 
VEGFR-A2 FW AGAAAATCACTGTGAGCCTTGCT 
101 60 
VEGFR-A2 RV TGCAACGTGAGTCTGTGAATTTG 
FLT-1 FW TCGACACTATCTTCACAGCGG 
95 60 
FLT-1 RV GCTTCTGCAGTTTGGGCT 
MMP-9 FW GGGGTTTCCTCACCTTCGAG 
349 55 
MMP-9 RV CGGGTCTTCACCTCTAAGCC 
18s FW GTAACCCGTTGAACCCCATT 
151 55 
18s RV CCATCCAATCGGTAGTAGCG 
ABCB1 RV TTGAAATGAAAATGTTGTCTGG 
110 55 
ABCB1 FW CAAAGAAACAACGGTTCGG 
2.2.5 Western Blot 
Cells were washed twice with PBS 1×, centrifuged at 300×g for 5 min and resuspended in lysis 
buffer (150 mM NaCl, 50 mM Tris (pH 8.0), 1× phosphatase inhibitor, 5 mM EDTA, 2% (v/v) tergitol 
(NP-40), 1× protease inhibitor, 1 mM PMSF, and 0.1% (w/v) DTT). Cellular extracts were sonicated 
(10 times, 1 min each) and centrifuged at 8000×g for 10 min. The supernatant was recovered, and 
protein concentration was determined using the Pierce 660nm Protein Assay Reagent per 
manufacturer’s specifications. Then, 25 μg total protein extracts were separated by SDS-PAGE in a 
10% (37.5:1) acrylamide-bisacrylamide gel. Following overnight electrophoretic transfer onto a 0.45-
μm nitrocellulose membrane and blocking with 5% (w/v) milk solution in Tris-buffered saline with 
0.1% (v/v) Tween 20 (TBST) for 1 h, blots were incubated per manufacturer’s instructions another hour 
at room temperature with primary antibodies and Anti-β-actin antibody. Membranes were further 
washed with 1× TBST and incubated with the appropriate secondary antibody conjugated with 
horseradish peroxidase. WesternBright ECL was applied to the membranes, and signal was acquired in 
a Gel Doc imager.  
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2.2.6 Synthesis and characterization of gold nanoparticles 
2.2.6.1 Synthesis of gold nanoparticles  
AuNP were synthesized by the citrate reduction method described by Lee and Meisel [334]. Briefly, 
to a boiling aqueous solution of tetrachloroauric acid (100 mL, 1 mM) was added a hot aqueous solution 
of trisodium citrate (5 mL, 2% w/v) under rapid stirring. Once a deep red colour, indicating the 
formation of nanoparticles, was observed, the solution was continuously stirred for 15 min and 
afterwards allowed to cool to room temperature. Citrate-capped AuNP (AuNP@citrate) were sterile-
filtered using a 0.2 µm syringe filter and stored at 4 °C until further use.  
2.2.6.2 AuNP characterization 
AuNP were characterized by ultraviolet-visible (UV-Vis) absorption spectroscopy, dynamic light 
scattering (DLS), Zeta potential and transmission electron microscopy (TEM). UV-Visible absorption 
spectra were recorded at room temperature on a UV-Vis spectrophotometer in the range 400–800 nm 
with 1 cm path quartz Suprasil® cuvettes. Nanoparticles’ hydrodynamic diameter and Z-potential was 
determined by DLS resorting to a Nanoparticle Analyzer SZ-100 at 25 ºC, with a scattering angle of 
90º. The AuNP formulations were diluted in milliQ water to a final concentration of 2 nM prior to 
analysis. A total of three measurements were performed for each sample.  
For TEM analysis, AuNP were prepared by depositing 10 µL of the gold colloidal solution on carbon 
copper grids, washing twice with milli-Q water, and air dried. TEM service was provided by Instituto 
Superior Técnico (ICEMS/IST), Portugal. 
2.2.6.3 Functionalization of AuNP with PEG (AuNP@PEG) 
Polyethylene Glycol (PEG) is commonly conveyed in nanoparticles to enhance its stability, confer 
functional groups and increase its biocompatibility. In general PEG is attached to AuNP via a thiol 
group. Au as high affinity to thiol, forming a quasi-valent bond. Different types of PEG were 
functionalized on the surface of AuNP, with a similar functionalization method. An AuNP solution (10 
nM) was incubated with 0.028 % (w/v) SDS, and PEG for a period of 16 h under agitation at room 
temperature. The excess of PEG chains was removed by centrifugation at 14 000×g for 30 min at 4 ºC 
and the degree of PEG coverage on the AuNP’ surface evaluated via Ellman’s Assay. The last PEG 
concentration that had no detectable thiols in the supernatant was defined as 100% coverage. AuNP 
functionalized with PEG (AuNP@PEG) were characterized by UV-Vis and DLS as described in section 
2.2.6.2. 
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2.2.7 Actinometry  
Actinometrical measurements were performed with Aberchrome 540TM, E-form ((E)-a-(2,5-
dimethyl-3-furylethylidene)(isopropylidene) succinic anhydride)) actinometer following literature 
recommendations [335]. A solution of 100 µM of Aberchrome 540 TM was dissolved in absolute ethanol 
and irradiated at 342 nm during 1 h until a photo-stationary state corresponding to the maximum 
conversion into the C-form was obtained. The C-form solution was irradiated using a continuous wave 
532 nm green diode-pumped solid-state laser coupled to an optical fibre. The solution was analysed by 
UV-Vis spectroscopy. For calculation of the photon flux, a photochemical quantum yield of ϕ=0.060 
was considered for the back reaction of C-form to E-form in ethanol. 
2.2.8 Statistical analysis 
In general, in all assays the mean of at least three independent experiments is represented and the 
corresponding standard deviation, except when stated otherwise. The appropriate statistical testing was 
used according to each case and is further stated. 
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 NOVEL INORGANIC MOLECULES FOR CHEMOTHERAPY 
 
The work presented in this chapter was possible due to the support of several colleagues. Their 
contribution will be further detailed. The ZnD compound was kindly provided by Luisa Martins (IST, 
Universaide Tecnica de Lisboa). The compound cytotoxic and cytostatic characterization was 
performed by Pedro Martins and Daniela Rosa (UCIBIO, Universidade Nova de Lisboa). The proteomic 
analysis was performed with the help of Margarida Ferreira-Silva (UCIBIO, Universidade Nova de 
Lisboa). The histological preparation and analysis were performed with the help of Pedro Costa 
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3.1 Introduction 
Apoptosis evasion is a milestone of cancer development and is nonspecific to the cause or type of 
cancer. Targeting apoptosis is an effective strategy for chemotherapy, since it is a general method for 
all types of cancer. Several anticancer drugs target various stages of apoptosis in both the intrinsic and 
extrinsic pathways [7–9]. Apoptosis can be triggered by severe damage to the DNA. Some 
chemotherapeutic agents cause cleavage of DNA strands, by direct interaction, or via the induction of 
ROS. In response to a DNA injury, cells induce a cell cycle arrest or delay it to repair the damage before 
arrival of the replication fork. In case of extensive damage, if repair systems fail, apoptosis is triggered 
[17]. Cancer cells often have an impaired DNA repair system as well. For this reason, damaged DNA 
will not be repaired as efficiently as in normal cells, causing more severe DNA damage in cancer than 
in normal cells. The concept of aiming at DNA as a target for anticancer drugs has inspired the 
development of numerous anticancer compounds: cisplatin, DOX, 5-fluorouracil, etoposide, and 
gemcitabine.  
Chemotherapy agents, such as DOX, are frequently used in first-line therapy against colorectal and 
lung cancer, but the efficacy of these agents is limited by the development of drug resistance and severe 
side-effects in normal cells. These are major problems to improve treatment outcomes and extending 
the overall survival of patients. One way to overturn this drawback has been via the synthesis of novel 
compounds and their incorporation in innovative formulations suitable for the selective delivery to 
cancer cells, thus optimizing the therapeutic window and circumventing drug resistance to conventional 
chemotherapeutics. Among these novel compounds, our group has been devoted to the study of the 
antiproliferative potential and mechanisms of action of several metal coordination compounds [336–
339]. One of such compound is ZnD ([Zn(1,10-phenanthroline-5,6-dione)2]Cl2)(Fig. 3.1), which is 
composed of a zinc coordinated with two 1,10-phenanthroline-5,6-dione (PhenDION) groups. 
PhenDION group has been described to cleave DNA [340], interact with proteins and oxidize NADH 
[341]. ZnD has showed a high cytotoxic potential towards cancer cell lines particularly colorectal 
carcinoma cell line in comparison to human normal fibroblasts [336] and in canine mammary tumour 
cell lines (FR37‐CMT) [141] . In fact, its IC50 at 48 h in HCT116 cells and FR37‐CMT was lower than 
that of DOX and cisplatin – common chemotherapeutic agents [141]. However, these two molecules 
tend to have undesirable side effects, and in some cases acquired resistance by the tumour, makes them 
unsuitable for cancer therapy. It is therefor, essential to discover their mechanism of action, to use as 
primary or alternative line of treatment, and ultimately achieve clinical success [342]. In what concerns 
DOX therapy, besides its toxic side effects, the development of resistance is a key obstacle to the 
effective treatment [186]. The high cytotoxicity of ZnD towards HCT116 carcinoma cells [336] prompt 
us to further investigate the mechanism underlying cancer cells death and to test its effectiveness against 
DOX-resistant colorectal carcinoma cells (HCT116 DR). 
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Fig. 3.1 Molecular formula of ZnD ([Zn(1,10-phenanthroline-5,6-dione)2]Cl2). 
3.2 Methods 
3.2.1 Cell death mechanism 
3.2.1.1  Hoechst 33258 labelling 
Hoechst dye specifically marks nucleic acids and is permeable to cell membranes. Through 
fluorescence microscopy, it is possible to observe non-condensed chromatin uniformly distributed over 
the entire nucleus, in case of normal cells, and apoptotic bodies, condensate or fragmented chromatin, 
in case of apoptotic cells. This method constitutes a preliminary assay to evaluate viability loss due to 
compound’s action.  
HCT116 cells were plated in 35mm dishes at 1.5×105 cells per dish. Culture medium was removed 
24 h after platting and replaced with 2 mL of fresh medium containing either free ZnD compound (IC50) 
or sterile water (vehicle control). Afterwards, cells were readily fixed with 4% (v/v) paraformaldehyde, 
at room temperature in dark for 20 min, in microscope slides. For cell staining, paraformaldehyde was 
removed, and cells were washed three times with PBS 1×. Hoechst (5 µg·mL-1) in PBS 1× was added 
and incubated in the dark for 15 min, followed by three times washing with PBS 1×, and lamellae 
deposition with a droplet of glycerol. The samples were photographed in a fluorescent microscope. 
3.2.1.2 Quantification of cell death by flow cytometry 
When cells enter apoptosis, a family of calcium-dependent phospholipid-binding proteins are 
exposed in the outer leaflet of the plasma membrane. the extracellular distribution of this proteins marks 
them for phagocytosis. These proteins can be detected by fluorescently labelled Annexin V marking 
apoptotic cells. propidium iodide (PI) is an impermeable dye, only staining cells in necroes, with 
compromised cell membrane.  
HCT116 cells were seeded into 35 mm dishes at 1.5×105 cells per dish. Culture medium was 
removed 24 h after platting and replaced with 2 mL of fresh medium containing ZnD compound (IC50) 
or sterile water (vehicle control). Cells were incubated in the presence the compound for 48 h and then 
stained with PI and fluorescein isothiocyanate (FITC) labelled annexin V according to the 
manufacturer’s instructions (Annexin V-FITC Apoptosis Detection Kit). Briefly, both floating and 
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adherent cells were collected, rinsed twice with cold PBS 1× and resuspended in 100 μL of 1× Annexin 
binding buffer. Annexin V-FITC and PI were added according to manufacturer’s directions and samples 
were incubated in the dark for 15 minutes. 400 μL of 1× Annexin binding buffer was added to each 
sample. Data was analysed with Attune® Cytometric software (Life Technologies, USA). 
3.2.1.3 Caspase-3/-7 Activity 
During apoptosis, caspases (cysteine-aspartic proteases) such as caspase-3 and -7 participate in a 
cascade of cleavage events that disrupts key homeostatic and repair enzymes bringing the structural 
disassembly of dying cells. Caspase-3/7 enzymes cleave of the C-terminal side of the aspartate residue 
DEVD (Asp-Glu-Val-Asp) in the substrate (peptide) allowing the rhodamine 110 that is attached to the 
peptide to become fluorescent. The amount of fluorescent product generated is representative of the 
amount of active caspase-3/7 present in the sample. 
HCT116 cells were plated at 7.5×103 cells per well in a black opaque 96-well microplate. Media 
was removed 24 h after platting and replaced with fresh media containing ZnD compound (IC50) or 
sterile water (vehicle control). The blank control was made with culture medium without cells. Cells 
were incubated for 48 h at 37 ºC and 5 % CO2. Caspase-3/-7 combined activity was quantified by using 
the Apo-ONE® Homogeneous Caspase-3/7 Assay according to manufacturer’s instructions. Briefly, 
100 μL of the mixture containing the profluorescent substrate was added to each well and after an 
incubation period of 2 h at 37 ºC and 5% CO2, fluorescence was measured in an Anthos Zenyth 3100 
plate reader with excitation and emission wavelengths of 485 and 535 nm, respectively. 
3.2.1.4 Mitochondrial membrane potential  
To evaluate the mitochondrial membrane potential, the fluorescent dye 5,5,6,6-tetrachloro-1,1,3,3 
tetraethylbenzimidazolylcarbocyanine iodide (JC-1) was used. JC-1 is a cationic dye, widely used in 
apoptosis studies to monitor mitochondrial health. It exhibits potential-dependent accumulation in 
mitochondria, with a fluorescence emission shift from green to red due to the formation of red 
fluorescent J-aggregates. The mitochondrial depolarization is indicated by a decrease in the red/green 
fluorescence intensity ratio. HCT116 cells were seeded with a cell density of 7.5×104 cells/well in a 6-
well plate for 24 h. After an exposure to the IC50 for DOX (0.42 µM) and ZnD for 48 h, JC-1 was added 
to the medium for 20 min. Fluorescence of the JC-1 monomer and dimmer was analysed on an Attune® 
Acoustic Focusing Flow Cytometer and Attune® Cytometric software (Life Technologies, USA). 
3.2.1.5 Cell cycle analysis 
When cells undergo division, they double their amount of DNA. PI stoichiometrically binds to DNA 
allowing its quantification. Thus, it is possible to distinguish the stage of a specific cell in the cell cycle 
by quantifying PI fluoresce. Cells in G1 phase have exactly half the DNA of G2, and all the in-between 
are in S phase.  
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HCT116 cells were seeded in 25 cm2 culture flasks with a density of 7.5×103 cells per well and were 
synchronized in early S-phase by a double thymidine block. Cells were release from the second block 
by substituting the medium with 2 mM thymidine for fresh medium without thymidine and either with 
ZnD compound (IC50) or sterile water (vehicle control). After incubation periods of 6 h and 12 h at 37 
ºC and 5 % CO2 the media was removed, and cells were trypsinised, transferred to microtubes, harvested 
by centrifugation (1000×g for 5 minutes) and washed with PBS 1×. Cell pellet was resuspended in 1 
mL of cold PBS 1× and 1 mL of cold 80 % ethanol was added drop by drop to each tube while gently 
vortexing. Cell suspension was kept on ice for 30 min and stored at 4 oC at least 14 h. Cells were 
pelleted, resuspended in 50 μg·mL-1 RNase A in PBS 1× and incubated at 37 oC for 30 min. PI was 
added to a final concentration of 2.5 μg·mL-1 and DNA content was analysed on an Attune® Acoustic 
Focusing Flow Cytometer and analysed with Attune® Cytometric software. 
3.2.2 Chromosomal DNA alterations 
3.2.2.1 Chromosomal Aberrations 
1×106 V79 cells were treated with 1.5 µM mitomycin C and ZnD compound (IC50) for 16 h in 37 ºC 
and 5 % CO2. After 14 h incubation, 0.1 mL of a 4 mg·mL-1 colchicine solution was added to each 
sample. Cell suspensions were then homogenized and incubated for another 2 h. Cells were harvested 
by centrifugation (1000×g for 5 min) and 8 mL of a pre-warmed (37 ºC) KCl solution (75 µM) was 
added to each pellet. Samples were thawed in a water bath at 37 ºC for 4 min, centrifuged (1000×g for 
5 min) and incubated for 15 min at -20 ºC with 5 mL of pre-chilled (-20 ºC) solution of methanol:acetic 
acid 3:1 (v/v) (fixing solution). Cells were washed twice with fixing solution and resuspended in 3 mL 
of this same solution. Each cell suspension was mounted on to a glass slide and chromosomal 
aberrations were evaluated under a bright-field microscope by using Giemsa staining. 
3.2.2.2 Genotoxicity assessment 
Genotoxic effects were assessed by quantification of DNA strand breakage, through the alkaline 
version of comet-assay and frequency of nuclear abnormalities. In comet assay, cell’s DNA undergoes 
electrophoresis, allowing the broken DNA fragments or damaged DNA to migrate away from the 
nucleus, resembling a comet. The amount of fluorescence in head and tail and length of tail indicate the 
extent of DNA damage. 
HCT116 cells were plated at 1×106 cells per dish in 35 mm dishes and allowed to attach for 24 h at 
37 ºC, 5% (v/v) CO2. Culture medium was removed and replaced with 2 mL of fresh medium containing 
either ZnD (IC50) or water (vehicle control) for 12 and 18 h, at 37 ºC, 5% (v/v) CO2. H2O2 was used as 
positive control at 0.05 % (v/v) for 30 min at room temperature. Glass microscope slides were initially 
prepared with a coating of 1% (w/v) agarose (normal melting point agarose) in Tris Acetate EDTA 
(TAE) 1× and left to solidify at 37 ºC for at least 48 h. Cells were harvested by scrapping and cell 
density was determined by the trypan blue dye-exclusion assay. Solutions of 1×105 cells·mL-1 in PBS 
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1× were prepared and from this 10 µL were added to 90 µL 1 % (w/v) low melting point agarose in 
PBS 1× and dropped in the slides prepared previously, making a cell density of 1×103 cells per slide. A 
coverslip was used to spread the sample across the agarose layer and the slides were allowed to dry at 
4 ºC for 15 min. Upon agarose solidification, coverslips were removed and the slides dipped into lysis 
solution (450 mM NaCl; 3.72% EDTA; 5 mM TRIS; to which 10% (v/v) DMSO and 1% (v/v) Triton-
X were added just before use) during 1 h at 4°C, followed by 40 min into cold electrophoresis solution 
(1 mM EDTA; 300 mM NaOH, pH 13) to ensure DNA unwinding and promote expression of alkali-
labile sites. Electrophoresis was carried out at 4°C, for 30 min, at 25 V using a Sub-Cell model 96 
apparatus. Afterwards, slides were placed into 0.1 M Tris-HCl buffer (pH 7.5) at 4 ºC during 15 min 
for neutralisation, followed by 15 min in methanol at 4 ºC and drying at 37 ºC. For comets visualization, 
slides were hydrated with distilled water at 4 ºC for 30 min and stained with 20 µL of an ethidium 
bromide work solution (20 µg·mL-1) and cover with new coverslips. The slides were observed under 
the fluorescence microscope Leica DFC 480 and analysed by the CometScore software v.1.5 (TriTek 
Corp., USA). About 100 cells per sample are analysed. The percentage of DNA in the tail was used as 
measure of the total DNA strand-breakage.  
3.2.3 Proteomics 
3.2.3.1 Preparation of protein extracts and two-dimensional electrophoresis 
HCT116 DR cells were seeded in 75 cm2 flask at a density of 4×106 cells per flask. Culture medium 
was removed after 24 h and replaced with fresh medium containing either 0.108 μM of ZnD or MilliQ 
water. Cells were incubated for 48 h, washed with PBS 1×, collected in ice-cold lysis buffer (50 mM 
Tris-HCl, 150 mM NaCl, 5mM EDTA, pH 8) supplemented with 0.1 % DTT), 0.4 % Nonidet P-40, 
1mM PMSF, 1× protease inhibitors and 1× phosphatase inhibitors and stored at -80 C. To lyse cells, 
short ultrasound pulses were applied to each sample, protein extracts were centrifuged at 10 000×g, 
during 5 min and the supernatant were collected and maintained in ice. Protein concentrations were 
determined using the Pierce Protein Assay Kit and then, 200 µL of each extract were purified with 2D 
Clean-Up Kit according to the manufacturer’s instructions. The pellets obtained were rehydrated in 120 
μL of rehydration buffer solution containing 7 M urea, 2 M thiourea, 2 % (w/v) CHAPS, 0.1 % (w/v) 
DTT, 1 mM PMSF, 1 x phosphatase inhibitor, 1 x protease inhibitor and bromophenol blue. Samples 
were incubated at room temperature for 48 h and centrifuged at 12 000 g for 10 min. Supernatants were 
collected and proteins were quantified with the same procedure than before. Samples with 100 µg of 
protein in 125 µL of rehydration buffer solution supplemented with 0.5 % (v/v) IPG buffer and 0.5 % 
DeStreak were used in the rehydration of 7 cm Immobiline Drystrip with 3-10 non-linear pH that were 
placed in Ettan IPGphor 3 IEF instrument. Isoelectric focusing was performed with a maximum voltage 
of 5000 V and then, IPG strips were incubated for 15 min in equilibration buffer (50 mM Tris-HCl pH 
8.8, 2 % (w/v) SDS, 6 M urea, 30 % (v/v) glycerol and traces of bromophenol blue) supplemented with 
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1 % (w/v) DTT, followed by another incubation for 15 min in equilibration. Finally, IPG strips were 
placed on top of a 10% polyacrylamide gel in SDS-PAGE Mini-PROTEAN®3 System. All 2-DE gel 
images were digitalized in an Image Scanner II. 
3.2.3.2 Analysis of differentially expressed proteins  
Gel images were analysed with Melanie 7.0 Software (GeneBio, Switzerland). Identification of 
protein spots was initially done by the software and afterwards there was a manual verification of each 
spot and the matching between spots in different gels. The ratio of the spot volume and the total volume 
of the spots with a match in all gels were used to calculate the protein expression and the concomitant 
fold variation between different conditions. It was considered that the protein expression level was 
different when the fold variation was lower than 0.7 (down-regulated) or higher than 1.5 (up-regulated).  
3.2.3.3 Protein spot identification 
For identification of proteins of interest, protein spots were manually excised from the gel and 
identified in the UniMS±Mass Spectrometry Unit, (ITQB/IBET, Portugal) using Peptide Mass 
fingerprint. The groups of altered proteins between conditions were analysed in STRING (Search tool 
for the retrieval of interacting genes/proteins) database [343] to infer possible protein-protein 
interactions, sub-cellular locations, and major altered pathways [344]. 
3.2.4 ABCB1 inhibition assays 
ABCB1 efflux pump is specifically inhibited using the small molecule – Tariquidar. HCT116 DR 
were seeded at a density of 2×104 cells per well on a 96-well plate. Cell viability of HCT116 DR was 
assessed, after exposure to 3.6 μM of DOX mixed with varying concentrations of Tariquidar. MTS 
assay was performed 24 h after initial stimulus. In further assays 60 nM of Tariquidar was used. 
3.3 Results and discussion 
3.3.1 ZnD as a cytotoxic and cytostatic molecule 
ZnD has shown a high cytotoxic potential towards HCT116 cell line in comparison to human normal 
fibroblasts [336]. We started by confirming these results in the same cell lines and two lung cancer cell 
lines A549 and H1975. A549 cells are human alveolar basal adenocarcinoma cells, and H1975 non-
small cell lung adenocarcinoma cancer cells. MTS assay revealed a higher sensitivity of H1975 than 
A549 to ZnD. In fact, the IC50 of fibroblasts is the double of H1975, but similar to A549 (Table 3.1). 
These results show the potential of ZnD to be used as an anti-proliferative compound. 
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Table 3.1 Relative IC50 (μM) of ZnD in HCT116, HCT116 DR, A549 and H1975 human cell lines at 
48 h.Values shown are relative to mean of three independent assays and the error are correspondent to 
SEM. 
Human cell line Relative IC50 ± SEM 
HCT116 0.215 ± 0.01  
A549 0.714 ± 0.09 
H1975 0.355 ± 0.04  
Fibroblasts 0.600 ± 0.13 
 
Understanding the mechanism of action of candidate compounds is of extreme relevance to ensure 
the selection of the pathways that can circumvent the known drug resistant mechanisms triggered by 
the conventional therapy. For that propose, cellular and molecular targets of ZnD were characterized. 
We exposed HCT116 cells to ZnD for 48 h at IC50, and stained them with Hoechst, a dye that binds to 
DNA allowing the morphological observation of nucleus. Morphological alterations were observed 
after nuclei staining which indicate chromatin condensation and nuclear fragmentation (Fig. 3.2), 
common in genotoxic events, that lead to apoptosis. Double staining cells with PI and annexin V-FITC 
(Fig. 3.3), allows the determination of the apoptotic/necrotic stage of cells. In early-stage apoptosis, 
cells stain with Annexin V but not with PI. In late stage apoptosis, the cell membrane loses integrity 
double staining with Annexin V and PI. Cells stained only with PI are generally necrotic, not exposing 
apoptosis markers on their surface. We observed that after exposure to ZnD, the number of apoptotic 
cells, either in early (FITC+/PI-) or later stages (FITC+/PI+), increased 4-fold with only ~2% of cells 
in necrosis when compared to the control.  
     
Fig. 3.2 Hoechst staining of HCT116 cells exposed to ZnD. Morphological alterations observed after 
nuclei staining with DNA-specific dye Hoechst 33258 in HCT116 cells exposed to ZnD (IC50; 0.217 
µM) (Fig. 3.2left) for 48 h compared to vehicle control (sterile water, right). Orange arrowheads 
indicate major alterations in nuclear morphology such as chromatin condensation and nuclear 
fragmentation. 
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Fig. 3.3 Evaluation of apoptosis level (Left). Caspase 3/7 activity of HCT116 cell exposed to ZnD 
(IC50) or water. (Right) Proportion of apoptotic and necrotic HCT116 cells after a period of incubation 
(48 h) in the presence of vehicle control (water), ZnCl2 (0.22 µM), DION (0.44 µM) and ZnD (IC50). 
Cell death was determined by flow cytometry after Annexin-V/FITC and PI double staining. Light 
Grey - Viable cells; grey - early apoptosis; dark grey - late apoptosis; black - necrosis. The results are 
expressed as the mean ± SEM percentage normalized to controls from three independent experiments.  
This prompted us to evaluate the activation of the apoptotic pathway via caspase-3/7 activity since 
the activity of these enzymes is increased in apoptotic cells. Results showed a 2-fold increase of in 
caspase-3/7 activity in HCT116 exposed to ZnD (Fig. 3.3) compared to control. To understand if the 
apoptotic signalling was intrinsic or extrinsic, we evaluated the depolarization of the mitochondrial 
membrane potential, characteristic of intrinsic apoptosis. JC-1 is a cationic dye, widely used in 
apoptosis studies to monitor mitochondrial health. It exhibits potential-dependent accumulation in 
mitochondria, with a fluorescence emission shift from green to red due to the formation of red 
fluorescent J-aggregates. The mitochondrial depolarization is indicated by a decrease in the red/green 
fluorescence intensity ratio. The assessment of the mitochondrial membrane potential in these cells 
showed a depolarization of the membrane potential (in similar levels of those induced by DOX) that 
agrees with the induction of the intrinsic apoptotic pathway (Fig. 3.4). Together, these results confirm 
that ZnD induces HCT116 cell death via activation of the apoptotic pathway. 
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Fig. 3.4 Mitochondrial membrane potential of HCT116 cells challenged with ZnD. The fluorescence 
of JC-1 monomer, corresponding to green fluorescence, was acquired using filter BL1 (excitation and 
emission range wavelengths of 488 nm and 515-545 nm, respectively). The fluorescence of JC-1 
aggregate, corresponding to red fluorescence, was acquired using filter BL2 (excitation and emission 
range wavelengths of 488 nm and 561-587 nm, respectively) JC-1 monomer/aggregate ratio obtained 
after 48 h incubation of HCT116 cells with DOX and ZnD. Values were normalized to the JC-1 ratio 
of control and are represented as the mean ± SD of three independent experiments. ***p<0.0005 
relative to control. 
To understand if ZnD also had a cytostatic potential, cell cycle analysis of HCT116 cells exposed to 
the compound was assessed at 6 h and 12 h. Staining the cells with PI (a nucleic acid dye) it is possible 
to assess the cell cycle stage by flow cytometry, since cells double their genetic material when dividing. 
Cells were synchronized in the same stage of cell division cycle using thymidine double blockage. 
Challenging cells with ZnD induced a cell cycle arrest avoiding cells to enter in G2/mitosis (Fig. 3.5). 
Indeed, most of ZnD-treated HCT116 cells at 6 h and at 12 h are at S-phase while untreated cells have 
progressed to G2/Mitosis. These findings indicate that DNA synthesis method has been halted and 
prompted us to evaluate the capability of ZnD to induce chromosomal alterations. We treated Chinese 
hamster pulmonary fibroblasts (V79) with either IC50 of ZnD for 24 h or mitomycin C (positive control) 
and stained the chromosomes with Giemsa. The results showed no alterations in chromosome number 
or structure in presence of ZnD (Fig. 3.6). 
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Fig. 3.5 Cell cycle evaluation. (Left) Percentage of HCT116 cells in the different phases of the cell 
cycle after incubation for 6 h (Left) and 12 h (Right) in the presence (0.217 µM, IC50 at 48 h) or 
absence (water) of ZnD compound. PI fluorescent levels were determined by flow cytometry. The 
results are expressed as the mean ± SEM percentage from three independent experiments.  
 
Fig. 3.6 Chromosomal Aberrations. Induction of chromosomal aberrations in V79 cells by 1.5 µM 
mitomycin C (black) and 0.217 µM of ZnD (light grey) exposure during 18 h. CTG, chromatid gap; 
CSG, chromosome gap; CTB, chromatid break; CSB, chromosome break; ACENT, acentric 
chromosome; DIC, dicentric chromosome; TRI, triradial chromosome; TETRA, tetraradial 
chromosome; ENDO, endoreduplication; RING, ring chromosome; MA, cells with multiple 
chromosomal aberrations. B. DNA percentage in the tail (% DNA in tail) and C. the comet class 
distribution in HCT116 cells treated with 0.217 µM ZnD for 9 and 18 h and H2O (vehicle control) for 
18 h. 
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To further analyse ZnD genotoxic potential, comet assays were performed in HCT116 cells exposed 
to its IC50 at 48h for 9 h and 18 h (Fig. 3.7). Comet assays allows the determination of DNA 
fragmentation in the nucleus after electrophoretic analysis of the nuclear migration profile. Intact 
nuclear DNA tends to stay in place while fragmented DNA migrates, creating a tail (resembling a 
comet). The DNA percentage in the tail was used as a measure for total DNA strand-breakage. Cells 
treated with ZnD for 9 h and 18 h exhibited an average 11.0 ± 2.4 % and 11.5 ± 2.5 % DNA in tail 
which was not significantly different from the control (average 11 ± 2 % DNA in tail, P < 0.05) (Fig. 
3.7). Furthermore, no major differences are observed in comet class distribution, where comets are 
normally distributed.  
 
 
Fig. 3.7 Comet assay. (Top Left) DNA percentage in the tail, (Top Right) the comet class distribution 
in HCT116 cells treated with 0.217 µM ZnD for 9 and 18 h and H2O (vehicle control) for 18 h. 
(Down) Comets of cells exposed to H2O, H2O2 and ZnD for 18h. 
Considering these results and the cytotoxicity results we can conclude that ZnD is a cytostatic and 
cytotoxic compound that does not induce significant genotoxicity in HCT116 cells (at the IC50 at 48 h). 
We then tried to track the internalization of ZnD in HCT116 cells. As the compound showed no 
fluorescence, we tested if it was possible to observed Zn by Inductively Coupled Plasma Mass 
Spectrometry (ICP-MS) analysis in different subcellular compartments and in the cytosol. To achieve 
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that we incubated the HCT116 with IC50 concentration for 6 h, 24 h and 48 h, and proceeded to the 
separation of cytosol, mitochondrial and nuclear fractions. After ICP-MS analysis all the samples but 
the supernatants revealed that Zn was under the limit of detection of the equipment. For that matter we 
tried to increase the amount of compound exposed to the cells by 10× and 20× the IC50 and decrease 
the exposure time to 6h to avoid killing all the cells. Again, the amount of Zn was only detectable in 
the supernatant. We also noted that after 6 h exposure, to such high concentration of ZnD cells started 
to detach from the flask, indicating cell death. It was therefore not possible to follow the intracellular 
localization of the compound.  
3.3.2 ZnD and DOX-resistant cancer cells 
We then tested the efficacy of ZnD to kill cancer cells with acquired resistance to DOX which is a 
commercial chemotherapeutic used for treatment of several cancer, and its capability to intercalate with 
DNA, RNA and proteins and to inhibit their synthesis, is well described. Interaction of DOX with the 
DNA molecule results in topoisomerase-II activity inhibition, the induction of single and double DNA 
strand breaks and chromosomal aberrations [190, 345]. Interestingly, the high cytotoxic and cytostatic 
potential of ZnD and the fact that it does not induce genotoxicity may indicate that its biological action 
is different from DOX, which might make ZnD suitable to inhibit the growth of DOX-resistant cancer 
cells. 
We started by inducing resistance to DOX in colorectal carcinoma cell line, HCT116 (ATCC® CCL-
247™) by passing the cells with increasing DOX concentrations up to 3.6 μM (Fig. 3.8).  
 
Fig. 3.8 Methodology for the growth of DOX resistant HCT116.  
Cells were incubated in successive passages with increasing concentrations of DOX). These cells 
started to show small morphological alterations, with increased cytoplasm volume, higher number of 
vesicles, and tendency to grow in small aggregates (Fig. 3.9). These modified DOX Resistant (HCT116 
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DR) cells did not show any significant reduction in cell viability up to 6 μM of DOX by MTS assay 
(Fig. 3.10). This acquired resistance is generally the result of high expression of efflux pumps that 
remove xenobiotics from the intracellular space in a non-specific way, constituting a first line of cell 
defence against chemical insult. To confirm if ABCB1 expression was responsible for DOX resistance, 
we looked for a blocker of ABCB1 activity, hoping to overturn HCT116 DR cells to a DOX sensitive 
state. Tariquidar is a specific blocker of ABCB1 that failed clinical trials due to excessive toxicity [346]. 
We observed that in the presence of DOX, with increasing concentrations of tariquidar, cells reduced 
viability and recovered its sensitivity (Fig. 3.10). In contrast, cells exposed to tariquidar alone showed 
no reduction in cell viability. With this assay, it was confirmed that the up-regulation of the efflux pump 
in HCT116 DR was a major responsible for the acquired resistance.  
 
  
 
Fig. 3.9 Microscopy Images of HCT116 DR. Microscopy images (100×) of HCT116 (Left), with the 
characteristic star shape, and HCT116 DR (Middle and Right) highlighting the aggregates of cells 
(Middle) and vesicles (Right). 
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Fig. 3.10 MTS assay of HCT116 DR. (Left) Cells were exposed to several concentrations of DOX for 
24h. (Right) Cells were exposed to 3.6 μM of DOX and varying concentrations of Tariquidar. MTS 
assay was performed 24 h after initial stimulus. 
Cytotoxicity of ZnD in HCT116 DR cells was assessed by MTS assay. Interestingly, HCT116 DR 
which showed no decrease in cell viability up to 6 µM of DOX (Fig. 3.10) have increased sensitivity to 
ZnD compared with HCT116 parental cell line. The IC50 at 48 h, 0.108 µM for HCT116 DR, was half 
the corresponding values in HCT116 sensitive cells, 0.217 µM. These values are both below the IC50 
for fibroblasts - 0.6 µM (Table 3.1). This indicates that ZnD mode of action is not affected by the 
overexpression of ABCB1 and its reduced effect on healthy fibroblasts, makes it a potential candidate 
for the treatment of DOX resistant colorectal cancers.  
To investigate the main molecular players involved in the response to ZnD in HCT116 DR, protein 
extracts from HCT116 DR cells treated for 48 h with ZnD and untreated (control) were compared via a 
two-dimensional electrophoresis (2-DE) comparative analysis. For each condition, more than 500 
protein spots were detected (Fig. 3.11 and Fig. 3.12) and to detect differences in protein expression, the 
fold variation between HCT116 DR cells treated with ZnD and the corresponding control was calculated 
(Table 3.2). Fold variations were considered significant compared to control cells if they were below 
0.7 (down-regulated proteins) or above 1.5 (up-regulated proteins) with a p-value bellow 0.05. The 33 
proteins that were most differentially expressed identified are described (Table 3.2, Fig. 3.11 and Fig. 
3.12). 
0
20
40
60
80
100
120
0 2 4 6
C
el
l 
V
ia
b
il
it
y
 (
%
)
DOX (µM)
0%
20%
40%
60%
80%
100%
120%
0 20 40 60 80 100
C
el
l 
V
ia
b
il
it
y
 (
%
)
Tariquidar (µM)
  66 
 
 
Fig. 3.11 2-DE proteome map of HCT116 DR untreated cells. Proteins were separated by isoelectric 
focusing (pI 3-10 non-linear) in the first dimension and SDS-PAGE in the second dimension. 
Visualization was done by staining with Coomassie brilliant blue R-350. Most relevant identified 
proteins are mentioned. 
 
Fig. 3.12 2-DE proteome map of HCT116 DR treated with ZnD (IC50) for 48 h. Proteins were 
separated by isoelectric focusing (pI 3-10 non-linear) in the first dimension and SDS-PAGE in the 
second dimension. Visualization was done by staining with Coomassie brilliant blue R-350. Most 
relevant identified proteins are mentioned.  
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Table 3.2 Fold variance of proteins between HCT116 DR cells treated for 48 h with ZnD compared 
with untreated controls.  
Uniprot 
Kb 
identifier 
Gene 
name 
Protein name 
HCT116 DR+ 
ZnD/HCT116 DR 
P10809 HSPD1 60 kDa heat shock protein, mitochondrial 1.6 
P38646 GRP75 Stress-70 protein, mitochondrial 1.5 
P0DMV8 HSPA1A Heat shock 70 kDa protein 1A 1.5 
P08238 HSP90B  Heat shock protein HSP 90 – beta 1.7 
P14625 GRP94 Endoplasmin 1.7 
P30041 PRDX6 Peroxiredoxin-6 1.7 
P00441 SOD1 Superoxide dismutase [Cu-Zn] 1.8 
P12956 XRCC6 X-ray repair cross-complementing protein 6 2.2 
P09211 GSTP1 Glutathione S-transferase P 0.7 
P32119 PRDX2 Peroxideroxin-2 0.2 
P04792 HSPB1 Heat shock protein beta-1 0.50 
P00367 GLUD1 Glutamate dehydrogenase 1, mitochondrial 0.6 
P31939 ATIC 
Bifunctional purine biosynthesis protein 
PURH 
1.9 
Q13011 ECH1 
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, 
mitochondrial 
0.6 
P06733 ENO1 Alpha-enolase 1.5 
P15311 EZR Ezrin 4.4 
P35232 PHB Prohibitin 0.4 
P63241 EIF5A Eukaryotic translation initiation factor 5A-1 0.3 
P63104 YWHAZ 
14-3-3 protein 
zeta/delta 
0.7 
P12004 PCNA Proliferating cell nuclear antigen 0.6 
P78371 CCT2 
T-complex protein 1 
subunit beta 
0.7 
P49368 CCT3 T-complex protein 1 subunit gamma 0.6 
P17987 TCP1 T-complex protein 1 subunit alpha 0.6 
P43487 RANBP1 Ran-specific GTPase-activating protein 0.6 
P31948 STIP1 Stress-induced-phosphoprotein 1 0.6 
P52565 
ARHGDI
A 
Rho GDP-dissociation inhibitor 1 0.5 
P60174 TPI1 Triosephosphate isomerase 0.6 
Q16576 RBBP7 
Histone-binding 
protein RBBP7 
0.3 
P04083 ANXA1 Annexin A1 1.6 
P27797 CALR Calreticulin 1.8 
O43852 CALU Calumenin 1.8 
P28838 LAP3 Cytosol aminopeptidase 2.2 
P08865 RPSA 40S ribosomal protein SA 1.9 
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ZnD-treated cells exhibited overexpression of heat shock proteins (HSPs) namely HSPD1, GPR94, 
GRP75, HSPA1A, and HSP90B. The HSPs are a heterogeneous group of chaperones whose functions 
include the protection of cells from environmental stress damage through a protein quality control 
mechanism and the cooperation in newly synthesized polypeptides transport to target organelles [347, 
348]. The high intracellular levels of these proteins could indicate a possible accumulation of radicals 
in the cells, culminating in cell death. These results agree with an increase in PRDX6 and SOD1 levels. 
These enzymes are involved in cellular protection against oxidative injury [348] suggesting that 
HCT116 DR cells tries to cope with the induction of ROS when exposed to ZnD. Interestingly, PRDX2 
and GSTP1 that are usually overexpressed in colorectal carcinoma cells [349, 350] and important for 
tumourigenesis are reduced in the presence of ZnD. XRCC6 is involved in non-homologous end-joining 
and ATIC1 is involved in de novo purine biosynthesis and their up-regulation in the presence of ZnD 
might indicate that HCT116 DR cells are trying to counteract the damage induced by the compound 
[351, 352]. HSPB1 is a “survival protein” that interferes with several cell death pathways, specifically 
in upstream events (e.g., the release of cytochrome-c) of the apoptotic cascade and its levels are reduced 
in response to ZnD promoting its antiproliferative action [353]. GLUD1 has a pivotal role in nutritional 
stress and is associated with tumour aggressiveness and poor prognosis in colorectal cancer and is an 
important target in the treatment of refractory colorectal cancer [354]. Interestingly, GLUD1 level are 
reduced in HCT116 DR cells after exposure to ZnD compound indicating its capability to cope with 
tumour aggressiveness. Reduced EZR expression plays a critical role in the development, epithelial-
mesenchymal transition induction and metastasis formation of colorectal carcinoma tumours [355]. 
ENO1 is a bifunctional protein which acts as a glycolytic enzyme and a transcription factor. In this last 
case, by repressing c-MYC gene which plays a critical role in cancer inhibition [356]. PHB 
overexpression has been also correlated with cancer. Considering this, exposure of HCT116 DR cells 
to ZnD allows to counteract these effects via EZR and ENO1 up-regulation and PHB down-regulation. 
EIF5A has been associated with cell proliferation and it can serve as a marker for malignant growth 
[357]. 1433Z is involved in the regulation of several signaling pathways including cell proliferation, 
cell apoptosis and angiogenesis. The overexpression of 1433Z can be positively correlated with cancer 
progression, metastasis and worse survival in patients [358]. PCNA is in the core of many essential 
cellular processes, such as DNA replication, repair of DNA damage, chromatin structure maintenance, 
chromosome segregation and cell-cycle progression [359]. All these proteins are repressed in the 
presence of ZnD which could be correlated with its antiproliferative/apoptotic effect. ANXA1 belongs 
to the family of phospholipid and calcium binding proteins, being involved in the anti-inflammatory 
process, regulation of differentiation, proliferation and apoptosis [360]. It has been described that 
increased expression of this protein promotes apoptosis with the activation of caspase-3 [361, 362]. 
CALU and CALR are a Ca2+ binding proteins that are normally found in the endoplasmic reticulum; 
however, CALU can be transported into the cytoplasm after cell cycle arrest or in late apoptosis and 
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CALR can be translated to cell surface and functioning as an “eat-me” signal during end stages of 
apoptosis [363–365] ANXA1, CALR and CALU are overexpressed in the presence of ZnD, which may 
indicate its ability to induce the apoptotic process as previously observed and that HCT116 DR cells 
are mostly found in late apoptosis  [363, 364] (Fig. 3.3). CCT2, CCT3, TCP1 are cytoskeletal proteins, 
including tubulins, actin, and proteins involved in the control of cell cycle [366]. Thus, their down-
regulation in the presence of ZnD might be correlated with a delay in the cell cycle progression and 
confirming the cytostatic potential of this compound (Fig. 3.5). This analysis confirmed that ZnD 
molecular targets are the induction of cell death, via ROS induction and apoptosis, and cell cycle arrest. 
Taken together these results reveal that, despite cancer cells - mostly the resistant to anticancer therapy 
- have an efficient mechanism of ROS detoxification that allows them to survival under pro-oxidizing 
conditions. The apoptotic and folding pathways that are activated upon ZnD treatment in HCT116 and 
HCT116 DR cells, lead to a concomitant high loss of cell viability. 
3.3.3 Assessment of cell viability in 3D models 
Cytotoxic efficacy of anticancer compounds has been extensively studied with monolayer-cultured 
cells. However, its efficacy under two-dimensional (2D) culture can differ from a three-dimensional 
(3D) arrangement. Growing cells in 3D culture, embedded on a matrix is physiologically more 
significant than would be possible in 2D, recapitulating tumour formation, cell adhesion, drug 
accessibility, etc [367, 368]. Alginate microbeads were reported for the first time in humans, in the 
1980s, mimicking pancreatic islets. Since then, they have demonstrated high applicability as a scaffold 
for cell immobilization, at physiological conditions with preservation of cell viability and function. The 
hydrogel mesh allows diffusion of nutrients and waste materials [369, 370]. For these reasons, by using 
an alginate hydrogel, we tried to assess the cytotoxicity of ZnD in a 3D model.  
Encapsulation of HCT116 cells in alginate beads were produced according to section 2.2.3.1. Bead 
diameter was measured by analysing Fig. 3.13, resulting in an average diameter of 2.5 ± 0.5 mm. 
Microscopic observation revealed individuals or pairs of cells immobilized in the matrix (Fig. 3.13). 
Trypan blue staining showed few cells were stained indicating that they remain viable in the beads for 
up to 72 h. Histological analysis of the alginate beads showed encapsulated cells, with uncondensed 
nuclei, typical of fast dividing tumour cells (Fig. 3.14). Cells seem to divide in small clusters, 
homogeneously distributed inside the bead, probably formed during bead gelation. 
  70 
 
   
Fig. 3.13 Alginate beads stained with trypan blue to ease its visualization (Left). An average diameter 
of 2.5 ± 0.5 was calculated. (Right) Optical microscopy images of HCT116 cells grown for 24h in an 
alginate hydrogel (200× magnification) 
 
 
Fig. 3.14 Optical microscopy images of histological cut of HCT116 cells grown for 24h in an alginate 
hydrogel, stained with eosin and haematoxylin (40× magnification). In is observable in grey the 
alginate matrix and in black, cell aggregates, inside cavities (yellow arrows). 
To accesses the toxicity of ZnD in 3D culture, we started by confirming the linear correlation 
between number of cells in the beads and MTS assay colour change (Fig. 3.15). We then exposed 
HCT116, HCT116 DR and Fibroblasts to ZnD and DOX and compared the results versus a 2D culture 
(Table 3.3). All 3D model conditions showed higher IC50 concentrations than 2D. Decrease in drug 
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efficacy in 3D cultures is reported in the literature by several groups. Ponce de León et al. described 
that lung cancer cells grown in 3D using agarose, had an increase in resistance to DOX, etoposide and 
methotrexate, compared with 2D cells. Our results show that, HCT116 DR for example, has an IC50 for 
ZnD, 30× higher in 3D culture compared with 2D monolayer. We have seen before that HCT116 DR 
are more sensitive to ZnD than HCT116, however that effect is not recapitulated in the 3D model. In 
fact, although the IC50 of ZnD in 3D cultured fibroblasts is still 85% higher than HCT116, it is lower 
than HCT116 DR. Meaning that ZnD could effectively kill HCT116 cells with a very low IC50 (1.01 
µM) with less effects on healthy fibroblasts (IC50 1.87 µM) but not HCT116 resistant cells (IC50 3 µM) 
   
 
Fig. 3.15 MTS assay of HCT116 cells inside alginate beads. Different cell densities were seeded 
inside alginate matrix and MTS assay was performed to assess the performance of the assay in a 3D 
model. 
Table 3.3 IC50 (µM) at 48 h of Dox and ZnD in monolayer and alginate hydrogel beads for HCT116, 
HCT116 DR and Fibroblasts.  
HCT 116 HCT 116 DR Fibroblasts 
 Monolayer Alginate Beads Monolayer Alginate Beads Monolayer 
Alginate 
Beads 
DOX  0.45 ± 0.3 3.51 ± 0.7 > 6  > 6 2.2 [140] > 6 
ZnD  0.22 ± 0.2 1.01 ± 0.4 0.1 ± 0.05 3 ± 0.4 0.6 ± 0.1 1.87 ± 0.8 
3.4 Conclusions 
Despite the effort put into the synthesis of novel compounds for cancer chemotherapy, they are often 
challenged by stability and solubility issues and, more importantly, lack of selectivity to cancer cells, 
thus inducing undesirable deleterious effects to healthy cells and tissues. In this chapter, we 
demonstrated that the high cytotoxic activity of the water-soluble Zn(II) coordination compound 
towards colorectal carcinoma cells. ZnD mode of action was associated with an increase of cell death 
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by intrinsic apoptosis and the induction of cell cycle arrest in S phase without observable genotoxicity. 
We developed a cell line derived from HCT116, resistant to DOX, and showed that ABCB1 efflux 
pump is the main responsible for the acquired resistance. We also show that ZnD is a promising 
chemotherapeutic agent against cancer cells refractory to DOX therapy, capable of bypassing the efflux 
pump overexpression. Cell cytotoxicity of ZnD in alginate hydrogels revealed that the IC50 of HCT116 
is higher in a 3D model than in monolayer, possibly resembling more its efficacy in a tumour. Although 
in this model the IC50 values of HCT116 were lower than fibroblasts, they were higher for HCT116 DR, 
raising the question if this could be an effective compound to circumvent DOX acquired resistance in a 
3D microenvironment.
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 NANOVECTORIZING MOLECULES FOR CHEMOTHERAPY 
 
The work presented in this chapter was possible due to the support of several colleagues. Their 
contribution will be further detailed. The EGFR expression analysis was performed with the help of 
Rita Mendes. Internalization studies were performed by Pedro Martins and Rita Cabral (UCIBIO, 
Universidade Nova de Lisboa). Cytotoxicity studies of nanoconjugates were performed with the help 
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4.1 Introduction 
Nanomedicine has provided a wide range of tools suitable for directed and selective delivery of 
drugs to cancer cells. Recent advances have been focused towards designed multifunctional 
nanoparticles able to integrate diagnosis, drug monitoring, targeted delivery, and controlled drug release 
functions into a single particle [206, 243, 263, 371–373]. The ability to specifically deliver synergistic 
combinations of targeting moieties and therapeutic agents on a single nanoparticle has prompt for an 
array of solutions aimed at selective combinatory delivery of drugs directed at cancer cells, lowering 
the toxic impact upon healthy tissues increasing therapy efficacy [217, 243, 372, 373]. AuNP, due to 
their ease of functionalization with functional biomolecules and low toxicity, are amongst the most 
promising solutions [216, 243, 373, 374]. Nanovectorization of chemotherapeutics to enhance 
therapeutic efficacy while circumventing drug resistance have provided for improved cancer 
management [375–377]. Selective delivery of these agents directly to the tumour site may be achieved 
by means of nanoparticle based vectorization, either via passive targeting associated to the EPR effect 
derived from the modified vasculature at the tumour site, or by using selective active targeting moieties, 
such as antibodies [378, 379]. The EGFR is often found overexpressed in cancer cells resistant to 
apoptosis, and may be specifically targeted via the therapeutic monoclonal antibody Cetuximab – FDA 
approved for clinical use in the treatment of colorectal cancer and lung cancer [129, 155, 156, 380–
390]. Cetuximab blocks the receptor-dependent-signal transduction of EGFR leading to cell-cycle 
arrest, induction of apoptosis, inhibition of angiogenesis, inhibition of metastasis, internalization and 
down-regulation of EGFR itself [391]. EGFR-binding antibodies have been used for decorating 
nanovehicles for active targeting of tumour cells, specifically delivering their cargo, reducing it and 
increasing its therapeutic index [392]. In this chapter, we present a nanovectorization system 
(NanoZnD) harbouring ZnD compound and Cetuximab for active targeting. Its efficacy was tested in 
DOX-resistance colorectal carcinoma and lung adenocarcinoma cells in vitro and DOX-resistant 
xenografts in vivo (Fig. 4.1).  
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Fig. 4.1 Schematic representation of the NanoZnD strategy. AuNP core is covered by PEG for 
improved biocompatibility and stability in complex media; the antiproliferative compound - ZnD - is 
embedded within BSA; and the targeting moiety Cetuximab. 
4.2 Methods 
4.2.1 Interaction studies of ZnD with albumin 
BSA stock solution awas prepared by gently dissolving the protein in phosphate buffer pH 7.0 with 
0.15M NaCl, gently swirled for 45 min to allow the protein to hydrate and fully dissolve. The 
concentration of BSA stock solution was determined by UV spectrophotometry using the molar 
extinction coefficient at 280 nm (43824 M-1·cm-1). Spectroscopic measurements were carried out on 
individually prepared samples to ensure the same pre-incubation time at 37.0 ± 0.5 ºC in each essay. 
BSA concentration was kept constant at 0.13 µM, while the concentration of the complex ranged from 
0 to 375 µM. Samples were incubated at 37ºC for 1 h. 
4.2.2 Western blot 
Western blot was performed according with section 2.2.5. The used primary antibody was against 
EGFR (EGFR (D-8), sc-365829, Santa Cruz, USA) and β-actin (reference no. A5441, Sigma, USA). 
The secondary antibody conjugated with horseradish peroxidase (reference no. 7074 or 7076, Cell 
Signaling Technology, USA) was used. 
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4.2.3 Assembly of Au-nanoconjugates and characterization 
AuNP and AuNP@PEG were synthesized with HS-PEG(8)-COOH and characterized as described in 
section 2.2.6. For the preparation of AuNP@PEG@TAMRA and AuNP@PEG@BSA, TAMRA and 
BSA were respectively conjugated to AuNP via an EDC/NHS coupling reaction. Briefly, 20nM of 
AuNP@PEG, 1.25 mg·mL-1 of sulfo-NHS and 312 μg·mL-1 of EDC were incubated in 10mM MES, 
pH 6.1, and allowed to react for 30 min to activate the carboxylic group, to which 10-7 M TAMRA or 
10 µg/mL of BSA were added. After an overnight period, the excess was washed twice by centrifuging 
at 14000×g for 30 min at 4 °C and removing the supernatant. For AuNP@PEG@BSA supernatants 
were recovered and tested for protein concentration using Bradford Assay. 
AuNP@PEG were also functionalized with Cetuximab (Erbitux®) (AuNP@PEG@CETUX) and 
with the same BSA concentration 1 h prior to antibody addition (AuNP@PEG@CETUX@BSA) under 
the previously described conditions. Cetuximab antibody was added to reaction mix at a final 
concentration of 3 mg·mL-1. Following 1 h incubation with Cetuximab, BSA was added to the reaction 
mix at a final concentration of 10 µg·mL-1 and the total volume allowed to react for 16 h at room 
temperature. Afterwards AuNP were centrifuged at 14 000×g for 30 min at 4 ºC to remove the excess 
of proteins and the supernatants were recovered and tested for protein concentration using Bradford 
Assay to determine AuNP coverage. The total amount of conjugated BSA and/or Cetuximab was 
estimated by subtracting the amount of removed protein (during the centrifugation steps) to the total 
protein amount added in the first place for functionalization purposes. Resorting to a polynomial 
regression of Bradford’s calibration curve it was possible to estimate the number of protein moles 
adsorbed at the surface of each AuNP hence allowing for the determination of the total number of 
protein molecules per nanoparticle.  
For ZnD functionalization, solutions of 6 nM AuNP@PEG@BSA and 6 nM 
AuNP@PEG@CETUX@BSA were mixed separately with 50 μM of ZnD (dissolved in water) and 
incubated for 1 h at 4 ºC to allow for compound adsorption to the nanoparticle systems to obtain 
AuNP@PEG@BSA@ZnD, and AuNP@PEG@CETUX@BSA@ZnD (NanoZnD), respectively. After 
this period, solutions were centrifuged at 14 000×g for 30 min at 4 ºC, to remove excess of ZnD. The 
supernatants were recovered and analysed by UV/VIS spectrophotometer and ICP-MS to assess ZnD 
functionalization and the number of compound molecules per nanoparticle.  
4.2.4 AuNP Internalization Studies 
4.2.4.1 Confocal Fluorescence microscopy 
Cells were seeded on coverslips in 24-well plates at a density of 1×105 cells per well and grown for 
24 h prior to incubation with 2.5 nM AuNP@PEG@TAMRA. Following 30 min or 4 h of incubation 
with AuNP, cells were fixed in 4% paraformaldehyde for 15 min, permeabilized with 0.1% (v/v) Triton 
X-100 (in PBS 1×) for 5 min and blocked with 3% (w/v) BSA (in PBS 1×) for 30 min. Cells were 
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incubated with Alexa Fluor 488-Phalloidin for 1 h and mounted with DAPI-containing Fluoroshield 
Mounting Medium. Confocal immunofluorescence microscopy Z-stack images were taken on a Zeiss 
LSM 510 META confocal point-scanning microscope. Images were processed using LSM image 
browser. 
4.2.4.2 Flow cytometry 
Cell uptake was also assessed by flow cytometry analysis. HCT116 cells and fibroblasts primary 
culture were seeded separately on 35 mm plates at a concentration of 1×104 cells per well in 2000 μL 
of DMEM with 10 % (v/v) FBS and maintained at 37 ºC, 5 % (v/v) CO2. Nanoformulation exposure 
(AuNP@PEG and AuNP@PEG@CETUX) was allowed to react for a total period of 6 h in the 
conditions mentioned above to ensure AuNP uptake. Upon DMEM growth medium removal, cells were 
extracted by trypsinisation and stored in 2 ml microfuge tubes. Cell samples were duly analysed by flow 
cytometry on an Attune® Acoustic Focusing Flow Cytometer, through acquisition of at least 10000 
events for each experimental condition. 
4.2.5 Co-cultures – Selectivity Assay  
HCT116 human colorectal carcinoma cell line and human primary fibroblasts were seeded at a cell 
density of 1 × 104 cell per well (1:1 ratio) over a cover slip within a 24-well plate well for 24 h, and 
then incubated with nanoconjugates for a further 6 h. Cells were fixed with 4 % (v/v) paraformaldehyde 
for 10 min at room temperature and permeabilized with 0.1 % (v/v) Triton X-100 for 5 min. Cells were 
double stained with anti-Vimentin 1:200 (fibroblasts staining that does not stain epithelial cells -
HCT116) for 1 h, anti-mouse TRITC 1:64 for 30 min, and with Phalloidin 488 Alexa Fluor 3:200 for 
20 min. Glass slides were mounted in ProLong® Gold Antifade Reagent with DAPI to allow for nuclear 
staining. Co-culture immunofluorescent images of HCT116 cell line and fibroblasts primary cell culture 
were acquired with a Zeiss Axioplan 2 Imaging Microscope and a Nikon DXM1200F digital camera. 
Cell number count and fluorescence quantification of co-culture’s immunofluorescent images were 
performed for exposition to: i) fresh growth medium (control), ii) ZnD at its respective IC50, iii) 
AuNP@ZnD and NanoZnD for 6 h using at least three different images. Cell number count and 
corrected total cell fluorescence (CTCF) ratio, of vimentin/phalloidin, was calculated through ImageJ 
software. 
4.2.6 Animal model assays  
All animal experiments were carried with the permission of the Portuguese Authority (Direcção 
Geral de Alimentação e Veterinária) and the study was approved by the Local Ethical Committee 
(Comissão de Ética Experimentação Animal da Faculdade de Farmácia, Universidade de Lisboa), and 
in accordance with the Declaration of Helsinki, the EEC Directive (2010/63/UE) and Portuguese law 
(DL 113/2013, Despacho no 2880/2015), and all following legislations for the humane care of animals 
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in research. Animals were kept under sterilized conditions using an Air Handling Easy Flow Ventilation 
Unit with single-sided racks and Blue Line NEXT individually ventilated cages. Animals were fed with 
sterilized commercial chow and given sterilized water ad libitum. Adequate measures were taken in 
order to minimize stress, pain or discomfort of the animals. A group of 30 (5 for each experimental 
condition) right hind leg of male BALB/c Nude Mouse (Charles River, France), 5 weeks old has been 
used. HCT116 DR-derived xenografts were induced by s.c. administration of 1×106 cells at the back 
hip of mice. Tumours were allowed to grow until an approximate size of 10 mm3 and treatments were 
performed with two i.v. injection in the tail vein separated by 4 days. The administrations were 
performed according with the following groups: PBS 1×, free ZnD, AuNP@PEG, 
AuNP@PEG@CETUX, AuNP@ZnD and NanoZnD) 5.6 ng·kg-1 of ZnD per mice per injection (free 
or in the AuNP conjugates). Tumour volume was determined three times a week by measuring with 
callipers in two dimensions and by image analysis. Tumour volume (V) was estimated assuming an 
ellipsoid conformation were the height was estimated according to the tumour proportions at the day of 
sacrifice.  Mice were monitored routinely for physical status. Mice were sacrificed 5 days after the last 
treatment. At the end of the experience mice were anesthetized with Isoflurane and animals were 
sacrificed by neck hyperextension and organs of interest (spleen and livers) and tumour were extracted 
weighted, washed with cold 0.154 M KCl to remove the excess blood and divided in two pieces: one 
for ICP-MS quantification of gold and the other for histological studies. 
4.2.7 Histological analysis  
Samples of liver, spleen and tumour were carefully excised fresh and immediately fixed in 10 % 
(v/v) neutral-buffered Formalin solution (Sigma-Aldrich, USA) for 24 h. After fixation, the samples 
were processed as described in [393]. Liver and spleen sections were stained with Gill's Alum 
Hematoxylin and counterstained with alcoholic Eosin Y (H&E). Tumours were stained with a 
tetrachrome stain for fibres and nuclei that include Alcian Blue, Weigert's Iron Hematoxylin and van 
Gieson's dye [394], similarly to our previous work [393]. Sections of all samples were stained with 
Neutral Red to enhance contrast and so detect metallic gold deposits with purplish colour. Finishing the 
staining, all sections were dehydrated in ethanol, cleared in xylene and mounted with DPX Mountant 
(Sigma-Aldrich, Portugal). Histological analyses were made with DM 2500 LED model microscope 
equipped with a MC 190 HD camera (both from Leica). 
4.3 Results and discussion 
4.3.1 Expression of EGFR in tumour and normal cells lines 
The altered vascular and lymph uptake functions induced by growing tumours may lead to the 
observed differential accumulation of nanoscale materials at the cancer site, in what is called the EPR 
effect. As such, nanoscale vectors may passively make use of this EPR effect for the targeted delivery  
of chemotherapeutics [219, 395, 396]. This may be associated to active targeting via target selective 
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moieties coupled to the nanoparticles, making these nanoconjugates valuable tools to direct 
chemotherapeutics selectively to the cells/tissue of interest. In the case of solid tumours, this active 
targeting potentiates selective uptake by cancer cells, thus avoiding that drugs exert their deleterious 
effect on healthy tissues. Active targeting of nanomedicines is usually achieved by formulations that 
incorporate moieties to selectively discern the molecular biomarkers of interest, such as the EGFR 
[124]. Together, EPR and active targeting synergistically improve efficacy against tumour cells by 
improving the therapeutic effective doses.  
Resistance of cancer cells to apoptosis has been linked to the overexpression of EGFR or EGFR 
mutations, observed in colorectal carcinoma and in 43-89% of NSCLC cases [186, 397–400]. As such, 
EGFR would be the obvious choice as a target for the selective delivery of a nanoformulation and it can 
be achieved via an anti-EGFR antibody, such as Cetuximab. Considering this, we confirmed the up-
regulation of EGFR expression in HCT116, HCT116 DR, H1975 and A549 compared to normal human 
primary fibroblasts by western blot. Indeed, all tested cell lines showed overexpression of EGFR, with 
HCT116 DR showing a 3.4-fold higher expression compared to fibroblasts (Fig. 4.2). This confirmed 
that EGFR would be the ideal choice for targeting DOX-resistant cancer cells. 
 
 
Fig. 4.2 Expression of EGFR in A549, H1975, HCT116 DR and HCT116 cells compared to 
Fibroblasts. (Top) EGFR (172 kDa) and ACTB (42 kDa) protein quantification was performed via 
western blotting on cell extracts. (Bottom) Fold expression of EGFR was compared with fibroblast 
expression for reach cell line. Band quantification was normalized against ACTB. The results are 
expressed as the mean ± SD percentage normalized to controls from two independent experiments (* 
P < 0.05; ** P < 0.01; *** P < 0.001).  
0
1
2
3
4
5
6
A549 H1975 HCT116 DR HCT116
E
x
p
re
ss
io
n
 o
f 
E
G
F
R
 
C
o
m
p
a
re
d
 t
o
 F
ib
.
*** 
* 
** 
* 
  81 
 
Despite the higher cytotoxicity of ZnD in HCT116, HCT116 DR, and H1975 cells compared to 
human primary fibroblasts (Table 3.1) we attempted to enhancement its cytotoxicity and at the same 
time its specificity by delivering ZnD to cancer cells using AuNP and an active targeting via Cetuximab 
[401, 402]. Due to the potential of AuNP as multifunctional delivery systems we looked forward to 
synthetizing and characterizing a nanoconstruct that harbours ZnD and Cetuximab (NanoZnD). 
4.3.2 Nanformulation synthesis and characterization 
It was previously described by our group that a Co(II) compound bearing the same ligand 
(PhenDION), could bind to serum albumin, and serve as “linker” to the AuNP. Serum albumin is the 
most abundant protein in blood plasma. This protein provides the intracellular binding, transportation 
and delivery of endogenous and exogenous compounds, such as fatty acids, steroids, metal compounds, 
metabolites and several pharmaceutical agents [403–405]. It is well known the ability of serum albumin 
to bind non-covalently to small molecules [403–405], resulting in an increased solubility of ligands in 
plasma and enhanced delivery to the target site [403–405]. Therefore, BSA has a great importance in 
nanomedicine due to its biocompatibility and water solubility. Its functionalisation with different 
functional groups on its surface makes it an interesting targeted based drug delivery system. Taking 
advantage of the intrinsic fluorescence of BSA due to its tryptophan residues, the fluorescence 
quenching of these tryptophan residues at various concentrations of ZnD was studied (Fig. 4.3). 
 
Fig. 4.3 Fluorescence spectra of BSA excited at 275 nm, with different concentrations of ZnD 
incubated for 1 hour at 37ᵒC. Data is representative of at least three different assays.  
In the absence of ZnD, the maximum emission wavelength was attributed only to the intrinsic 
fluorescence of BSA molecule and was observed at 350 nm (black line in Fig. 4.3). The effect of ZnD 
on BSA molecule was very pronounced, in which there was a remarkable decrease of BSA intrinsic 
fluorescence with the increase of compound concentration, reaching a decrease of about 89 % at the 
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highest ZnD concentration used (i.e. 400 µM) indicating the interaction between ZnD and BSA. 
Considering this interaction, we looked forward to developing a formulation harbouring AuNP, ZnD 
and Cetuximab.  
AuNP were synthetized resorting to citrate reduction method. After characterization with methods 
described in 2.2.6.1 we observed a maximum absorption peak of 519 nm by UV-Vis Abs spectrum, an 
hydrodynamic diameter of 15 nm by DLS and a spherical shape of 14.2 (± 1.2) nm average diameter 
by TEM (Table 4.1 and Fig. 4.4). Solution concentration was estimated by Beer-Lambert law using the 
molar extinction coefficient predicted by Mie theory of 2.95 M-1·cm-1 for 14 nm AuNP. AuNP were 
further functionalized with a coverage of PEG, harbouring a thiol group in one end and a carboxylic 
group in the other. The excess of PEG chains was removed by centrifugation and the degree of PEG 
coverage on the AuNP’ surface evaluated via Ellman’s Assay. The first PEG concentration that had 
detectable thiols in the supernatant was defined as 100% coverage (0.01 mg·mL-1) (Fig. 4.5). 
AuNP@PEG were characterized by DLS and Zeta potential showing a slight increase in hydrodynamic 
radius and a decrease zeta potential indicating successful functionalization.  
 
Fig. 4.4 TEM image of spherical citrate AuNP (Left). Histogram of diameter of AuNP with an 
average diameter of 14 ± 1 nm diameter (Right). 
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Fig. 4.5 Characterization of PEG functionalization at AuNP surface. (Left) Calibration curve of 
Elman’s assay for amount of PEG and absorption at 400-500 nm. (Right) Percentage of PEG 
measured in the supernatant compared with PEG added to the AuNP.  
AuNP@PEG were further functionalized with BSA (AuNP@PEG@BSA) and/or with Cetuximab 
(AuNP@PEG@CETUX; AuNP@PEG@CETUX@BSA) by EDC/Sulfo-NHS reaction. After 
successful functionalization, AuNP@PEG@BSA and AuNP@PEG@CETUX@BSA were 
subsequently functionalized with ZnD (AuNP@ZnD and NanoZnD respectively) and the amount of 
ZnD remaining in the supernatants quantified via UV-spectroscopy and ICP-MS. After each 
functionalization step, nanoconjugates were characterized by UV/Vis spectroscopy and DLS, consistent 
with increasing functionalization at the NPs’ surface (Table 4.1 and Fig. 4.6). Bradford assay revealed 
a functionalization efficiency of approximately 7 BSAs (BSA:AuNP ≈ 7) per gold nanoparticle. BSA 
is bound to the AuNP via covalent binding between amine groups present in both proteins and the PEG 
carboxyl group. AuNP@PEG@CETUX quantification of the supernatants using the Bradford assay 
revealed 2 Cetuximab per AuNP (Cetuximab: AuNP ≈2).  
Table 4.1 Nanoconjugates’ functionalization moieties and hydrodynamic size determination by DLS. 
The different functional moieties and DLS size are discriminated (represented as means ± SEM of at 
least three independent experiments). 
AuNP Conjugate Protein/AuNP ZnD/AuNP DLS (nm) 
AuNP citrate -- -- 15.3 ± 0.2 
AuNP@PEG -- -- 18.6 ± 0.3 
AuNP@PEG@TAMRA -- -- 22.5 ± 0.3 
AuNP@PEG@BSA 7.0 ± 0.5 -- 27.4 ± 0.4 
AuNP@PEG@CETUX 1.6 ± 0.2 -- 78.3 ± 0.7 
AuNP@PEG@CETUX@BSA  6.9 ± 0.5 -- 110.4 ± 0.8 
AuNP@ZnD 7.0 ± 0.5 402 ± 32 118.7 ± 0.9 
NanoZnD 6.9 ± 0.5 438 ± 19 126.3 ± 0.9 
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Fig. 4.6 AuNP construct with several functionalization layers: 1st PEG, 2nd BSA, 3rd Cetuximab, 4th 
ZnD compound. The numbers represent the maximum absorption peak after each functionalization 
step. A red shift is observed after each functionalization step. 
4.3.3 AuNP internalization studies 
There is plenty of literature on AuNP constructs that act inside animal cells. Despite some efforts to 
understand the mechanisms of internalization of AuNP they have not still been totally unravelled [406–
408]. For that matter we wanted to confirm that our AuNP were accumulating inside cells, and that 
CETUX targeting could enhance internalization. We started by incubating HCT116 cells with AuNP 
functionalized with PEG and TAMRA for tracking internalization (at 30 min and 4 h) by confocal 
fluorescence microscopy. Cells were further stained with Alexa Fluor 488-Phalloidin (which labels F-
actin) and Z-stacks were performed. Fig. 4.7 shows that after 30 min of incubation, the majority of 
nanoconjugates appear to be localized at the cell membrane. However, after 4 h of incubation, most 
nanoconjugates were localized closer to the nucleus (blue) and within the actin filaments (green), 
demonstrating internalization. This showed us that we needed at least 4 h of incubation with the 
nanoparticles to have internalization. To confirm that Cetuximab lead to an increase in internalization 
of AuNP, flow cytometry was used (Fig. 4.8). Observing the side scatter of HCT116, we can picture 
AuNP interaction with cells [409]. Cells challenged with AuNP@PEG, showed an increase in side 
scattering which we attribute to AuNP@PEG inside or at the membrane of cells (Fig. 4.8). The increase 
is even higher for AuNP@PEG@CETUX than AuNP@PEG. Although this technique cannot 
distinguish internalized from membrane bound AuNP, it indicates that AuNP@PEG@CETUX are 
interact more with HCT116 than AuNP@PEG. 
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Fig. 4.7 Confocal fluorescence microscopy of HCT116 cells incubated with AuNP@PEG@TAMRA 
(red). Cells were stained with Alexa Fluor 488-Phalloidin (green) and the nuclear stain DAPI (blue). 
(Left) Cells exposed for 30min of AuNP where AuNP are mostly on cell surface and (Right) Cells 
exposed to 4H AuNP where AuNP are mostly inside cells.  
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Fig. 4.8 Flow Cytometry of AuNP@PEG@CETUX. Forward and side scatter profiles at 488 nm of 
HCT116 cells after being exposed for 6 h to fresh growth medium (Top Left), and to the nanoparticle 
formulations, AuNP@PEG at 2nM (Top Right) and AuNP@PEG@CETUX (Down Left). Histogram 
plot evidencing the scattering profiles of HCT-116 cells when exposed to nanoparticle constructs 
(Down Right). FSC-A - Forward Scatter; SSC-A - Side Scatter. 
4.3.4 Cytotoxicity of nanoconjugates in EGFR overexpressing cell lines  
To test the efficacy of the NanoZnD compared with free ZnD we tested four cell lines (HCT116, 
HCT116 DR, A549 and H1975) expressing EGFR and incubated them for 24 h and 48 h in the presence 
of both formulations and respective controls (Fig. 4.10). The concentration of nanoconjugates used in 
all the assays were calibrated to deliver the same concentration of ZnD (IC50 at 48h for each cell line) 
and the control formulations without ZnD were used at the same AuNP concentration. Control AuNP 
without ZnD do not impair cell viability for all the cell lines tested (Fig. 4.9), which agrees with previous 
data that states that neither AuNP nor PEG nor BSA have cytotoxicity [206, 263, 393]. No cytotoxic 
effect was expected for AuNP@PEG@CETUX, since Cetuximab’s concentration is at nanomolar 
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concentration in the formulation, which is largely below any reported cellular toxicity [410], acting only 
as targeting moiety.  
 
  
Fig. 4.9 Cell viability assessment of the control nanoconjugates in HCT116, HCT116 DR, A549, 
H1975 cell lines after 24 and 48 h incubation.  
A strong reduction in cell viability for all four tumour cell lines (~20-50%) was observed when they 
were exposed to NanoZnD compared to free ZnD (Fig. 4.10) demonstrating the in vitro potential of 
ZnD nanoformulations particularly in DOX-resistant colorectal cancers and EGFR-overexpressing cell 
lines (mutated or not). Among the tested cell lines, the ZnD nanoconjugates seems to induce a higher 
cytotoxicity in lung adenocarcinoma cell lines (A549 and H1975) than colorectal cell lines (HCT116 
and HCT116 DR) (Fig. 4.10 and Table 4.2). Also, lung adenocarcinoma cells with L858R/T790M-
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EGFR mutations (H1975) are more susceptible to ZnD than Wild Type EGFR (A549) (IC50=0.355 ± 
0.04 μM compared to 0.714 ± 0.09 μM, respectively (Table 4.2).  
 
  
Fig. 4.10 Cell viability assessment of the nanoconjugates in various cell lines after 24 and 48 h 
incubation. Antiproliferative activities were assessed and compared to free ZnD at its IC50 at 48 h for 
each cell line. Cell viability was normalized to the control group without nanoparticle 
systems/compound. *p-value < 0.05 for AuNP@ZnD and NanoZnD compared to free ZnD. 
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Table 4.2 Cell viability obtained for HCT116, HCT11 DR, A549 and H1975 cell lines for the several 
nanoconjugates’ formulations evaluated after 24 and 48 h after exposure. Data expressed as mean 
±SEM of at least three independent experiments. 
Nanoparticle/drug formulation Cell viability (%) (± SEM) 
24 h 48 h 
 
HCT116 
AuNP@ZnD 43.8 (± 1.4) 31.3 (± 1.0) 
NanoZnD 42.3 (± 2.1) 34.5 (± 1.7) 
ZnD IC50 61.2 (± 1.3) 56.0 (± 1.5) 
 AuNP@ZnD 49.4 (± 1.3) 37.7 (± 1.3) 
HCT116 DR NanoZnD 43.1 (± 1.3) 41.1 (± 2.0) 
 ZnD IC50 64.0 (± 1.3) 55.6 (± 2.0) 
 AuNP@ZnD 20.2 (± 6.9) 13.1 (± 2.5) 
A549 NanoZnD 21.8 (± 4.5) 12.2 (± 0.3) 
 ZnD IC50 64.3 (± 7.4) 44.9 (± 3.3) 
 
H1975 
AuNP@ZnD 30.3 (± 4.1) 20.4 (± 2.9) 
NanoZnD 31.3 (± 3.5) 22.5 (± 5.1) 
ZnD IC50 87.4 (± 7.0) 67.8 (± 12.6) 
 
We also tested the same concentration of ZnD (IC50 of H1975) and nanoformulation for all cell lines 
(Fig. 4.11). The nanoconjugates showed a similar trend of relative cytotoxicity to that of the free ZnD 
with HCT116 DR > HCT116 > H1975 > Fibroblasts ~ A549 but with a higher cytotoxic effect compared 
with free ZnD. Despite the higher effect of the nanoformulation in A549 compared to ZnD free, the 
cytotoxicity of this compound is very similar to fibroblasts, hinders its use for this cell line.  
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Fig. 4.11 Cell viability assessment of Free ZnD and nanoconjugates in fibroblasts, A549, H1975, 
HCT116 and HCT116 DR cell lines after 48 h incubation. Concentration of ZnD nanoconjugates 
correspond to same concentration of free ZnD (0.355 µM). Data represented as mean ± SEM of at 
least three independent experiments. Cell viability was normalized to the control cells without 
nanoparticles. 
After examination of these results (Fig. 4.10 and Fig. 4.11) it seems that the active targeted 
nanoconjugate (NanoZnD) attained similar cell viability compared to the non-targeted counterpart 
(AuNP@ZnD) for all the tested cancer cell lines. To confirm if cetuximab was conferring selectivity to 
the formulation we co-cultured HCT116 cells and fibroblasts incubated with free ZnD and both 
nanoconjugates with and without Cetuximab for 6 h. Cell were stained with Vimentin that stains 
mesenchymal cells (fibroblasts), phalloidin that stains actin filaments (HCT116 and fibroblasts), and 
DAPI that stains nuclei (HCT116 and fibroblasts) – Fig. 4.12. Immunofluorescent images show that 
prior to incubation with the nanoconjugates both cell types are present at equivalent number in the co-
culture. All formulations induced a decrease in the cellular density of each preparation, which is more 
evident in the NanoZnD nanoconjugates. What is more, the NanoZnD nanoformulation showed the 
highest degree of mortality to cancer cells, thus evidencing the effect of Cetuximab for selective 
targeting the cancer cells. The cell counts of co-cultures’ immunofluorescent images evidences that 
NanoZnD nanoformulation targeting appears to elicit significant increase in the Fibro/HCT116 count 
ratio in an order of magnitude of 2- fold when compared with ZnD free compound and the control group 
(Fig. 4.13). This effect is more pronounced for the Cetuximab functionalized nanoconjugate than for its 
AuNP@ZnD counterpart. To corroborate these analyses, we quantified the corrected total cell 
fluorescence (CTCF) ratio vimentin/phalloidin of each sample. Co-culture preparations exposed to ZnD 
at its IC50 and AuNP@ZnD does not exhibit significant changes to CTCF ratio. Conversely, NanoZnD 
induces a vimentin/phalloidin 5.6- fold increase. Although in vitro monoculture results indicate that 
Cetuximab targeting is no efficient, the higher fluorescence rate of vimentin/phalloidin provides a direct 
indication of the targeting success of NanoZnD (Fig. 4.13).  
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Fig. 4.12. Immunofluorescent images of HCT116 and Fibroblasts primary cell co-culture (Vimentin 
stained in orange). Co-cultures were incubated with fresh growth medium (a, b, c), ZnD at its 
respective IC50 at 48h (d, e, f), AuNP@ZnD nanoconjugate (g, h, i) and NanoZnD (j, l, m) for an 
incubation period of 6 h. Immunofluorescent images were acquired with a Zeiss Axioplan 2 Imaging 
Microscope and a Nikon DXM1200F digital camera. 
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Fig. 4.13 Co-culture fluorescence analysis. (Left) Ratio of Fibroblasts/HCT116 cell count performed 
using ImageJ Software. (Right) Average corrected total cell fluorescence (CTCF) ratio, 
vimentin/phalloidin, of the co-cultures exposed to fresh growth medium, ZnD (IC50) and with 
nanoparticle constructs functionalized with ZnD, AuNP@ZnD and NanoZnD. Data represents the 
mean of the fold variation compared to control sample without AuNP (fresh growth medium). Data 
represents the mean ± SEM of at least three different images; *p < 0.05 compared to control. 
4.3.5 In Vivo Assays 
Proved the active targeting and cytotoxic potential of these gold nanoconjugates in vitro, we 
evaluated the in vivo efficacy on HCT116 DR-derived xenografts induced by sub-cutaneous 
administration of 1×106 cells at the right hind leg of male BALB/c Nude Mice (n=30). Tumours were 
allowed to grow until ~10 mm3 in size and treatments were performed with two intravenous tail 
injections separated by 4 days with the following formulations: PBS (n=5); free ZnD (n=4); 
AuNP@PEG (n=3), AuNP@PEG@CETUX (n=2); AuNP@ZnD (n=4); NanoZnD (n=5); and 
NanoZnD 2× (n=2). The tumour growth was followed every two days, by two calliper measurements 
per tumour and photographed. Five days after the second dose, mice were sacrificed, and tumour, 
spleen, and liver were extracted and divided for ICP-MS and histology. After sacrifice, one mouse from 
group NanoZnD revealed a tumour implant in the spleen and was not considerate for further analysis. 
To analyse tumour growth data, it is generally assumed that tumours have an ellipsoid shape and 
two calliper measurements are taken corresponding to the shorter and larger diameters of the ellipse. 
Since not all tumour present a regular shape, to mitigate the errors of the latter assumption we tested if 
image analysis could better estimate tumour growth. Photographs can in theory estimate more 
accurately the tumour size than calliper because they take in consideration the tumour area instead of 
estimating it by longitudinal and transversal calliper measurements. It also reduces animal handling and 
operator error. To test the approach, we compared the real measurements of the tumour in the day of 
sacrifice, after tumour extraction, with the measurements estimated by the photograms and by the 
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calliper and observed that photographs have a better correlation at predicting tumour area than calliper 
(Fig. 4.14). For that reason, photography images were considerate for further analysis. 
 
Fig. 4.14 Comparison of tumour area measured after excision (real area) with the area estimated by 
photograph and calliper prior to mice sacrifice.  
To determine de tumour volume, it is necessary to know the tumour height. As the tumour height is 
difficult to measure, it is generally estimated as being equal to the smallest diameter of the ellipse. We 
observed that our tumour had irregular shapes and that the height was not correctly estimated by this 
method. So, to calculate tumour volume, we measured the real height of each tumour after the mice 
sacrifice and set a proportion of its area/height. We used that proportion to estimate the height and 
volume of the mouse during its growth. This method assumes that the shape of the tumour remained 
similar during its growth. For PBS, AuNP@PEG and AuNP@PEG@CETUX no reduction in the 
average tumour growth rate prior injection vs. after injection was observed. For ZnD free there was a 
reduction of tumour growth rate by 43%. For AuNP@ZnD we observed a reduction of 65% in tumour 
growth rate. For NanoZnD all the injected mice responded to treatment either in the first or the second 
injection, in such cases the average reduction in tumour growth rate was 84%. We also tested a single 
dosage of double concentration of NanoZnD, in this case the tumour growth rate reduced in average 
152%. Both NanoZnD in single or split dosage revealed a significant decrease in tumour growth after 
injection compared to controls (PBS, AuNP@PEG) (Fig. 4.15 and Fig. 4.16E). These results show that 
NanoZnD efficiently reduced tumour growth with a reduction in tumour size. However, AuNP@ZnD 
and NanoZnD did not show a statistically significant difference, remaining the question of the impact 
of cetuximab active targeting in increasing the formulation efficacy. Although we cannot conclude it 
from our data, adding active targeting might reduce side effects with less accumulation in non-tumoural 
tissue. 
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Fig. 4.15 Tumour growth rate in mice model. Ratio of tumour growth rate before (T0) and after 
injection of formulation (T1 or T2). Each point represents one injection. Values greater than one 
represent increase in tumour growth rate after injection. Values between one and zero represent 
decrease in tumour growth rate. Negative values indicate not only decrease in tumour growth rate but 
also tumour remission (Kruskal-Wallis test * P < 0.05). 
The subcutaneous tumours presented a similar histological morphology between controls and 
treatments. Most tumours showed a mixed border configuration, which means that tumours had a 
fibrous encapsulation. However, in some cases, the mass was found to be aggressively intruding the 
surrounding mouse tissue (Fig. 4.16B). The neoplastic cells were actively proliferating, as indicated by 
a high frequency of cells in mitosis (Fig. 4.16B – Inset) independently of treatment. This is indicative 
of continuous development of the tumour mass. The central area of the tumour was invariably 
characterized by massive infiltration of inflammatory cells and lymphoid tissue (Fig. 4.16C). ICP-MS 
quantification showed the presence of gold only in the tumour samples with no detectable gold in spleen 
nor liver. Small metallic agglomerates were detected, in the histological preparations, inside a 
macrophage in tumours from mice injected with AuNP (Fig. 4.16C – Inset). No visible 
histopathological alterations were found in the liver (Fig. 4.16D) and spleen (Fig. 4.16E) of mice 
subjected to any of the experimental treatments, including controls. Oppositely to what was found in 
tumours, no metallic deposits consistent with AuNP agglomerates were detected in the liver and spleen 
of tested mice. These shows that the nanoformulations accumulate at the tumour by EPR and/or active 
targeting, confirming the delivery of ZnD.  
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 Fig. 4.16 A. Images of mice tumour xenografts on the day of injection of each formulation and four 
days later. B. Example of micrographs of representative histological sections of tumour, liver and 
spleen from tested mice. Mixed tumour border configuration, showing part of the fibrous 
encapsulation (between arrowheads), formed by connective tissue and muscle fibres (mf). Inset: 
Detail of a mitosis in tumour cells. C. Tumour presenting a compact mass of neoplastic cells (nc) and 
foci of infiltrating inflammatory cells (ic), within which are found debris of necrotic cells 
(arrowheads). Inset: Detail of a small metallic agglomerate inside a macrophage found in a tumour 
from a mouse injected with AuNP. D. Representative micrograph of the hepatic tissue of mice, 
showing the normal architecture of the organ, i.e. with regular-sized hepatocytes (hp) arranged in 
trabeculae. bd) Bile duct, ec) endothelial nucleus cell, kc) Kupffer cells, sn) sinusoids, ve) venule. E. 
Representative micrograph of the spleen of tested mice. Regardless of experimental treatment, no 
histopathological alterations were found in the organ. rp) red pulp, wp) white pulp. B and C, 
tetrachrome stain. D and E, H&E, Insets, Neutral Red. Scale bars: A: 100 μm, B - D: 50 μm. 
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In the batch of inoculated mice, 5 individuals did not grow a tumour after 50 days. In those cases, 
5× (n=1), 10× (n=2), and 20× (n=2) the dosage of NanoZnD was tested to assess its toxicity levels. 
After 4 days all mice were sacrificed and spleen, and liver were weighted and cut in half for ICP-MS 
and histology. No visible alterations were detected in these mice, the ratio of organ to body weight of 
the tested organs was normal in all individuals (Fig. 4.17), and no visible histopathological alterations 
were found in the excised organs. No metallic deposits consistent with AuNP agglomerates were 
detected in the liver and spleen of this mice. These results indicate that 20× dosage of NanoZnD is safe 
to administer without acute reaction. These results, together with the increased effect of single dosage 
administration of NanoZnD show that there is chance for improving efficacy by escalating the dose 
without increasing toxicity, since neither accumulation of the vehicle for the remaining formulations 
nor toxicity effects were perceptible 
 
Fig. 4.17 Organ to body weight of liver and spleen of tested mice. Mice were weighted before 
sacrifice and liver and spleen were weighted after sacrifice. The organ to body weight was calculated 
for all tested formulations. 
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4.3.6 Conclusions 
In this Chapter we successfully synthetized and functionalised AuNP with an anti-proliferative 
compound (ZnD) and an Anti-EGFR antibody (cetuximab). The gold nanoparticle-based formulation 
improved in vitro the potential of the compound against sensitive and DOX resistant colorectal 
carcinoma cell lines and two lung adenocarcinoma cancer cell lines (with and without EGFR mutation). 
Moreover, conjugation of Cetuximab provides for selective targeting capability in vitro and increased 
cell uptake of ZnD, resulting in enhanced selectivity towards cancer cells. The selective active targeting 
was clearly demonstrated through comparative experiments in non-tumourigenic cell line (fibroblasts 
primary cell culture), corroborated by fluorescence and flow cytometry data. The conceptual 
nanovectorization system here described may be used to target specifically DOX sensitive and resistant 
cancer cells and EGFR mutated lung adenocarcinoma cells with reduced cytotoxicity towards normal 
fibroblasts. The promising anti-cancer capability of this nanoformulation was further demonstrated in 
vivo, where it selectively hindered tumour growth without any deleterious effect to healthy tissues. The 
analysis of mouse xenografts revealed to be more accurate when analysed by photographs than calliper. 
What is more, the nanoformulation was capable to effectively reduce a xenograft of DOX-resistant 
colorectal cancer cells in a single dose without systemic toxicity. The advantage of active targeting with 
cetuximab, lacked more research, since it was not observed a statistical difference of adding cetuximab 
active targeting in vivo.  
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7(7):10872 DOI: 10.1038/s41598-017-11491-8 
• Pedrosa P, Mendes R, Cabral R, Martins L, Baptista PV, Fernandes A. Combination of chemotherapy 
and Au-nanoparticle photothermy in the visible light to tackle doxorubicin resistance in cancer cells. 
Scientific Reports. 2018, 8:11429 DOI: 10.1038/s41598-018-29870-0 
• Pedrosa P, Lima JC, Fernandes A, Baptista PV. Temperature and salt mediated semi-reversible 
aggregation of PEG coated gold nanoparticles. (in preparation)  
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5.1 Introduction 
PTT is a minimally-invasive therapeutic strategy, where light irradiation is converted by 
photothermal agents to heat, thus increasing the temperature of specific tissues [202]. Heating sources 
range from NIR and visible light to radiofrequency waves, microwaves, and ultrasound waves. PTT in 
cancer allows to selectively destroy cancer cells and spare healthy cells in the vicinity, since the former 
are more sensitive to an increase in temperature [202, 411]. Tissues and cells have got their natural 
photothermal agents, e.g. haemoglobin, cytochromes, but their absorption efficiency is very low, 
requiring high amounts of photon energy [202]. To enhance the photothermal effect, synthetic organic 
dyes are used, which may be selectively delivered to cancer cells, thus potentiating the destruction of 
malignant cells. Tumour environment is more hypoxic, acidic and nutrient-deficient than normal 
tissues, which are believed to increase the sensitivity of cancer cells to heat [412]. However, these dyes 
are prone to photobleaching that results in loss of anticancer activity [411]. Recently, the generation of 
nanoscale-based photothermal agents, such as AuNP, with higher absorption efficiency and without 
suffering from photobleaching, has relaunched PTT as an anti-cancer therapy [412]. AuNP exhibit 
unique physicochemical properties, including their surface plasmon resonance (SPR), which relies on 
the interaction between an electromagnetic wave and free conduction electrons at the AuNP’ surface, 
causing them to oscillate coherently in resonance with the frequency of visible light, resulting in strong 
electromagnetic fields. This phenomenon greatly enhances both the scattering and the absorption of 
light by the AuNP suitable for different biomedical applications [295, 413]. AuNP are also recognised 
by their PTT capacities, converting electromagnetic radiation into heat due to electron excitation and 
relaxation [413], which has been used for thermal ablation of tumour cells. Indeed, AuNP of specific 
sizes and shapes, including gold nanorods, nanocages and nanoshells are capable to convert NIR 
radiation into heat [414–418]. NIR lasers are commonly used in AuNP induced PTT due to the optical 
window in the NIR, where haemoglobin, melanin and water absorption is reduced, allowing deeper 
light penetration into fluids and tissues [419]. Although visible light has been applied to superficial 
epithelial cells or in transparent organs (e.g. the eye), aiding in surgical ablation of cells or photo 
cauterisation of blood vessel, visible irradiation using AuNP has had less application to cancer therapy 
than the NIR. Visible light penetration into the tissue is reduced to less than a millimetre, which provides 
for higher precision in certain medical procedures [202]. Green lasers (495-570 nm) for instance have 
been used for decades in medical surgery for photocoagulation in several ocular disorders as a safe tool 
for tissue ablation without bleeding, such as in retinoblastoma [111, 420] focal therapy and vocal cords 
surgery [421, 422]. Spherical AuNP with diameters ranging from 10 to 30 nm are ideal photothermal 
agents for biomedical applications since they have been shown to be non-toxic [206, 265] and present 
a characteristic localized SPR band around 520 nm, i.e. in the visible region of the spectrum, with an 
efficient light-to-heat conversion because absorption corresponds almost totally to extinction [202, 299, 
423, 424]. As such, AuNP as photothermal agents are an efficient way to induce precise heating, leading 
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to less damages to surrounding tissues, while destroying malignant, more thermosensitive cells [299, 
413].  
Thermal therapy is strongly dependent on cancer type, and tumour adaptation to temperature (i.e. 
thermos tolerance) may easily impact efficacy of PTT. The use of combined therapeutic approaches, 
relying on the synergistic interaction between heat and cytotoxic treatments has been proposed with 
clear advantages [175, 412]. For instance, preclinical studies showed a synergistic interaction between 
heat and cytostatic treatments [176, 425]. Several reports have demonstrated that DNA damaging 
agents, such as DOX, see an increase in efficacy by combination with hyperthermia, since DNA repair 
processes are temperature-dependent [175, 426].As previously stated, DOX toxicity in healthy cells 
poses major concerns in effective treatment of patients, as well as increasing reports of therapy relapse, 
leading to increase in dosage with concomitant more severe adverse-effects [136, 187]. As 
demonstrated in section 3.3.2 the non-response in cancer cells can be associated to drug resistance  over 
time namely by overexpressing of efflux pumps (Fig. 3.10) [187, 427] . 
Here, we show that PTT using visible light and AuNP as photothermal agents enhance the cytotoxic 
effect of DOX in cancer cells. By using a traditional drug as DOX, we illustrate the possibility to easily 
combine chemo- and PTT with improved efficacy and doing so by irradiation with existing lasers 
currently used in the clinics. We also show that the combination of an anti-tumour Co(II) metal 
compound (CoD), previously described and extensively studied by our group [393, 428, 429], and 
similar to ZnD (see section 3.3.1) has anti-tumour effect and can be coupled to photoinduced 
hyperthermia results in increased tumour cell death, and can circumvent DOX resistance (Fig. 5.1).  
 
Fig. 5.1 Schematics of combined chemo-hyperthermia to tackle Resistant DOX HCT116. After 
induction of DOX resistance, cell death is assessed after chemotherapy, hyperthermia and 
combination of both therapies.  
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5.2  Materials and Methods 
5.2.1 AuNP@PEG synthesis and characterization 
AuNP@PEG were synthesized, functionalized and characterized as described in section 2.2.6.  
5.2.2 Irradiation of cells 
Prior to irradiation the laser source performance was characterized by actinometry as described in 
section 2.2.7. For HCT116 cell experiments, they were seeded with a density of 2×104 and then 
incubated with 8.2 nM AuNP@PEG (ε = 2.85×10-8 M-1·cm-1) for 4 h. For MCF-7 cells were seeded as 
described above and then challenged with 15 nM AuNP@PEG (ε = 2.85×10-8 M-1·cm-1) for 2 h. 
Subsequently, the culture medium was replaced by supplemented DMEM medium without phenol red 
pH indicator and irradiated with a continuous wave 532 nm green diode-pumped solid-state laser 
coupled to an optical fibre with a power set to 3.44 W·cm-2 for 60 s. Cell membrane integrity was 
immediately evaluated after irradiation by trypan blue assay and cellular viability by MTS assay 24 h 
after irradiation as described in section 2.2.2. For temperature measurements, a thermocouple was 
inserted in the wells (in contact with the cell culture medium) before and immediately after visible light 
irradiation. Cell viability was immediately evaluated by trypan blue assay.  
For combined therapy, MCF-7 cells were seeded and incubated at 37 ºC in the absence or presence 
of DOX (3 µM) for 6 h, after which they were challenged with 15 nM AuNP@PEG (ε = 2.85×108) for 
2h. Medium as washed with phenol red free DMEM and irradiated (3.44 W·cm-2 for 60 s as described 
above). As controls, cells without DOX, without AuNP@PEG and/or irradiation were assessed. Cell 
viability was evaluated by MTS and trypan blue assays (below) after 16 h. For HCT116, HCT116 DR 
and Fibroblasts the several formulations were incubated with a cell density of 2×104 for 4 h. The 
medium was replaced by phenol red free DMEM and irradiated (3.44 W·cm-2 for 60 s as described 
above). 
5.2.3 Statistics 
Statistical significance of all data was verified by One-way ANOVA. The Tukey method allowed to 
determine statistically significant differences between mono and combined therapeutics. This analysis 
was performed with GraphPad Prism 6.0 (GraphPad Software, Inc) and results were considered 
statistically significant for p < 0.05. Data are the average of quadruplicated assays and the errors are 
calculated by the standard error mean. 
5.3 Results and discussion 
5.3.1 Laser Characterization 
Laser irradiation was setup as shown in Fig. 5.2 and the photon flux characterised by actinometry to 
determine the exact amount of energy being irradiated in each experiment. Aberchrome 540TM is often 
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used for actinometry studies in the near-UV and visible regions due to its reversible photocyclisation to 
the deep red cyclised valence isomer 7,7a-dihydro-2,4,7,7,7a-pentamethylbenzo(b)furan-5,6-
dicarboxylic anhydride (C-form). When irradiated with UV light E-form turns in C-form, which can in 
turn be reverted to E-form when irradiated with visible light. For these measurements, Aberchrome 
540TM was dissolved in absolute ethanol and irradiated at 342 nm during 1 h until a photo-stationary 
state corresponding to the maximum conversion into the C-form was obtained. The C-form solution 
was irradiated using a continuous wave 532 nm green diode-pumped solid-state laser coupled to an 
optical fibre. The solution exposed to the green laser undergoes back conversion to the E-form and the 
number of converted molecules was quantified by UV-Vis spectroscopy (ε=8038 M−1⋅cm−1). For the 
calculation of the photon flux, a photochemical quantum yield of ϕ=0.060 was experimentally 
calculated (Fig. 5.3) for the back reaction of C-form to E-form in ethanol. We were able to establish a 
linear correlation between the laser input current and the amount of energy arriving to the microplate 
well (Fig. 5.3). 
 
 
Fig. 5.2 Strategy for assessing efficacy of AuNP based PTT in the visible. 
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Fig. 5.3 Laser calibration measurements. (Left) AberChrome540 quantum yield of 0.06 defined by the 
slope of the curve of converted moles of actinometer per absorbed photon of light. (Right) Linear 
relation between input laser current and light power arriving to the sample.  
5.3.2 AuNP@PEG irradiated by laser  
AuNP were synthetized and characterized according to section 2.2.6. A maximum absorption peak 
of 520 nm was observed by UV-Vis, a hydrodynamic diameter of 19 nm by DLS and an average 
spherical shape of 14 nm diameter by TEM.  
 
Fig. 5.4 TEM image of spherical citrate AuNP (Left). Histogram of diameter of AuNP centred at 14 ± 
0.8 nm diameter (Right). 
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Fig. 5.5 Characterization of PEG functionalization at AuNP surface. Percentage of PEG measured in 
the supernatant compared with PEG added to the AuNP.  
AuNP@PEG were further synthetized with increasing concentrations of PEG. The PEG coverage 
on the AuNP’ surface was evaluated by Ellman’s Assay. The concentration of 0.01 mg·mL-1 of PEG 
was defined as 100% coverage, since it was the first concentration where PEG was detected in the 
supernatant (Fig. 5.5). It is noteworthy that the same concentration had been determined in section 4.2.3 
in Fig. 4.5. To determine the capacity of AuNP@PEG to generate heat upon irradiation, we irradiated 
increasing concentrations of AuNP@PEG in water and measured the variation in temperature with a 
thermocouple. The observed increase in temperature, showed the photothermal capacity of 14nm 
diameter AuNP. We then determined the total heat (Q) generated per assay upon irradiation using 
 ( 
Equation 5.1. The variation in temperature (ΔT) was calculated by subtracting the final temperature 
to the initial temperature in each nanoparticle assay, minus the variation in temperature for irradiating 
only water. The thermal capacity of water 4.18 J·g-1·K-1 (q), and the irradiated mass (m) of 0.2 g were 
used. Thus, we have only the heat generated by the AuNP irradiation (Fig. 5.6). The number of 
nanoparticles was calculated by using beer lambert law with an ε = 2.85×10-8 M-1·cm-1 at 520 nm for 14 
nm nanoparticles according to Navarro et. al [430] and Avogadro number. Then, by dividing the total 
heat generated per assay by the number of particles and by the irradiation time (60s) we obtained a 
photothermal power of 7.1×10-13 W per particle (Fig. 5.7 left). 
Q = q × ΔT × m  (Equation 5.1) 
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Fig. 5.6 Heat capacity of AuNP. The heat generated by the particles upon irradiation was calculated 
using the Equation 5.1.  
However, this value is dependent on the irradiation power, therefor not comparable with other 
photothermal capacitors or laser intensities. We then calculated the photothermal efficiency of the 
nanoparticles by dividing the generated heat energy by the absorbed light energy. The generated heat 
was calculated using the  ( 
Equation 5.1 as previously described. The light energy that gets to each sample solution is equal to 
the number of photons arriving during irradiation, multiplied by the energy of each photon. However 
not all the energy that arrives to the samples is absorbed. However, from the irradiated light, only a 
fraction is absorbed. To calculate amount of energy that was absorbed we first determined the absorbed 
intensity (IA), using the equation ( 
Equation 5.2. The intensity absorbed fraction of laser (IA) can be calculated, where I0 is the irradiated 
intensity of the laser source and A is the absorption at irradiated wavelength. 
IA  =  I0 × (1 − 10
−A) (Equation 5.2) 
An efficiency of 77 % of photothermal conversion was determined (Fig. 5.7 right), which is in 
concordance with previous studies that projected an efficiency of 78 % for citrate capped 15.7 nm AuNP 
[431]. This shows that 14 nm AuNP are indeed strong visible light absorption agents capable to generate 
heat in a precise zone, and thus have a great potential to be applied in hyperthermia regimens [299, 413, 
424, 432].  
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Fig. 5.7 Characterisation of Photothermal Effect of Gold Nanoparticles.(Left) Heat generated per 
second in function of number of particles irradiated. Several concentrations of AuNP were irradiated 
at 1.7 W·cm-2 for 60s and the temperature variation was measured. The slope of the curve gives the 
heat generated per nanoparticle per second. (Right) Photothermal efficiency of AuNP 14 nm. 
To resemble more a biological environment, we also irradiated AuNP@PEG in PBS 1×, an isosmotic 
buffer that mimics the pH and ionic strength of biological fluids, instead of water. Surprisingly as 
temperature rose, AuNP spectrum red shifted, indicating aggregated nanoparticles. After a few minutes, 
the solution turned red again showing that this aggregation was reversible (Fig. 5.8 inset). To understand 
if this phenomenon was light dependent or temperature dependent, we exposed an AuNP solution with 
PBS to increasing temperature in a Peltier cell. We observed that specially around 80ºC, the spectrum 
started to red shift, with a maximum absorption peak at 730nm, at 100ºC (Fig. 5.8). After cooling down 
the solution, the same reversibility was observed. Meaning that the aggregation was temperature 
dependent, not light dependent.  
 
Fig. 5.8 AuNP@PEG UV-Vis variation with temperature increase. The red shift in nanoparticle 
absorption indicates nanoparticle aggregation. Inset it is a photo of irradiated particles for 1 min 3.44 
W·cm-2 (right) (100ºC) and particles irradiated at the same condition, after 10 min (left) (20 ºC). 
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We also looked at the solution side scattering (90º) during temperature increase in PBS 1×. An 
increase in scattering is observed with the increase in temperature, reinforcing AuNP aggregation (Fig. 
5.9 Left). With the system cooldown the side scattering decreases but not to the same values as before, 
indicating that some particles remain aggregated and the system is not totally reversible (Fig. 5.9 Right).  
 
Fig. 5.9 AuNP side scattering in PBS 1× and increased temperature. (Left) The side scattering at 90º 
was measured indicating AuNP aggregation with increase in temperature. (Right) After system 
cooldown the scattering decreased. The values on top represent the temperature of the system in ºC.  
To investigate the effect of salt in solution, we added to the AuNP@PEG to PBS 2× and 10× and 
increased the temperature. We observed that the temperature needed to aggregate the particles decreased 
with the increase in ionic strength (Fig. 5.10).  
 
Fig. 5.10 AuNP@PEG aggregation profile at different temperatures and ionic strength. It is observed 
a decrease in the temperature needed to aggregate the particles with increasing ionic strength.  
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AuNP@citrate are known to aggregate with the addition of ions to solution due to creation of 
momentary dipoles at the surface of the particles [433]. PEG confers stability to the nanoparticles by 
creating steric hindrance with the increase in ionic strength, not allowing the AuNP to approximate. 
This aggregation phenomena suggest that the PEG structure collapses with the increase in temperature. 
This collapse is described for thermo responsive polymers [434, 435], but it was never described for 
this type of PEG. We believe that, PEG chains create Van-der-Wall bridges with the solvent keeping it 
in a strait conformation, when temperature increases these bonds are broken, leading to the collapse of 
PEG structure, and reduce its ability to create steric hindrance. When no salt in present in solution, the 
PEG ‘shrinks’ with the increase in temperature, and stretches again with the decrease in temperature 
but the particles remain disperse, as no force is promoting their aggregation. However, in the presence 
of salt, it generates particle dipoles strong enough to promote aggregation and the plasmon coupling. 
When PEG stretches the interparticle distance is higher, hindering the plasmon coupling. Interestingly 
we tested the aggregating conditions with nanoparticles functionalized with a similar PEG but this time 
with a carboxylic group in the end. In that case no aggregation was observed, not even at 100 ºC at 10× 
PBS. When we reduced the pH to 3 at PBS 1×, 100 ºC we observed nanoparticle aggregation. This can 
be explained since at pH 7 most carboxyl groups will be deprotonated conferring charge to the particles 
and promoting AuNP repulsion and dispersion. Only at pH 3 when the carboxyl groups are protonated, 
the particles can aggregate. These finding are relevant to understand the stability of these AuNP 
constructs when irradiated inside cells.  
5.3.3 Photothermal Therapy induced by visible irradiation on AuNP in cells 
To assure reproducibility in our experiments, to irradiate our samples in the same spot, with the same 
distance, we designed a manual plate mover that was further 3D printed in plastic PLA (Fig. 5.11D). It 
was placed inside a laminar flow chamber to avoid microbial contamination of animal cell cultures. An 
optic fibre was coupled to the laser source (Fig. 5.11A), a thermocouple was added to the system to 
measure temperature variations (Fig. 5.11B) and an infrared camera (Fig. 5.11C). Manual plate mover 
blueprints are represented in Fig. A.1 and Fig. A.2. 
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Fig. 5.11 Photograph of laser irradiation setup. (A) optic fibre (B) thermocouple (C) infrared camera 
(D) manual plate mover 
To understand the effect of irradiation of AuNP within cells, MCF-7 breast adenocarcinoma cells 
were incubated with AuNP (15 nM) for 2 h and irradiated at different exposition times and intensities. 
The initial and final temperature was measured and trypan blue assay (section 2.2.2.2) was performed 
following irradiation. In the absence of AuNP and for all irradiation conditions, no trypan blue staining 
was observed despite an increase of the medium temperature, indicating that the membranes were intact 
and that cells were not affected by the laser. Some reports suggest that, at 40ºC, cells are thermosensitive 
and their membranes ought to suffer permeability changes [175]. However, in our case, no damage of 
cell membranes was observed for all the exposure times and laser potencies, probably due to the 
transient nature of the temperature increase. Conversely, irradiation in presence of AuNP, cells showed 
a strong compromise to cell membranes (Table 5.1). Because the AuNP are inside, or at the membrane 
of cells when irradiation occurs, the intracellular surge in temperature strongly impacts cell membrane 
integrity. It seems that a minimum final temperature of 52ºC is needed to damage the cellular membrane, 
since trypan blue only stained cells exposed to above temperatures. A laser potency of 3.44 W·cm-2 for 
60 s was chosen for the subsequent cell assays relying on the highest temperature reached for cells 
irradiated with AuNP (∆T 12 ºC) compared to cells irradiated without nanoparticles. 
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Table 5.1. Optimization of AuNP-induced PTT. MCF-7 Images of irradiated cells without AuNP and 
with AuNP under different laser intensities and exposure times. In all condition’s cells were incubated 
with Trypan Blue dye for 10 min and pictures were taken right after in bright field (400× objective) 
using an inverted microscope. Final achieved temperatures are indicated at the bottom right in each 
picture. 
Intensity - Time 
(total energy) 
Cells Cells + AuNP@PEG  
3.99W·cm-2 30s 
(33.7J) 
42ºC 50ºC 
2.37 W·cm-2 60s 
(47J) 
 
38ºC 43ºC 
3.44W·cm-2 60s 
(51.1J) 
40ºC 52ºC 
3.99W·cm-2 60s 
(67.3J) 
48ºC 58ºC 
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2.9W·cm-2 90s 
(67.6J) 
43ºC 52ºC 
3.44W·cm-2 90s 
(67.6J) 
48ºC 56ºC 
2.37W·cm-2 120s 
(93.8J) 
 
43ºC 55ºC 
2.9W·cm-2 120s 
(114.8J) 
46ºC 58ºC 
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We tested similar conditions with HCT116 colorectal carcinoma cells. They were incubated with 
8.2 nM of AuNP@PEG and irradiated for several exposure times after medium replacement (3.44 
W·cm-2) and the results were compared with irradiated HCT116 cells not exposed to the nanoparticles. 
Cells without AuNP@PEG were not affected by irradiation for all tested exposure times, whereas cells 
harbouring AuNP@PEG showed increased membrane permeability by trypan blue assay for exposure 
times of more than 60 s (Fig. 5.12).  
 
 
Fig. 5.12 Trypan blue assay of HCT116 cells irradiated with green laser. Cells were incubated with 
8.2 nM AuNP@PEG for 4 h and medium was replaced. Later, they were irradiated with a power of 
3.44 W·cm-2 for different exposure times and trypan blue assay was performed. Cells stain with 
trypan blue for exposure times greater than 60 s. 
To assess how cell viability was affected by irradiation, we performed an MTS assay with and 
without AuNP at different exposure times, 24 h after irradiation. In contrast, with trypan blue results, 
for an irradiation time of 90 s, in the absence of AuNP, a decrease of viability was observed. For cells 
incubated with AuNP, the loss of cell viability starts much earlier, with only 45 s of exposure (Fig. 
5.13). The reduction in viability of cells without AuNP might be explained due to the excitation at 532 
nm of the cytochrome c [436–438], thus compromising mitochondrial activity and not affecting 
membrane integrity. In the case of cells with AuNP, loss of cell viability may be due to localized heat 
at the membrane, destabilizing the lipid bilayer, and permeabilizing it [439]. Also, endoskeleton damage 
is likely to happen, since it is where AuNP are mostly located at 4 h as seen in section 4.3.3. [440]. 
Interestingly, when this irradiation procedure was performed with HCT116 DR an increased sensitivity 
to AuNP’ irradiation compared with HCT116 was observed. After 90 s of irradiation the percentage of 
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cell death was 91 % compared with 66 % for HCT116 (Fig. 5.14). However, HCT116 DR seem to be 
less sensitive to laser alone when compared with HCT116. These can be explained if by the Warburg 
effect which is associated with acquired drug resistance. With reduced mitochondrial activity, 
irradiation alone has less impact on these cells. Together these results demonstrate that irradiating ~14 
nm AuNP@PEG with a green laser promotes a photothermal injury in different type of cancer cells, 
particularly improving cell injury in DOX resistant colorectal carcinoma cell line.  
 
Fig. 5.13 Cell viability of HCT116 exposed to AuNP@PEG and Laser.  (Left) HCT116 and (Right) 
HCT116 DR irradiated with a power of 3.44 W·cm-2 with (White) and without (Black) previous 4 h 
exposure to 8.2 nM of AuNP@PEG. MTS assay was performed 24 h after irradiation.  
Fig. 5.14 Reduction in cell viability by MTS of HCT116 DR and HCT116 exposed to 8.2 nM of 
AuNP and irradiated with 3.44 W·cm-2 for 90 s normalized to the same irradiation without AuNP.  
To further understand if this approach could be translated to a 3D model of cell culture, we tried to 
irradiate cells embedded in a calcium alginate matrix. HCT116 DR cells were grown in this hydrogel 
for 24 h and then incubated with AuNP@PEG for 4 h. After medium replacement the hydrogel was 
irradiated for different exposure times at 3.44 W·cm-2. We observed that the AuNP could internalize 
the alginate matrix and stayed inside for several minutes after washing (Fig. 5.15 Right). An increase 
in final temperature of the media was achieved, 67 ºC in alginate beads compared with 53 ºC in 
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monolayer. Cell viability assays with alginate beads revealed an increase standard error, this can be due 
to the increased complexity of a 3D model, which is more variable than monolayer, also because the 
alginate bead is not fixed in the middle of the well, partially missing the laser beam. Cells showed to be 
more sensitive to 60s irradiation in the 3D model (23% of cell viability) than in monolayer (56% of cell 
viability) (Fig. 5.13 Right and Fig. 5.15 Left). The confinement of the cells in a smaller area, compared 
with 2D model, also favours the concentration of heat. This result indicates that irradiating tumours 
with accumulation of nanoparticles is a promising strategy to destroy tumours. 
 
Fig. 5.15 Irradiation of HCT116 DR in a 3D model of alginate. (Left) Cell viability of HCT116 DR 
exposed to 8.2 nM AuNP@PEG for 4h and later laser irradiation with 3.44 W·cm-2. MTS assay was 
performed 24 h after irradiation. (Right) Alginate beads with HCT116 DR, after exposure with 
AuNP@PEG for 4 hours and medium replacement.  
5.3.4 Combined photo-chemotherapy Therapy 
DNA repair processes, which are crucial for the cell’s response to aggression by cytotoxic drugs, are 
temperature dependent. As such, hyperthermia enhances the cell killing efficacy of antitumor drugs that 
rely on DNA damage [175, 426]. DOX is one of the most widely used anticancer drugs, particularly 
against breast cancer [441]. As such, with the aim of improving DOX efficiency against cancer cells, 
we combined DOX and hyperthermia with AuNP as heat-generator following irradiation with visible 
light. MCF-7 cells were exposed to 3 µM DOX for 6 h, and then incubated in presence or absence of 
AuNP and irradiated as depicted in Fig. 5.16. Cells challenged with DOX alone or DOX plus laser 
irradiation showed no staining with trypan blue (Fig. 5.16b and c), indicating that the membrane was 
still intact, since there was no heat shock. However, when cells are challenged with DOX plus AuNP, 
and laser irradiation is performed, almost all cells show clear signs of losing cell integrity (Fig. 5.16d). 
The combined effect of AuNP coupled to green laser irradiation and chemotherapeutic drug was further 
evaluated by the MTS assay. Cells exposed to laser only or AuNP only, show no decrease in cell 
viability. The combined therapy leads to loss of viability of 58% of cancer cells with an increase in 
0
20
40
60
80
100
120
140
160
0 20 40 60
C
el
l 
V
ia
b
il
it
y
 (
%
)
Exposure Time (sec)
  115 
 
temperature of 22 ºC. For DOX or photothermal alone, we observed a reduction of cell viability of 25% 
and 42%, respectively (Fig. 5.17). DOX irradiated with laser shows a synergistic reduction of 46% in 
cell viability with an increase of 11ºC. These data are in accordance with previous reports that highlight 
DOX’s increased toxicity at higher temperature in a trigger-dependent manner. This enhanced effect of 
DNA-damage has been attributed to a slowdown of the replication fork, leading to double strand breaks 
formation, which reduces cell survival [426]. Our combined strategy achieved the higher temperature 
and showed higher reduction in cell viability. 
Fig. 5.16 Combined chemo and PTT induced by visible light and AuNP as photothermal agent. 
Schematic representation (above) and respective image after cell staining with trypan Blue (800×) 
(below). Cells were (a) exposed to AuNP (15 nM) and irradiated; challenged with DOX (3 µM) for 6 
h (b) without or (c) with laser irradiation; or (d) combined DOX with AuNP and irradiation. Cells 
were incubated with trypan Blue dye for 10 min, 16 h after laser irradiation. Images acquired in bright 
field using an inverted microscope. 
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Fig. 5.17 Cell viability via the MTS assay in MCF-7 cells 16 h after combined therapy with DOX and 
AuNP induced PTT. Cells were incubated in DMEM supplemented with DOX (black bar); 
combination of DOX plus laser irradiation (light grey bar) (p = 0.0016); incubation with AuNP + 
Laser irradiation (dark grey bar) (p = 0.0002); or combined DOX + Laser irradiation with AuNP 
(white bar) (p < 0.0001). Cell viability of mono- and combined therapies normalised to the respective 
controls (not irradiated + 0.2 % DMSO), which were set to 100 %. Data are the average of 
quadruplicated assays and error bars correspondent to SEM (** p ≤ 0.01, **** p ≤ 0.0001).  
Proven the efficacy of combining DOX with irradiation we wanted to evaluate the efficacy of our 
combined approach against cancer cells resistant to traditional chemotherapy. To achieve this we used 
CoD, a compound from the same family of the previously studied in chapters 3 and 4 but with a cobalt 
metal centre instead of zinc metal centre. This compound has been previously studied by our group with 
similar results to ZnD [393]. We assessed its cytotoxicity in HCT116 DR cells aiming to chemically 
circumvent DOX resistance in these cells. As such, we determined the relative IC50 of CoD in HCT116 
DR and compared it to the normal HCT116 (DOX sensitive cells). After 24 h exposure, the relative IC50 
of CoD in HCT116 DR and HCT116 was 0.14 and 0.13 μM, respectively. These data clearly show that 
as ZnD (Table 3.1), CoD is highly effective (within very low micromolar range IC50) against a cancer 
cell line resistant to a first line chemotherapeutic – DOX. The effect of CoD in presence of tariquidar 
was also evaluated, which showed no difference in the IC50, i.e. CoD effect is not affected by efflux 
pump activity (Table 5.2). Together, these data show that CoD might be used to tackle DOX resistance 
in colorectal carcinoma cells.  
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Table 5.2 Values for the relative IC50 of HCT116 and HCT116 DR after 24 h exposure to DOX, CoD 
and their individual combination with tariquidar (inhibitor). Concentrations are expressed in μM. 
Cell Culture DOX CoD 
DOX + 
Inhibitor 
CoD + Inhibitor 
HCT116 0.38 ± 0.04 0.13 ± 0.01 0.38 ± 0.03 0.12 ± 0.01 
HCT116 DR > 6 0.14 ± 0.02 0.81 ± 0.06 0.15 ± 0.04 
 
We then combined CoD and irradiation using AuNP to increase killing of drug resistant cancer cells 
without affecting normal cells. For that, we coupled CoD with AuNP in a similar process that ZnD (see 
methods section 4.2.1 and 4.2.3 and [393]) naming the formulation NanoCoD. The nanoformulation 
was characterized by UV-Vis absorption spectrum, with the maximum peak shifting to the red, 
indicating functionalization (Fig. 5.18). Nanoformulations were also characterized by DLS, showing 
increased hydrodynamic diameter with consecutive functionalization layers. That the hydrodynamic 
diameter of AuNP@PEG@BSA and NanoCoD seems to decrease upon functionalization but we believe 
that the diameter is actually very similar, and the standard error gives the false impression of decrease 
(Table 5.3). To determine proportion of each component in the nanoformulation, supernatants were 
measured. For PEG Ellman’s assay was performed, for BSA Pierce method was used, and for CoD we 
did ICP-MS. By subtracting the amount detected on the supernatant to the added amount, we obtained 
the results summarized in Table 5.4.  
 
Fig. 5.18 AuNP construct with several functionalization layers: 1st PEG, 2nd BSA, 3rd CoD 
compound. The numbers represent the maximum absorption peak after each functionalization step. A 
red shift is observed after each functionalization step. 
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Table 5.3 Characterization of AuNP by Dynamic Light Scattering and Zeta Potential 
 DLS Zeta 
 Average (nm) St Dev Average (mV) St Dev 
AuNP 19.2 0.7 -60.1 2.1 
AuNP@PEG 18.6 2.8 -74.9 2.9 
AuNP@PEG@BSA 82.4 28.7 -14.8 3.9 
NanoCoD 72.0 12.7 -21.1 2.2 
Table 5.4 Characterization of NanoCoD.PEG was calculated using Ellman’s assay to measure thiols 
in the supernatant. BSA was calculated using Pierce assay to measure protein in the supernatant. CoD 
was calculated by ICP-MS of Co in the supernatant.  
Conjugate per 
AuNP 
Average St Dev 
PEG 2320 280 
BSA 6 2 
CoD 186 23 
 
We then incubated HCT116, HCT116 DR and fibroblasts (normal cell line) with NanoCoD (0.7 nM 
AuNP) corresponding to the IC50 of free CoD. Data show a 20 % reduction in cell viability for colorectal 
carcinoma cell lines – DOX sensitive and resistant (Fig. 5.19), and no significant reduction in fibroblasts 
(Fig. 5.20). This illustrates the higher cytotoxicity of this nanoformulation to cancer cells with limited 
toxicity to normal cells. Cells were then exposed to NanoCoD for 4 h with subsequent irradiation for 
60 s at 3.44 W·cm-2 with the green laser. Despite that, a temperature increase of ~5 ºC was observed for 
all culture media, but only HCT116 DR suffered a significant decrease in cell viability (61 % reduction), 
corroborating that his cell line is more sensitive to a raise in temperature.  
To escalate the photothermal effect, we increased the concentration of AuNP in the media. To 
warrant that, the concentration of CoD remains constant, a mix of NanoCoD and AuNP@PEG was 
prepared at a final concentration of 8.9 nM AuNP and added to the cell culture. Following irradiation, 
we attained a raise of ~12 ºC for all cell lines, resulting in a reduction of cell viability of ~63 % for 
HCT116/HCT116 DR and 31 % for fibroblasts. This increase in temperature largely increased cell death 
of HCT116, without significative increment to HCT116 DR, where irradiated NanoCoD alone 
represented 61% of cell death (Fig. 5.19).  
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Fig. 5.19 Cell death induced by the combined AuNP@PEG based photothermy and CoD.Reduction in 
cell viability of HCT116 (Top Left) HCT116 DR (Top Right) and Fibroblasts (Down) exposed to 
different formulations for 4 h. The concentration of AuNP is 8.2 nM. The concentration of NanoCoD 
is 0.7 nM of nanoparticles equivalent to the IC50 of CoD free at 24 h. Irradiated cells were exposed to 
3.44 W·cm-2 for 60 s. MTS assay was performed 24 h after irradiation. Data are the average of at least 
three independent assays and error bars correspondent to standard deviation.  
When we look at HCT116 DR irradiated with CoD Free it is interesting to note that it has a decrease 
in cell viability of 54% (Fig. 5.20). This result might be explained by the higher sensitivity of these cells 
to temperature. Possibly, even the increase of temperature of ~3ºC of laser alone, has a synergic effect 
with CoD, that is not observed with hyperthermia or chemotherapy alone. It is important to note that 
chemotherapy has a systemic administration, and fibroblasts did not show toxicity with NanoCoD 
without irradiation. Although cell death is observed in fibroblasts when irradiating AuNP and NanoCoD 
+ AuNP we should not forget that irradiation can be very precise, irradiating only desired tissues, thus 
fibroblasts should not be irradiated in the combined therapy. Together these results demonstrate the 
additive effect of CoD and photothermy that allows to kill HCT116 cells and HCT116 DR with the 
same efficacy. Since fibroblasts are less sensitive to temperature variation, this approach is highly 
selective towards cancer cells.  
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Fig. 5.20 Cell death induced by AuNP@PEG and CoD. Reduction in cell viability of HCT116, 
HCT116 DR and Fibroblasts exposed to different formulations for 4 h. The concentration of AuNP is 
0.7 nM, which is the equivalent to the AuNP concentration of NanoCoD. The concentration of CoD 
Free is the IC50 at 24 h. Irradiated cells were exposed to 3.44 W·cm-2 for 60 s. MTS assay was 
performed 24 h after irradiation. Data are the average of at least three independent assays and error 
bars correspondent to standard deviation. 
5.4 Conclusions 
Several studies have highlighted the potential use of nanomaterials for hyperthermia approach 
against cancer cells. Most of these reports have focused on the use of NIR to raise the temperature 
locally and, thus, induce cell death in a controlled way. However, despite the higher light to heat 
conversion of visible light upon irradiation of spherical 14-20 nm AuNP, visible light irradiation for 
PTT has been neglected. In fact, only but a few reports describe the use of visible region lasers for 
cancer treatment, despite its extensive medical applicability [442–444]. In this chapter, we showed that 
spherical AuNP of 14 nm are perfect photothermal agents when irradiated with a green laser. In fact, a 
photoconversion efficiency of 77% was attained, which is much higher than conventional NIR. We 
showed that AuNP@PEG reversibly aggregates at high temperatures with high ionic strength medium, 
such as PBS. This phenomenon might be due to the collapse of the PEG structure at high temperatures, 
and consequent particle approximation due to increased ionic strengths. Regarding, PTT in the visible, 
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we reduced breast cancer cell viability by 60%, which was potentiated when used in combination with 
DOX. What is more, because green lasers have already been in use for surgical purposes, their 
combination with standard chemotherapy, allows for targeted and selective killing of cancer cells and/or 
the possibility of reducing the dosage of chemotherapeutic agents, without compromising efficacy but 
reducing side effects. We showed that CoD is a promising chemotherapeutic agent against cancer cells 
refractory to DOX therapy. DOX resistant cancer cells are more sensitive to hyperthermia than 
fibroblasts. However, since we are using visible radiation, it is possible to easily target and direct 
irradiation to the tumour with superior precision, minimizing its effect in healthy cells, which is not 
possible to achieve in chemotherapy, since its effect is systemic. Combination of selective anti-cancer 
compound (CoD) with AuNP enhanced photothermy selectively kills resistant cancer cells while 
sparing healthy tissues. What is more, the additive affect allows to use smaller dose of chemotherapeutic 
agent, which further reduces adverse side effects associated to systemic delivery of chemotherapy. The 
described approach has great potential to be translate to clinical settings, since green lasers are 
commonly used for skin and retinal treatment with great promise to treat drug resistant tumours. This 
study paves the way for the use of green laser irradiation combined with AuNP in PTT regimens with 
impact in epithelial cancers. 
  
  122 
 
 
 AUNP PHOTOTHERAPY TO PREVENT NEO-ANGIOGENESIS 
 
The work presented in this chapter was possible due to the support of several colleagues. Their 
contribution will be further detailed. The synthesis and characterization of the nanoparticle formulations 
was performed by Amelie Heuer-Jungemann and Antonios Kanaras (ILS, University of Southampton). 
The in vivo assays were performed with the help of Pedro Baptista. All the work in this chapter was 
performed under the supervision and guidance of P.V. Baptista and A.R. Fernandes (UCIBIO, 
Universidade Nova de Lisboa). Data enclosed in this chapter were originally published in the following 
issues: 
• Pedrosa P, Heuer-Jungemann A, Kanaras AG, Fernandes, AR, Baptista PV. Potentiating 
angiogenesis arrest in vivo via laser irradiation of peptide functionalised gold nanoparticles. Journal of 
Nanobiotechnology. 2017, 15:85 DOI: 10.1186/s12951-017-0321-2 
 
  
  123 
 
6.1 Introduction  
In cancer development, tumour growth is associated with increasing need for oxygen and nutrients 
to supply the uncontrolled multiplication of malignant cells. As such, tumours release a series of growth 
factors to stimulate the formation of new blood vessels – neo-angiogenesis, which in turn provide for 
the very needed nutrients [42, 445]. Among these, the VEGF is responsible for the angiogenic trigger, 
leading to the foundation of new blood vessels surrounding the tumour tissue, thus allowing for its 
exponential growth [163, 446]. Upregulation of VEGF is a critical step in endothelial cell growth, 
survival and proliferation. The rapid growth of endothelial around tumours, results in an unorganised 
and leaky vasculature that potentiate further tumour growth and metastasis [446, 447]. Several FDA 
approved anti-angiogenic agents have already shown the potential to decrease tumour-induced neo-
angiogenesis, but the considerable side effects towards the normal vascular architecture in other organs, 
and the development of resistance to these drugs decreases their effect [166, 445, 448, 449].  
Nanoparticles hold great promise to deliver therapeutic agents selectively to tumours by increasing 
the local concentration of active molecules via the EPR effect at the tumour site [219, 396, 450]. EPR 
allows for the passive accumulation of the nanoparticles within the tumour site, where the confinement 
in a reduced volume permits lower dosages, improving the therapeutic effect while decreasing side 
effects [396, 448]. Our group have previously shown that AuNP functionalised with an anti-angiogenic 
peptide targeting the neuropilin-1 receptor (NRP-1), promote receptor internalisation and efficiently 
arrest angiogenesis in vivo [275, 451]. NRP-1 is a transmembrane glycoprotein and a co-receptor for 
VEGF [163, 452]. Although the precise mechanism for VEGF binding to NRP-1 in angiogenesis and 
in endothelial function remains to be unveiled, pre-clinical studies have linked NRP-1 blockade to 
suppression of tumour growth by blocking angiogenesis [453, 454]. The effect of our peptide-
functionalised nanoparticles on human umbilical vein endothelial cells was potentiated by the 
simultaneous combination of laser irradiation in the NIR [276, 455]. However, precise irradiation on 
the target site is possible by using a laser of visible light (green). Indeed, green lasers have been used 
in medical surgery as a safe tool for tissue ablation without bleeding, inducing photocoagulation of 
capillaries and minimal destruction of surrounding tissue [421, 456, 457]. Initially used in 
retinoblastoma focal therapy, their applications were broadened to hyperthermia directed at epithelial 
cancers or photodynamic therapy, for accurate tumour removal or photo activation of chemotherapeutic 
agents [421, 456–459]. AuNP with a diameter <20 nm show a very intense LSPR band centred at 520 
nm (close to the standard wavelength of surgical green lasers) that can be used for localised plasmon 
photothermal therapy. Spherical AuNP coupled to visible lasers have been reported as an efficient tool 
for hyperthermia, with increased photothermal efficiency [431] and are less influenced by particle 
polydispersity compared to gold nanorods [424]. In addition, green lasers have an increased effect on 
blood vessels, being an active tool against angiogenic conglomerates around tumours.  
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Here, we propose the combination of green laser irradiation with administration of a 
nanoformulation of 13 nm spherical AuNP functionalised with an anti-angiogenic peptide for the 
focalised phototherapy towards blockade of neovascularisation in vivo. For this, we used the chicken 
CAM model of angiogenesis to evaluate the anti-angiogenic effect of gold nanoconjugate formulations. 
CAM is a simple, highly vascularized extraembryonic membrane that is used as model of angiogenesis, 
tumour growth and metastasis [460], biocompatibility of engineered materials, drug distribution and 
toxicology, etc. It has been used as an in vivo platform for experimentation for the last 50 years. The 
main advantages of this model are its easy access, visibility, and capacity to from a small vascular 
network in a short period of time. This process occurs over a period of about 7 days starting of 
embryogenic development day 3 to day 10.  
6.2 Materials and Methods 
6.2.1 Synthesis and functionalization of AuNP 
The synthesis of AuNP was performed as described in 2.2.6.1. For functionalization, a freshly 
prepared aqueous solution of monocarboxy(1-mercaptoundec-11-yl) hexaethylene glycol (PEG, MW = 
526.7 g·mol-1, 200 μL) was added to a moderately stirring gold nanoparticle solution (10 mL, 5 nM). 
The mixture was continuously stirred for 2 h followed by an overnight incubation at 4ºC. AuNP@PEG 
were then purified from excess PEG by three rounds of centrifugation (16 400 rpm, 15 min) and re-
dispersion in borate buffer (10 mL, 0.01 M, pH 9). AuNP@PEG were stored at 4ºC until further use. 
Scramble and antiP peptides were then conjugated to AuNP@PEG. The peptide solution (100 μL, 1 
mg·mL-1, MW scramble = 922.1 g·mol-1, MW antiP = 968.2 g·mol-1, in 0.01 M sodium borate buffer, 
pH 9) was added to AuNP@PEG (5 mL, 1.5 nM in 0.01 M sodium borate buffer, pH 9) followed by 
aqueous solutions of EDC, 50 μL, 0.2 M and sulfo-NHS, 100 μL, 0.2 M. After shaking at room 
temperature for 24 h, the reaction mixture was purified by three rounds of centrifugation (16 400 rpm, 
15 min) and re-dispersion in water followed by lyophilization.  
6.2.2 RNA expression analysis 
The description of the procedures followed in this chapter are described in section 2.2.4. 
6.2.3 Ex ovo CAM assay 
All the in vivo CAM experiments were performed according to the Directive 2010/63/EU of the 
European Parliament and of the council of 22 September 2010 on the protection of animals used for 
scientific purposes, which does not contain any kind of restriction to the use of non-mammal embryos. 
The use of this alternative animal model fits in the “3Rs policy” that was strictly followed during 
experiments. 
Fertilised eggs were incubated at 37ºC, 99% (v/v) relative humidity, until 72 h and gently opened 
into a petri dish, with the chicken CAM facing upwards. Afterwards four transparent plastic, O-rings (6 
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mm inside and 9 mm outside diameter) were placed on the CAM. Inside each O-ring, 40 μL of free 
peptides or peptide-conjugated AuNP were pipetted (0.01 pmol·μL−1 for peptide concentration) [277]. 
For blood vessel modulation experiments each O-Ring per CAM contained PBS, scramble and antiP in 
the free form or in formulation with AuNP (AuNP@scramble and AuNP@antiP) and were further 
irradiated or kept in dark. Thus, each CAM is exposed to four different stimuli, one in each O-ring. 
After stimuli, the embryos were then incubated at 37ºC, 99% (v/v) relative humidity for 24 h. Images 
were acquired at 0 and 24 h of incubation using a Digital USB Microscope Camera (Opti-Tekscope 
OT-V1). For mRNA expression analysis, all the O-rings in each CAM were pipetted with the same 
solution of PBS, scramble and antiP, in free form or in formulation with AuNP, and were after irradiated 
or kept in dark. Thus, each CAM was exposed to only one stimulus, the same in all O-rings. After 
stimuli, the embryos were then incubated at 37ºC, 99% (v/v) relative humidity for 24 h and total mRNA 
was extracted. 
6.2.4 Blood vessel modulation experiments 
After image acquisition, the internal area of each O-ring was extracted from all imagens, then the 
green channel of the images was extracted using ImageJ 1.49k (Wayne Rasband, National Institutes of 
Health, USA). For image analysis, a noise tolerance of eight was considered for segmentation, 
excluding the edge maxima and binary performed. Using the skeleton plugin of ImageJ the number of 
branches was counted within the region treated with the sample formulations. The blood vessels in the 
image obtained after channel split were also counted manually for comparison. The formed blood 
vessels were calculated for 0 and 24 h. The percentage of newly formed vessels is given by dividing the 
values at 24 h by the values at 0 h. 
6.2.5 Statistical analysis 
Results are presented as average ± standard deviation of triplicate experiments. An unpaired, 
parametric, T-student test was performed between each group and the respective scramble. Differences 
between groups were considered significant at P < 0.05 using GraphPad Prism 7.00. 
6.3 Results and Discussion 
6.3.1 Nanoconjugate characterisation 
Spherical AuNP were synthesised as previously described in section 2.2.6.1. TEM imaging revealed 
an average size of 13 ± 2 nm which agrees with the previous synthesis (Fig. 6.1). AuNP@PEG were 
synthesised and showed an average hydrodynamic diameter of 21.0 ± 0.2 nm by Dynamic Light 
Scattering. Zeta potential measurements of AuNP@PEG and showed a negative charge (-27.53 ±1.5 
mV) possible derived from the presence of carboxylic groups. AuNP@PEG were subsequently 
conjugated with an anti-angiogenic peptide – KATWLPPR, (AuNP@antiP), capable to interact with 
NRP-1 receptor and inhibit the VEGF pathway. As a control, a scramble peptide (KPRQPSLP) 
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(AuNP@scramble) was used (Table 6.1). AuNP@scramble had a hydrodynamic diameter of 22.7 ± 3.3 
while zeta changed by 4 mV (-23.40 ± 2.3 mV) due to the formation of amide bonds between carboxylic 
groups from the outer shell of PEG and N-terminus lysins form positively charged peptides; 
AuNP@antiP had a similar net charge with an average size of 22.2 ± 2.2 nm. All measurements were 
obtained in PBS 1×.  
Table 6.1 Peptide Amino Acid Sequences 
Name Function Sequence 
Scramble Scramble control  KPRQPSLP 
AntiP Anti-angiogenic  KATWLPPR 
 
 
Fig. 6.1 TEM images of AuNP@antiP (A) and AuNP@scramble (B). Scale bars are 100nm. 
6.3.2 Laser effect on albumen and blood 
To understand the impact of irradiating AuNP on the biological matrix (chicken egg), we irradiated 
the egg white. It proved to be a good model matrix since it is transparent to visible light and mostly 
composed of water and albumin, where the effect of irradiation combined with AuNP@PEG could be 
easily perceived via the protein denaturation at high temperatures. We irradiated a solution of albumen 
with 0.3 nM of AuNP@PEG with different intensities and time exposures. Without AuNP@PEG the 
temperature only increased by 4.5 ºC (ΔT) while in its presence the temperature increased up to 22 ºC 
(ΔT) which led, in some conditions, to coagulation of the albumen (“boiled egg”) (Fig. 6.2). We chose 
two conditions (3.83 W·cm-2 300s and 5.1 W·cm-2 180s) and irradiated the albumen containing 
increasing concentrations of AuNP@PEG (Fig. 6.3). Both irradiation settings showed similar 
increments in temperature (Fig. 6.4).  
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Fig. 6.2 Green laser irradiation of albumen (500uL) mixed with AuNP@PEG (Vf- 700uL) at varying 
potencies and time periods, with 0.43 nM AuNP@PEG. The ∆T (ºC) after irradiation is represented at 
the bottom left of each assay. The initial temperature was 29 °C ± 1 °C for all assays. 
 
Fig. 6.3 Green laser irradiation of albumen (500uL) mixed with AuNP@PEG (Vf- 700uL) at fixed 
potencies and time periods, varying gold nanoparticle final concentration. The ∆T (ºC) after 
irradiation is represented at the bottom left of each assay. The initial temperature was 29 °C ± 1 °C for 
all assays. 
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Fig. 6.4 Temperature variation of albumen after green laser irradiation. Albumen was mixed with 
AuNP@PEG at fixed potencies and time periods varying gold nanoparticle concentration. The initial 
temperature was 29 °C ± 1 °C for all assays 
We then assessed the effect of irradiating a blood sample with and without AuNP@PEG, at 
previously determined concentration that inhibits angiogenesis (16.4 nM), to mimic blood capillary 
cauterisation [275]. One minute of irradiation at 0.61 W·cm-2 without AuNP@PEG caused blood to 
coagulate, thus setting the upper threshold for irradiation. Between 0.49 and 0.61 W·cm-2, blood only 
cauterises in the presence of AuNP@PEG, determining the effective window for the CAM assay (Fig. 
6.5). This clearly demonstrates the heating efficacy of AuNP@PEG when irradiated at their LSPR peak, 
where relatively low concentrations can induce high temperature variations in biological matrices. 
  
Fig. 6.5 Green Laser Irradiation of blood (87 μL) mixed with AuNP@PEG (16.4 nM) or water (Vf= 
100 µL) at varying potencies for 1 min at of AuNP@PEG. (Left) Cauterization of the blood samples 
can be seen as black spots. (Right) Infrared image of the blood well with nanoparticles irradiated with 
0.61 W·cm-2. The sample achieved a final temperature of 92 °C. 
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6.3.3 Irradiating CAM with AuNP@antiP 
To perform angiogenesis analysis in CAM we cracked the eggs at the third day of embryogenic 
development and placed them in a petri plate, inside an incubator. Transparent plastic O-Ring were 
placed on top of the CAM to restrict nanoparticle administration place (Fig. 6.6).  
   
Fig. 6.6 Photographs of CAM (Left) after placing the O-Rings (Right) after application of 
AuNP@antiP at 16.4 nM. 
We divided the ex-ovo CAMs into two groups: one exposed to AuNP@scramble and AuNP@antiP 
and not irradiated; and the test group, where embryos were exposed to each nanoformulation and 
irradiated with a potency of 0.49 W·cm-2 for 1 min with the green laser. An additional control ring with 
PBS 1× was also used. To calculate the percentage of formed blood vessels we took photographs of the 
O-Rings at 0 h and 24h after administration of the nanoformulations. The images were processed by 
ImageJ, with the following steps: the image was circular cut to contain only the vasculature inside the 
O-ring; the blue and green channels were removed from the photos to have a black and white image of 
the vasculature only; skeleton tool was used to draw the vasculature network; the number of branches 
was used as an indication of vascularization degree. The percentage of the newly formed arterioles was 
compared from the images taken at 0 h and 24 h. By looking at Fig. 6.7 we can observe a cauterisation 
spot, ranging from 0.8 to 2.6 mm in diameter, solely for the CAMs challenged with AuNP and irradiated 
with the green laser (Fig. 6.7). Coagulation occurs due to photothermal conversion by AuNP, and not 
by the laser alone. This shows that irradiation of AuNP can be used for safe localised photothermal 
cauterisation without affecting the surrounding vessels. One can also observe that, nor the 
AuNP@scramble alone nor irradiated affect the formation of new blood vessels when compared with 
PBS (Fig. 6.8). The anti-angiogenic nanoformulation (AuNP@antiP) in the group kept in dark, induced 
a 73% reduction in the formation of new arterioles when compared to the scramble nanoconjugate, in 
accordance to previously reported results [277]. What is more, irradiation of the nanoconjugates 
potentiates this effect, mounting on its anti-angiogenic effect and leading to a 91% reduction of newly 
formed arterioles.  
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Fig. 6.7 CAM images 24 h after application of the nanoformulation and irradiation. (A) images before 
software analysis. (B) images after software analysis. The nanoparticle formulations were at 16.4 nM 
concentration and the irradiated conditions were exposed to 0.49 W·cm-2 for 60 sec.  
 
 
Fig. 6.8 Percentage of newly formed vessels over 24 h in CAM model compared with respective 
control. AuNP@scramble (16.4 nM) were compared with PBS and AuNP@antiP (16.4 nM) were 
compared with AuNP@scramble. Irradiated formulations (Laser) were exposed to 0.49 W·cm-2 for 60 
sec. Differences between groups were considered significant at P < 0.05 (*). 
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6.3.4 Gene Expression Analysis 
Neuropilin-1 is a protein encoded by the NRP-1 gene in humans and has been shown to interact with 
VEGF-A forming a co-receptor complex with VEGFR-2 and mediating VEGF signalling [452, 453]. 
VEGFA encodes for the most common growth factor of VEGF pathway. Fms Related Tyrosine Kinase 
1 (FLT-1) encodes for the human VEGFR-1. It is a transmembrane protein with tyrosine kinase activity, 
important for the signalling of cell proliferation and differentiation, where the main function of VEGFR-
1 is to regulate blood vessel morphogenesis. NRP-1 expression is upregulated in several human 
tumours, e.g. brain, prostate, breast, colon, and lung cancers, promoting the vascularisation and 
progression of cancer, as well as contributing to invasiveness and metastasis [163, 446]. To further 
understand the molecular mechanisms of angiogenesis modulation by the AuNP@antiP, we used qPCR 
to look for variations in mRNA expression of genes involved in VEGF pathway, IL-8, VEGF-A and 
MMP-9, when compared to the scramble peptide alone or conjugated to AuNP. MMP-9 is a involved 
in the breakdown of extracellular matrix, and facilitates the vascularisation network growth [448, 461, 
462]. Evidence show that MMP-9 is up-regulated in some tumours and plays an important role in cancer 
angiogenesis, possibly by facilitating the access of VEGF to its receptors [448, 461, 462]. Concordantly, 
down-regulation of MMP-9 was shown to repress metastasis [448, 461, 462]. IL-8 is a chemokine that 
enhances endothelial permeability during early stages of angiogenesis, which requires activation of 
VEGFR-2 [463–466]. No alterations to gene expression were observed with the scramble peptide, 
neither free nor in nanoconjugate, when irradiated (Fig. 6.9 and Fig. 6.10). This indicates that laser 
irradiation per se does not affect VEGF pathway, despite vascular cauterisation. Irradiation of 
AuNP@antiP promotes a clear downregulation of FLT-1 and VEGF-A, 4- and 3.5-fold, respectively. 
Together, these data indicate that NRP-1 regulation over FLT-1 and VEGF-A expression is clearly 
enhanced upon laser irradiation. Our results show that MMP-9 is down-regulated in embryos exposed 
to AuNP@antiP by 1.9-fold and further repressed when irradiated (down 3.5-fold). IL-8 expression was 
not altered by the peptides or irradiation, indicating that the NRP-1 pathway does not influence IL-8 
expression in our CAM angiogenesis model (Fig. 6.9 and Fig. 6.10). Together, these results show that 
green laser irradiation of AuNP@antiP modulates neovascularisation via VEGF pathway, regulating 
FLT-1, MMP-9, VEGF-A expression but not IL-8. In vivo cauterisation of vessels coupled to blockade 
of angiogenesis clearly shows the potential to be used in cancer therapy, hindering vascular supply 
required for tumour progression. 
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Fig. 6.9 Gene expression heatmap for data retrieved from qPCR. Gene expression measured for 
scramble peptide irradiated (S IR); antiP and antiP irradiated (antiP and antiP IR, respectively); and 
the respective nanoconjugates. The nanoparticle formulations were at 16.4 nM concentration and the 
irradiated conditions were exposed to 0.49 W·cm-2 for 60 sec. 
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Fig. 6.10 Gene expression analysis of CAM for FLT-1, MMP-9, IL-8, VEGFA genes. Normalisation 
was performed with housekeeping GAPDH. The nanoparticle formulations were at 16.4 nM 
concentration and the irradiated conditions were exposed to 0.49 W·cm-2 for 60 sec. 
6.4 Conclusions 
In this chapter, we showed that spherical AuNP conjugated to anti-angiogenic peptides may be used 
as efficacious photothermal agents in the visible region of the spectrum. These conjugates can denature 
albumin and haemoglobin via an extremely focalised irradiation that does not require guide light, since 
it is itself visible. This way, existing surgical green laser mays be used directly to cauterise tissues 
harbouring these nanoconjugates. Furthermore, green laser irradiation of the gold nanoconjugates 
potentiates the anti-angiogenic effect in vivo via down regulation of the VEGF pathway. With this 
approach, we can specifically destroy vessels surrounding the tumour by laser ablation and inhibit 
neovascularisation through NPR-1 blockage. The proposed combination of chemo- and phototherapy 
allows for a reduction of dose of anti-angiogenic peptide, thus reducing possible side effect to the 
neighbouring tissues, while arresting blood vessel supply critical for tumour progression, which might 
become a valuable strategy for cancer treatment.  
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 AUNP GENE SILENCING TO OVERCOME DRUG RESISTANCE 
 
All the work in this chapter was performed under the supervision and guidance of P.V. Baptista and 
A.R. Fernandes (UCIBIO, Universidade Nova de Lisboa). Data enclosed in this chapter were originally 
published in the following issues: 
Pedrosa P, Mendes R, Cabral R, Martins L, Baptista PV, Fernandes A. Combination of chemotherapy 
and Au-nanoparticle photothermy in the visible light to tackle doxorubicin resistance in cancer cells. 
Scientific Reports. 2018, 8:11429 DOI: 10.1038/s41598-018-29870-0 
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7.1 Introduction 
The impact of ABCB1 in cellular acquisition of resistance prompted us to investigate alternative 
ways to prevent tumour cells to become resistant. The main mechanisms involved in drug resistance is 
pump cellular resistance which involves the up regulation of membrane ATP-dependent efflux pumps 
which excrete the drug to the extracellular medium, decreasing the intracellular concentration of the 
drug below effective levels. These pumps are characterized by transmembrane domains and nucleotide-
binding domains with the Walker A, Walker B, and Signature C motifs [192]. The human ABC 
transporters consist of a protein family of 49 members where, P-glycoprotein (ABCB1), breast cancer 
resistance protein (BCRP/MXR/ABC-P/ABCG2), and MDR-associated proteins (MRP1/ABCC1 and 
MRP2/ABCC2) are the most studied. ABCB1, encoded in humans by the ABCB1 gene, confers cross-
resistance to a variety of cytotoxic agents. The overexpression of ABCB1 is described as the main cause 
of pump cellular resistance. Downregulation of these mechanisms have indicated reversal of tumour 
cells to the sensitive state. Some studies have taken advantaged of ASOs targeted against ABCB1 
mRNA to suppress MDR [193, 194]. However, vectoring nucleic acids into cells is a challenging task, 
their therapeutic efficacy is low, with low transfection efficiency and stability, being degraded by 
enzymes, and rapidly cleared from the systemic circulation. New vehicles of transfection have been 
tested to surpass this. Extensive investigation is being made in the design of AuNP formulations to 
improve siRNA [263, 467–469] delivery and efficiency, without undesirable immune response or off-
target effects. AuNP-siRNA have been tested in cell cultures targeting reporter genes, such as luciferase 
or green fluorescence protein [263, 265]. AuNP can be optimal delivery vehicles for gene therapy 
because they protect the oligonucleotides against RNases and can easily functionalized with targeting 
moieties. AuNP tend to be internalized by cells and showed to outperform traditional delivery systems 
with effective gene silencing [263, 467–470]. Previous studies show the capacity of ASO functionalized 
AuNP to knockdown gene expression at lower cell toxicity than lipofectamine antisense DNA [206, 
263, 471]. In the following work we will try to silence ABCB1 mRNA through AuNP ASO technology, 
to decrease the levels of ABCB1 expression, and increase the effectiveness of DOX by avoiding its 
excretion (Fig. 7.1). For that purpose, a cell line described as expressing ABCB1, HCT116 was chosen 
for the experiments. 
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Fig. 7.1 Schematics of the hypothesis of ABCB1 silencing. (Left) ABCB1 pumps DOX outside the 
cells. (Right) AuNP@ASO enters the cell and silences the ABCB1 mRNA, the protein is not 
translated and DOX concentration inside the cell, increases, reducing its viability.  
7.2 Materials and Methods 
The description of the procedures followed in this chapter are described in section: Cell culture 2.2.1; 
Cell Viability 2.2.2; Western Blot 2.2.5; RNA expression analysis (qPCR) 2.2.4. 
7.2.1 Functionalization of AuNP with ASO 
In this chapter we used AuNP previously characterized in section 5.3.2. AuNP@PEG with a 
coverage of 30% were synthetized and characterized as described in section 2.2.6.3. Thiol-modified 
oligonucleotide (STAB Vida, Portugal) was dissolved in 0.1M DTT for 4h to reduce the sulphide bonds. 
DTT was extracted through ethyl acetate by washing three times. The aqueous phase was filtered in a 
NAP-5 and further incubated with AuNP@PEG in a ratio of 1:200 (AuNP:ASO) and 0.01% (w/v) of 
SDS. Increasing concentrations of sodium chloride were added for every 20 min to the mixture up to a 
final concentration of 0.3M to promote AuNP@PEG and ASO interaction. The mixture was let stand 
in agitation for 16h. The solution was washed 4× with Mili-Q water by centrifugation 14 000×g for 
45min. The resulting oily pellet stored in the dark at 4 ºC till further use.  
7.3 Results and discussion 
7.3.1 AuNP@ASO synthesis and characterization 
We choose an ASO sequence previously described in the literature as bearing the highest silencing 
activity of ABCB1 gene, of the tested sequences [194]. To increase the specificity of this sequence, a 
hairpin structure was designed to open, only in the presence of a full complementary target. The capacity 
of the hairpin to open in the presence of the target was tested in silico confirming its function (Fig. 7.2). 
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Fig. 7.2 In silico hybridization analysis. The probe and the complementary portion of mRNA was 
analysed at 37ºC using standard Nupack settings[472]. 
The thiol modified ASO was functionalized by salt aging method into the spare spaces of 
AuNP@PEG surface. Functionalization was confirmed by a red shift in the UV-Vis absorption peak of 
5 nm and an increase in the hydrodynamic diameter of 8 nm by DLS (Fig. 7.3).  
 
 
Fig. 7.3 DLS AuNP characterization of AuNP@ASO.  
The amount of functionalized ASO was defined by measuring the supernatant optical absorption of 
DNA at 260 nm. By subtracting the amount of added DNA, we were able to establish the number of 
oligonucleotides attached to the AuNP, resulting in 1:30 AuNP:ASO proportion. 
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7.3.2 Gene Silencing 
To assess the capacity of AuNP@ASO to silence ABCB1 in vitro, we performed an RNA expression 
analysis by qPCR for HCT116 cells exposed to increasing concentrations of particles for 24 h, 48 h and 
72 h. Ribosomal 18s gene was taken as reference and AuNP@PEG were used as control. We could 
observe a decrease in gene silencing with increasing concentrations of silencer, being the most effective 
the 48 h exposure with 50 mM of ASO, reducing almost 3-fold the expression of the gene compared 
with control (Fig. 7.4). We observe that in general concentrations over 50 nM of ASO do not increase 
silencing. Also, incubation times longer than 48h seem to be less effective at silencing than 48h. This 
might be due to a cellular response to the silencing.  
 
Fig. 7.4 Expression analysis of ABCB1 mRNA, normalized to 18s, and AuNP@PEG. Different 
concentrations of AuNP@ASO were tested, for incubation times of 24h, 48h and 72h. The values in x 
axis represent the concentration of ASO added in each assay. 
We then tested our hypothesis, if by silencing ABCB1 we could increase the effect of DOX. We 
tested if by exposing cells at the optimal silencing conditions we could reduce HCT116 viability in 
combination with DOX. We could not observe a significant decrease in cell viability, for AuNP@ASO 
formulation, showing that it is not toxic. Also, the combined therapy compared with DOX alone showed 
no significant difference, against what was expected (Fig. 7.5). This could be explained by the low 
turnover of ABCB1 protein, of up to 72h in some cell lines [473], meaning that even if we were silencing 
the gene, the protein would still be active and pumping the DOX out of the cell. To confirm this, we 
added, as in Fig. 3.10, the specific blocker of ABCB1 protein, tariquidar. It is a molecule that showed 
remarkable inhibition of ABCB1 with Kd of 5.1 nM, although it failed clinical trials for excessive 
toxicity. Tariquidar showed no toxicity at tested conditions, and again no significant change in cell 
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viability was observed when cells were exposed to DOX, and the inhibitor compared with DOX alone 
(Fig. 7.5).  
Fig. 7.5 Cell Viability of AuNP@ASO, DOX and Tariquidar. Cell viability was measured by MTS 
assay after an incubation period of 48h. Cell viability was calculated using cells as reference.  
This means that blocking ABCB1 has no effect on HCT116 viability, which lead us to check the 
protein expression levels of ABCB1 in this cell line. Despite expressing ABCB1 gene, we could not 
detect ABCB1 protein in HCT116 by western blot (Fig. 7.6).  
  
 
 
Fig. 7.6 Western blot of ABCB1 and β-Actin (control) in HCT116 and HCT116 DR.  
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We decided to repeat our silencing experiments in HCT116 DR to see if we could revert the 
resistance. After incubating HCT116 DR with DOX and AuNP@ASO at optimal conditions we could 
not observe significant alterations in cell viability. Again, this raised the question if the existing protein 
was still active, despite inhibition of synthesis. To confirm that we tried to add Tariquidar to block the 
active protein and at the same time silence ABCB1 mRNA. This way we wanted to see if we could 
increase the effect Tariquidar by adding AuNP@ASO. We tested 10, 30, and 60 nM of tariquidar with 
AuNP@ASO and in all cases AuNP@ASO plus tariquidar and tariquidar alone, showed the same effect, 
at 24 h or 48 h exposure. This means that despite blocking the active protein the silencing is not being 
efficient at reverting the resistant phenotype (Fig. 7.7). 
 
Fig. 7.7 Cell viability of HCT116 DR exposed to different concentrations of Tariquidar (10, 30, 60 
nM) and DOX (3.6 µM) with and without AuNP@ASO 
Although not conclusive we can propose a hypothesis to these results. AuNP@ASO can silence 
ABCB1 in HCT116 but it has no effect, since basal protein levels could not be detected. In HCT116 
DR, a cell line that expresses ABCB1 in higher levels, we assumed that AuNP@ASO had a similar 
silencing effect, however it was not confirmed. This inefficient silencing effect of AuNP@ASO might 
be due to accumulation of mutations after several passages in ABCB1. Genetic instability has been 
described in long term passage in cell culture [474–479]. Another possibility is that HCT116 DR might 
have different optimal conditions for effective silencing compared to HCT116. To confirm this last 
hypothesis, we should perform a mRNA expression analysis for HCT116 DR upon incubation with 
AuNP@ASO and optimize the silencing conditions for this cell line. 
7.4 Conclusions 
In this chapter we synthetized a nanoformulation of AuNP and an ASO to silence ABCB1 gene. We 
showed that it is possible to downregulate the expression of ABCB1 by using AuNP@ASO, with 
optimal conditions at 50 nM of antisense oligo and 48 h exposure in HCT116 cells. Although we 
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observed an expression of the ABCB1 gene, we did not observe the expression of ABCB1 by western 
blot nor any evidence of its activity was observed since there was no effect in the presence of tariquidar. 
Despite the efficacy in ABCB1 silencing in HCT116, we did not observe any addictive effect of DOX 
in the presence of AuNP@ASO in HCT116 DR. Even when blocking ABCB1 protein, AuNP@ASO 
did not show an increasing effect to the blocker. We propose that the silencing conditions of HCT116 
could be different from HCT116 DR, leading to an inefficient silencing. Optimization of silencing 
conditions for the resistant cell line ought to be performed to conclude the viability of this approach for 
acquired resistance cancer.  
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 CONCLUSIONS AND FUTURE PERSPECTIVES 
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8.1 Conclusions 
Acquired drug resistance by cancer cells is one of the main reasons for therapeutic failure. Therefore, 
the development of new therapeutic compounds that can overcome this resistance are widely needed. 
In this thesis we demonstrated that the novel water-soluble molecule, Zn(II) coordination compound 
(ZnD) exhibits a with high cytotoxic activity towards colorectal carcinoma (HCT116) and one lung 
cancer cell line (H1975) without impacting healthy cells (fibroblasts), either in monolayer or in a 3D 
culture. We showed that ZnD induces cell death by intrinsic apoptosis following cell cycle arrest in S 
phase but without noticeable genotoxicity.  
To further our knowledge on cancer cell resistance to chemotherapy and on how to circumvent it, 
we developed a cell line resistant to DOX derived from HCT116 (HCT116 DR). We then showed that 
the ABCB1 efflux pump is the main mechanism responsible for the acquired resistance, since it is 
markedly upregulated in these resistant cells. Still, ZnD was able to kill HCT116 DR, bypassing the 
efflux pump. This way, ZnD can be taken as a good example to tackle this type of resistance, since cells 
do not seem to be able to remove the compound via efflux pumps. 
Nanomedicine, in special AuNP, are attractive due to their low toxicity and capacity to interact with 
small molecules in a plethora of medical applications, namely on smart vectorization of compounds and 
treatments. So, we decided to vectorize ZnD on a gold nanoparticle to increase efficacy in tackling cell 
growth of both normal and resistant cells. Our nanoconjugate showed increased toxicity against the 
studied cell lines, decreasing the respective IC50. Active targeting is settled to direct therapeutics 
selectively to the target cells and tissues, thus sparing healthy tissues from the deleterious effect of 
chemotherapy. Cetuximab is a monoclonal antibody that may be used as an effective targeting molecule. 
As such, we grafted Cetuximab to our nanoconjugates, providing for selective targeting capability and, 
consequently, increased cell uptake of ZnD. This targeting resulted in enhanced selectivity towards 
cancer cells in vitro. Also, in vivo studies proved the potential of the new nanoformulation, reducing 
tumour size in mice xenografts. Still, additional studies are required to confirm the full potential of the 
targeting strategy. 
It is in general believed that combination therapy can be a more efficient therapeutic strategy than 
monotherapy. For that reason, we tried to take advantage of the photo-hyperthermia of AuNP and tested 
a combined photo-chemotherapy. We proved that spherical 14nm AuNP have a photoconversion 
efficiency of 77% when irradiated with a green laser, which is much higher than conventional NIR. We 
showed that cancer cells are more sensitive to hyperthermia than fibroblasts, and that photothermal 
therapy alone could reduce a breast cancer cell line viability by 60%, which was potentiated when used 
in combination with DOX. CoD, which is a promising chemotherapeutic agent against cancer cells, 
from the same family of ZnD, was able to kill HCT116 cell line, refractory to DOX therapy and in 
combination with AuNP enhanced photothermy, selectively killing resistant cancer cells while sparing 
healthy tissues. This combined therapy has great potential to be translated to clinical settings, since 
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green lasers are commonly used for skin and retinal treatment because they can cauterize blood vessels 
precisely. 
For that reason, we tested the viability of using AuNP coupled to green laser irradiation to arrest 
angiogenesis. It is one of the major milestones of the development of solid tumours, either sensitive or 
resistant to chemotherapy. We showed that AuNP conjugated to anti-angiogenic peptide may be used 
as efficacious photothermal agents, desaturating haemoglobin via an extremely focalized irradiation 
and at the same time inhibiting neovascularisation through NPR-1 blockage. We proved that the anti-
angiogenic effect in vivo acts via down regulation of the VEGF pathway. The proposed combination of 
chemo- and phototherapy selectively destroys blood vessels critical for tumour supply and progression, 
which might become a valuable strategy for cancer treatment. 
In the end of our work we synthesized a nanoformulation of AuNP and an ASO to silence ABCB1 
gene. We showed that it is possible to downregulate the expression of ABCB1 by using AuNP ASO, 
however we did not observe any additive effect of DOX in the presence of AuNP@ASO in HCT116 
DR. Even when blocking ABCB1 protein AuNP@ASO did not show an increasing effect to the blocker. 
As the regulation of efflux pumps in cells are complex, further studies needed to be performed to 
develop a gene therapy strategy to circumvent drug resistance. 
8.2 Final considerations and future perspectives 
In the beginning of this project we defined five topics we wanted to explore to expand the knowledge 
in the fight against resistant cancer. Throughout the chapters we addressed these topics, answering some 
questions, and leaving some for further work. In the first topic, i) Characterization of novel chemical 
agents in biological context, whose mechanism may override existing drug resistance/adaptation 
mechanism from tumour cells, we were pioneers with the characterization of the ZnD compound that 
might be a future second line of treatment for colorectal, or lung cancer. To get there, it would be 
important to know more about the cellular interaction mechanisms of this compound, i.e. to understand 
its mechanism of internalization by cancer and healthy cells. It would be interesting to block some 
active/passive transporters and check if we could see a reduction in ZnD cytotoxicity. Following its 
intracellular path could also give us some answers on its molecular targets. One approach could be to 
tag the molecule with a fluorophore and try to follow it by microscopy. The problem is that by 
modifying the molecule we could also be modifying its internalization pathway and mechanism of 
action. We also described for the first time the development of a new cell line resistant to DOX 
(HCT116 DR), whose resistance mechanism is due to ABCB1 overexpression, and the ability of ZnD 
to circumvent its resistance. Is this effect only for this type of resistance mechanism? Testing for a 
similar efficacy of ZnD in other resistant cell lines (due to different resistance mechanisms) could be 
extremely important to prove its value. Also, a better knowledge of the genomic alterations resulting 
from the continuous exposure of cancer cells to DOX such as changes in cell metabolism, are of utmost 
importance for finding personalized medicines. Whole genome sequencing, RNAseq, and mass 
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spectrometry to compare with the parental cell line would allow a better understanding of the 
constitutive genomic expression and metabolic alterations.  
The next topic we proposed to address was ii) Targeted vectorization of compounds using AuNP 
towards active targeting to tumour cells and loading of effector cargos and assessment of therapeutic 
effect in vitro and in vivo. Our results clearly show in vitro and in vivo the advantage of vectorizing 
ZnD in a nanoparticle formulation. The vectorization revealed to be an effective strategy in vivo, 
especially when the total dosage was given in a single administration. Since 20× the dosage revealed 
no acute toxicity it would be important to test the effect of increasing concentrations of the 
nanoformulation. It would be interesting to proceed with studies of toxicity in vivo, of other organs, 
calculate the circulation time, half-life, excretion mechanism of the nanoformulation and perform long 
term survival studies. It is also important to test the formulation against other cell lines. Due to the 
promising results against DOX resistant cell line and depending on the results of the proposed pre-
clinical trials, clinical trials could give us a definite answer on the feasibility of bringing this product to 
the clinic. The advantage of Cetux targeting was not conclusive. Raising the question of the advantage 
of active targeting over nanoparticle passive targeting. What is more, for each layer of complexity we 
add to a formulation we must always weight its cost/benifit to the final product. Antibodies such as 
Cetux are expensive and can increase the cost of the formulation. Unless further results reveal a drastic 
increase in the formulation efficacy and/or reduction of side effects, cetuximab targeting should not be 
used. The third proposed topic of this thesis was iii) the use of AuNP for photothermal conversion 
towards directed hyperthermia capable of effectively killing cancer cells, and tackle survival/evasion 
mechanism (e.g. arrest neo-angiogenesis). Only a few papers describe the use of hyperthermia using 
AuNP and visible irradiation. There is a general preference to explore NIR irradiation, due to the 
advantage in tissue penetration. In my opinion, visible irradiation has several advantages over NIR, 
especially in superficial or accessible tumours, that make it more suitable for tumour/tissue ablation. As 
it is visible you can precisely see the irradiation site without need of a guide light; only the irradiation 
focus is affected, not affecting other tissues, and it has an increased effect in blood vessels, destroying 
tissue blood supply. In this thesis, we showed the efficacy of this strategy in vitro, killing sensitive and 
resistant cancer cells to chemotherapy. Testing the performance of visible irradiation in vivo would 
elucidate the feasibility of this approach in clinical settings. It would be interesting to test this approach 
in mice or CAM xenografts, by administering AuNP, which would be irradiated after accumulation in 
the tumour. By combining in vivo chemotherapy, with hyperthermia and blood vessel ablation, we 
would be attacking a tumour in different fronts, reducing the probability of acquiring resistances.  
Another topic we proposed to explore was iv) Specific and selective gene silencing to switch off 
critical genes responsible for drug resistance, thus increasing the efficacy of the compounds and 
decrease resistance. It was the least explored topic in this thesis. We showed that AuNP can be used as 
gene silencing moieties, downregulating ABCB1. However, the regulation mechanism of efflux pumps 
is not linear, therefore were not able to observe significant reduction in cell viability derived from gene 
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silencing. Further testing would be needed to better understand the effect of silencing ABCB1 mRNA, 
in the overall protein expression levels.  
The last topic proposed was v) combining the approaches in a single AuNP formulation, providing 
cues to optimize cancer cell killing, circumventing drug resistance and decreasing toxic side effect. We 
showed the advantages of combining therapy strategies. We combined novel ZnD chemotherapy 
compounds with AuNP. We further combined AuNP with hyperthermia and chemotherapy. The next 
step would be to combine all these strategies in a single platform, ZnD and AntiP peptide functionalized 
in AuNP irradiated with visible laser for hyperthermia and test it in vivo. The combination of these 
strategies that have different mechanisms of action in tumour cells, not only reduces the possibility of 
resistances, but was also proven to be effective in resistant tumours.  
One of the biggest revolutions enabled by nanotechnology is the possibility of theragnostic, which 
was not explored in this thesis. Regarding that matter, imaging tools, such as x-ray fluorescence, or 
photoacoustic, could be used to visualize the accumulation of AuNP in tumour. This enables the specific 
irradiation of marked tissue, localizing metastasis.  
In a distant future we can envision the use of a similar approach as the ones developed in this thesis 
in the clinics, where patients are injected with a nanoformulation that not only points the tumour location 
but can be directly irradiated, specifically killing cancer cells and surrounding blood vessels with 
precision, performing real time theragnostic. Coupling all the concepts of this thesis with robotic 
surgery used nowadays, it would be possible to have a fully autonomous surgeon robot that 3D scans 
patients, looking for tumour targeted AuNP and applies a laser mediated hyperthermia treatment. I hope 
for a time when cancer treatment side effects shall be a thing of the past, and cancer will be as harmless 
as the common flu. 
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APPENDICES 
 
Fig. A.1 Top view of the blueprint of manual well plate mover. 
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Fig. A.2 Perspective view of the blueprint of manual well plate mover. 
